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Scope of the thesis 
Scope of the thesis 
In 1941, Charles Huggins and Clarence Hodges made the most 
significant discovery in relation to prostate cancer, namely that 
adenocarcinoma of the prostate was a hormonally dependent disease. They 
developed the following biologic syllogism: "In many instances a malignant 
prostatic tumor is an overgrowth of adult epithelial cells. All known types 
of adult prostatic epithelium undergo atrophy when androgenic hormones 
are greatly reduced in amount or inactivated. Therefore significant 
improvements should occur in the clinical condition of patients with far 
advanced prostatic cancer subjected to castration. " Huggins and Hodges 
were awarded the Nobel Prize for Medicine in 1966 for their discovery. 
Serum testosterone originates from the testicles and, in addition, 
androgens from the adrenals are converted to dihydrotestosterone (DHT). 
Bruchovsky and Wilson have performed studies on rats and showed that 
DHT is the major intracellular androgen responsible for the growth and 
function of the prostate gland. 
In the Introduction, a review of the epidemiology of prostate cancer 
is presented. In the past decade, the large increase in prostate cancer 
incidence in western societies has been mainly due to increased awareness 
and screening for the disease. Furthermore, the shift from intense advanced 
metastatic bone lesions to more local, and less advanced, prostate cancer 
with decreased tumour burden has led to changes in therapeutic strategies 
with greater emphasis on quality of life. The neuroendocrine control of 
gonadotropin secretion was firmly established by the experiments of Harris 
in 1955. However, it was not until 1971 that Schally confirmed the 
structure of the key mediator: luteinizing hormone-releasing hormone (LH-
RH). As LH-RH has only a short duration of action, several LH-RH agonist 
analogues with vastly improved potency and duration of action have been 
introduced. 
Hoechst was the first company to develop a nasal spray formulation 
of their LH-RH agonist, buserelin; although more acceptable than a daily 
subcutaneous injection, the nasal spray suffered from low, variable 
absorption and compliance problems for the patient. The next major 
advance since 1985 was the introduction of a biodegradable sustained-
release formulation of the LH-RH analogue Zoladex (Goserelin Acetate). The 
drug is dispersed throughout a matrix of poly-lactide-glycolide which 
releases it slowly over 28 days. Nevertheless, as patients may still not wish 
to remind themselves to attend the clinic for a painful monthly injection, 
even longer-acting formulations are now being assessed. The aim of our 
investigation was the clinical evaluation of a three-month Zoladex depot and 
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this is described in Chapter 3. 
Initially, the growth and function of the normal and prostatic 
carcinoma cell is largely dependent upon androgens, the primary source of 
which is the testis, with a small contribution from the adrenal glands. The 
added clinical value of total blockade of both sources of androgen, known 
as maximum androgen blockade (MAB), over surgical castration alone is 
described in Chapter 4. The results of our double-blind, randomized, 
prospective study comparing nilutamide and orchidectomy versus 
orchidectomy alone are discussed in relation to a number of endpoints 
including objective and subjective improvements, the impact on survival, 
and changes in serum prostatic specific antigen. 
The androgen sensitivity of prostate cancer cells is of limited 
duration and about 30 percent will become hormone insensitive within one 
year. Until now, the response to advocated treatment regimens has been 
disappointing. Chapter 5 discusses the results of investigations into the in 
vivo anti-tumoral effects of an imidazole derivative, liarozole hydrochloride, 
on androgen-dependent and androgen-independent Dunning prostate cancer 
cell sublines. Liarozole inhibits tumour cell proliferation and increase cellular 
differentiation by inhibition of retinoid acid metabolism and, thus, enhances 
the antiproliferative effects of retinoid acid. The favourable in vivo data 
prompted us to treat in phase I and II trials a group of hormone-refractory 
prostate cancer (HPRC) patients with liarozole hydrochloride to assess its 
efficacy and tolerability. 
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Chapter 1 
Abstract 
Prostate cancer is currently one of the most common malignancies 
worldwide. The incidence of prostate cancer has risen dramatically over 
the last decade, more so than can be explained by increasing longevity. 
Mortality rates have also risen, though not as dramatically. There is a wide 
geographic variation in the incidence of clinical prostate cancer, with 
higher rates in the United States than in China. One risk factor which could 
explain this variation is high fat intake associated with a Western diet. It is 
also apparent that prostate cancer is now being detected at less advanced 
stages than in the past. Increased awareness of the disease and improved 
detection methods are thought to contribute to this earlier detection. 
Introduction 
Over the past four decades prostate cancer has become a major 
health problem in Western societies [1]. The incidence rate of prostate 
cancer and to some degree the mortality are rising faster than can be 
explained by increasing longevity alone. The reasons for this are unclear 
but are mainly attributed to early detection initiatives [2]. 
In The Netherlands, prostate cancer was responsible for 14% of all 
malignancies in men and ranked second with respect to male incidence and 
death rates in 1991 [3] (fig. 1). In the United States, during the period 
1987-1991, prostate cancer became the most commonly diagnosed 
malignancy as well as the second leading cause of male cancer death (fig. 
2) [4, 5]. It was estimated that a new diagnosis of prostate cancer was 
made every 3 minutes and a man died from the disease every 15 minutes 
[6]. Moreover, the lifetime risk of a newborn male developing prostate 
cancer was 13% and almost 3% of men older than 55 years would die 
from the disease [7]. Unfortunately this disease usually remains 
undiagnosed until it becomes so advanced that only palliative measures are 
possible. At the time of diagnosis 50-70% of patients have locally 
advanced and/or metastatic disease [8]. This review gives a comprehen-
sive account of the incidence, prevalence, mortality and risk factors 
associated with prostate cancer. The disease stage at diagnosis is also 
discussed. 
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Fig. 1. incidence of male cancers in The Netherlands in 1991 (adapted from Visser et 
al. 1991 [ЗЛ. 
Incidence 
In the United States, since 1973 the National Cancer Institute has 
co-ordinated the Surveillance Epidemiology and End Results (SEER) pro­
gramme, a network of nine population-based cancer incidence registries 
[9]. From the SEER data, it is clear that there was a steep increase in the 
incidence of prostate cancer during the period 1986-1990 among black 
and white Americans compared with the last decade. This increase 
occurred in all age groups but the overall age-adjusted rise in incidence 
was primarily due to increases at older ages. Age-specific rates are shown 
in fig. 3 [10]. The age-adjusted incidence rates for prostate cancer among 
American blacks and whites nearly tripled between 1973 and 1992 [ 1 1 -
13] (fig. 2). 
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Fig. 2. Based on 1992 SEER rates (adapted from Lynn and Ries 1995 [5]. 
The American Cancer Society estimated that in 1996, 317,000 
new cases of prostate cancer would be diagnosed in the United States in 
men over 50 years of age [7, 14]. This represents an increase of 73,000 
new diagnoses in 1 year alone compared with 244,000 new cases in 1995 
[14] (table 1). Rising patterns of prostate cancer incidence have been 
observed around the world, even in Asia and Eastern Europe where the 
rates have been lower than those observed in Western Europe and the 
United States [15-20]. 
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Table 1. Estimated new cases and deaths due to prostate cancer in the United States 
by the American Cancer Society in men over 50 year of age" (adapted from 
Wingo et al. 1995 [14]. 
1958 
1965 
1975 
1976 
1980 
1985 
1988 
1989 
1991 
1992 
1993 
1994 
1995 
1996 
New cases 
ND 
ND 
56,000 
60,000 
66,000 
86,000 
90,000 
103,000 
122,000 
132,000 
178,000 
200,000 
244,000 
317,000 
Death 
14,071 
15,900 
18,700 
19,300 
21,000 
25,000 
28,000 
28,500 
32,000 
34,000 
36,000 
38,000 
40,400 
41,400 
ND = not determined. 
• Estimated, that in 1995, 27 million men would be over 50 years of age 
Interestingly, the incidence of prostate cancer in the United States 
is 50% higher in African Americans than in white Americans. In fact 
blacks have the highest prostate cancer incidence rates in the world (age-
adjusted relative risk = 1.8) compared with whites, for all age groups [ 21 , 
22]. Clinical studies have shown that blacks present with prostate cancer 
at a younger age and have a higher grade and later stage of the disease (at 
diagnosis) than whites [23]. 
A recent analysis, however, has demonstrated a marked increase, 
particularly in the incidence of early stage disease, among American 
whites compared with African Americans [7, 12]. This increase was 
largely attributed to more frequent detection of the disease in younger 
patients. As well as personal and environmental causal factors [4, 20, 24, 
25], the more frequent use of transurethral resection (TUR) during the 
1980s compared with the 1970s has led to increased detection of 
unexpected tumour lesions (T1a or T1b according to the TNM system) 
[26, 27]. Although the rate of TUR has now levelled off, other modes of 
detection have increased such as: annual prostate examinations by means 
of digital rectal examination (DRE), due to heightened patient awareness 
[24, 28]; serum prostate specific antigen (PSA) monitoring, and transrectal 
ultrasound needle-biopsy [29,30,31]. 
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The incidence of prostate cancer in Europe tends to be lower than 
in the United States. The highest incidence rate in Europe, between 1983 
and 1988, was in Iceland with 52.4 per 100,000 men having the disease. 
Examples of the rising incidence of prostate cancer in Europe from around 
1960-1963 to 1983-1988 in countries with high incidence rates include: 
Sweden, 26.5 to 50.2 (per 100,000 men); Norway, 25.0 to 43.8; Finland, 
17.6 to 3 6 . 1 ; Denmark, 17.7 to 29.9 and in the UK (Birmingham), 17.3 to 
25.0 [32]. The age-adjusted incidence in the Southeast of The Netherlands 
has increased from 36 to 60 per 100,000 (ESR) men per year [13] since 
the mid 1970s (fig. 4). 
• 
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al. 1995 [13], source: Eindhoven Cancer Registry). 
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According to the International Prostate Health Council approximate-
ly 89,000 new cases are diagnosed each year in the five major European 
countries, where prostate cancer represents 13% of all male cancer 
incidences [33, 34]. In France, The Federal Republic of Germany, Italy 
(Varese) and Spain (Zaragoza) prostate cancer age-adjusted incidence rates 
have been reported as 25.7, 32.9, 22.8 and 20.7 per 100,000 men, 
respectively in 1992 (28]. At this time in Central and Eastern Europe age-
adjusted incidence rates varied between 10 and 15 per 100,000 men [35]. 
The lowest incidence rates have been observed in Asian popula-
tions: 8.2 in Bombay, around 6 in Japan and less than 2 in the Republic of 
China, although the rates in Asians increase after immigration to the 
United States [18, 36]. Indeed, migration studies demonstrate that men 
tend to take on the risk of their host country [15, 16, 37] (fig. 5). 
US, SEER: Black 
US, SEER: White 
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France, Bas Rhin 
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Fig. 5. Age-adjusted rates of prostate cancer per 100,000 men, standardised to the 
world population (adapted from Parkin 1992 [32]). 
11 
Chapter 1 
Prevalence 
Based on its high incidence, it can be assumed that prostate cancer 
is one of the most prevalent forms of cancer in men. The exact prevalence 
of prostate cancer, however, remains difficult to quantify. In prostate 
specimens obtained from TURs, prostate cancer is detected in approxi-
mately 10-12%; while at autopsy, the disease is found in up to 15-30% of 
men over the age of 50 years [36, 38]. Overall prevalence in 1993 was 
estimated at approximately 942,000 world-wide and is expected to reach 
nearly 1.6 million by the year 2007 for an average annual population 
growth of 3.8% [34]. In The Netherlands, a prevalence of 253 per 
100,000 men can be calculated and about 18,000 men diagnosed with 
prostate cancer in 1995 are alive. Taking into account that 2100 men died 
each year it can be concluded that a large percentage must have disease 
which progresses slowly [13]. 
The age-specific prevalence of clinical prostate cancer varies widely 
in different geographical areas, i.e. between Western countries and 
Oriental countries [15, 37, 39]. However, the age-specific prevalence of 
histological prostate cancer (at autopsy) is uniform world-wide, and this 
frequency is many times greater than would be expected from the inci-
dence and mortality of clinical prostate cancer [15, 25, 35, 37, 38]. 
In the United States, it is calculated that approximately 11 million 
men over 45-50 years of age will have histological prostate cancer. Five 
million men are in the 55-69 years age group and 1.4 million of these will 
have prostate cancer. During a 50-year-old mane lifetime, the risk of 
having a prostate cancer develop that will be detected at autopsy is over 
14 times greater than the risk of dying from the disease [40]. 
Prevalence of Latent Cancers 
The overall prevalence of small latent cancers has been reported at 
about 12% and this was unrelated to age or area. In marked contrast, the 
frequency of medium and large latent cancers increased steadily with age 
in 5% of men dying between the ages of 45 and 54 years and 29% of 
men dying at ages greater than 75 years. The frequency of latent prostate 
cancers for each of the areas in this study was the same ranking as that 
for the mortality from prostate cancer and the clinical incidence of prostate 
cancer for each of the areas. Breslow et al. concluded that the demo-
graphic behaviour of latent cancer of the prostate is similar to that of 
clinical cancer in its geographical and age distribution [15]. 
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Similar to these findings, in other studies advancing age is accom-
panied by a steady increase in larger latent cancer of the prostate, the rate 
of increase being roughly four-fold over 40 years and this increase is more 
rapid than for any other form of cancer [25, 38]. 
Franks in 1954 [41] and Scott et al. in 1969 [38] and other 
investigators have shown that there is a negligible incidence of prostate 
cancer in the 40-49 year age group in contrast to Moore in 1935 [42]. 
Every decade of ageing thereafter nearly doubles the incidence of such 
latent tumours from 10% in men in their 50s, to 70% in men in their 80s. 
Most of such cancers remain clinically undetected and unimportant for 
decades [38, 41]. 
Recently, Sakr et al. reported latent cancers of the prostate in 27% 
of 30-39 year olds and in 34% of 40-49 year olds [24]. These tumours 
were histologically defined as prostatic intraepithelial neoplasia (PIN), 
which is thought to be a precursor for the onset of prostate cancer in 5-10 
years. 
Mortality 
Prostate cancer is a disease of old men, more of whom die with the 
disease than from the disease (fig. 3) [10]. For a 50-year-old man, the 
lifetime risk of developing cancer in the prostate is about 42%, the risk of 
developing the disease clinically is 6 . 1 % at the age of 60 years, and the 
risk of dying from the disease is 2.9% [39, 40, 43]. 
Mortality rates for prostate cancer, standardised to the world 
population, ranged from 1.3 to 22.1 per 100,000 men, as compiled from 
causes of death reports from the respective governments of several 
countries [15]. Hence, prostate cancer is a significant health problem. One 
per cent of all deaths in males are accounted for by this disease; and about 
13% of all cancer deaths can be explained by prostate cancer in most 
Western countries [4, 33]. 
In the United States, between 1975 and 1979 and between 1987 
and 1991 the age-adjusted incidence of all cancers combined increased by 
18.6% (391.2 to 464.0 per 100,000 person years). However, the mortal-
ity rates were relatively stable with a 3 . 1 % increase for all cancers. In 
men older than 55 years, the incidence of prostate cancer increased by 
65.6% while mortality due to prostate cancer increased by 14% [4]. 
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In 1988, death rates were 15.7 for men in the United States 
compared with 3.5 for men in Japan. However, when the mortality ratio 
(mortality divided by incidence) was examined nearly the opposite geo-
graphic distribution was obtained: i.e. a Japanese man diagnosed with 
prostate cancer has a much higher chance of dying from this disease than 
an African American in the area of Atlanta, Detroit or San Francisco, 
2.5/5.1 versus 45.8/108.9 (relative risks 0.49 versus 0.42, respectively) 
[22]. 
In the United States, total cancer death increased from 15,900 in 
1965 to an estimated 41,400 in 1996 (table 1) [14]. This is an increase of 
3.2% per year. If the current trends continue, the death rate in the United 
States will increase by approximately 50% over the next 15 years as the 
incidence rate climbs in proportion to the average age of the population 
[14]. However, although the New Mexico Tumour Registry reported an 
increase of prostate cancer incidence from 1989 to 1992, from 1992 to 
1993 incidence rates unexpectedly decreased from 203 to 158 per 
100,000 in non-Hispanic whites and from 125 to 119 per 100,000 in 
Hispanics [44]. 
In Europe, nearly 304,000 men had prostate cancer and approxi-
mately 33,000 died of prostate cancer in 1992 [33, 34]. In most European 
countries, mortality from prostate cancer has risen over the past decade. 
As an example, the trend in mortality from prostate cancer in The Nether-
lands is shown in table 2 [45]. 
In the southern countries of Italy, Spain and Portugal the incidence 
of prostate cancer is increasing more rapidly than elsewhere in Europe with 
more than 25% every 5 years; however, mortality is actually falling 
steadily in these countries. This is in contrast to other European countries, 
except for Romania where since the mid 1960s mortality has fallen 
significantly [46]. 
Risk Factors 
Risk factors for prostate cancer are primarily age, African American 
race and family history. This group of prostate cancer patients represents a 
relatively small proportion of the total prostate cancer disease burden, 
therefore, an understanding of other risk factors is also important [22, 47-
49]. 
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Table 2. Mortality from prostate cancer in The Netherlands per 100,000 men (adapted 
from Van der Gulden et al. 1994 [45]) 
Age (years) 
Period 
1950-
54 
1955-
59 
1960-
64 
1965-
69 
1970-
74 
1975-
79 
1980-
84 
1985-
89 
1989-
91 
N 
20.5 
22.0 
24.0 
26.3 
25.5 
27.6 
28.4 
30.6 
28.5 
55-59 
8.0 
7.6 
8.4 
9.0 
9.2 
8.9 
9.5 
11.1 
12.6 
60-64 
24.6 
21.7 
21.2 
25.5 
23.4 
24.4 
28.0 
32.1 
34.0 
65-69 
61.4 
60.8 
62.8 
64.4 
62.0 
68.2 
72.2 
72.2 
71.7 
70-74 
120.1 
130.1 
126.9 
139.8 
132.8 
149.5 
151.5 
156.1 
162.8 
75-79 
250.6 
244.7 
273.1 
290.1 
279.9 
287.6 
293.2 
300.7 
309.5 
80-84 
351.2 
396.2 
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Age 
Prostate cancer increases faster with age than any other major 
cancer and with lengthening longevity the burden of illness of prostate 
cancer will increase in the future. Adenocarcinomas of the prostate can be 
detected with increasing frequency in prostates of individuals over the age 
of 40 years (fig. 6) [3]. This age-associated incidence increase is more 
striking if the risk of prostate cancer is high in the area. For example, the 
age-specific incidence curve is particularly steep in American Blacks. 
It is noteworthy that the age-related frequency of histological 
cancers is similar for numerous ethnic and racial groups in contrast to 
differences in the incidence of clinical prostate cancer [24]. Indeed, it is 
well established that there are similar age-specific prevalences of 
histological prostate cancer in the United States and Japan but marked 
differences for clinical prostate cancer [17, 37]. These data suggest that 
the initial rate of prostate cancer may be the same in these two continents 
but that there may be differences in the rate of progression to clinically 
evident disease [16, 18, 19]. As well as age, other risk factors are known 
to be involved in the clinical development of prostate cancer [37]. More-
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over, a rapid and progressive rise in the incidence of cancer with increas­
ing age suggests that the tissue is regularly exposed to a carcinogenic 
agent over a long period [50]. 
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Fig. 6. Age-specific incidence of prostate cancer and mortality per 100,000 men in 
The Netherlands 1991 (source: Eindhoven Cancer Registry 13]). 
A surprisingly high frequency of PIN and histological carcinoma of 
the prostate has been reported in young men [24). PIN was identified in 
0 % , 9%, 2 0 % and 4 4 % and small foci of histological cancer in 0%, 0%, 
2 7 % and 3 4 % of male patients in the second, third, fourth and fifth 
decades of life, respectively. It is plausible that small histological cancers 
and high grade PIN are linked to, and possibly progress to, clinically 
diagnosed larger neoplasms. 
Interestingly, Miller advocated recently that the number of cancers 
found in the prostates of 60-80-year-old Chinese men (33%) was approxi­
mately equal to the number in 40-49-year-old men from Detroit [51]. 
Similar data are emerging from a study performed on autopsy prostates 
from Vietnam. 
Ethnic Groups and Race 
Wide variations exist in the incidence and mortality rates of pros­
tate cancer among ethnic groups world-wide. Historically, the African 
American population in Atlanta, the San Francisco Bay area and the United 
States as a whole (SEER) have had the highest incidence and mortality 
rates of prostate cancer per 100,000 men (108.9/45.8; 92.2/25 and 
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120.3/44.5, respectively). The geographic patterns of prostate cancer 
mortality in African Americans during the period 1970-1989 are presented 
in fig. 7 [52]. 
Fig. 7. Prostate cancer in African Americans by state economic areas, based on 
National Center for Health Statistics 1970-1989 (adapted from Dosemeci 
19941521). 
In the United States the overall incidence rate among African 
Americans is 82 per 100,000 men in contrast to the incidence of 61.8 in 
American whites, and the chance of being diagnosed with prostate cancer 
is 9.6% for African Americans and 5.2% for American whites [22]. The 
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age-adjusted relative risk for prostate cancer in African Americans is 1.8 
times that of American whites even when adjusted for socio-economic 
status [21]. Related to prostate cancer-specific mortality the risk in African 
Americans is 3% over the course of a lifetime, while for American whites 
the risk is only 1.4%. These data translate into an 85% greater chance of 
an African American being diagnosed with prostate cancer and a 114% 
greater chance of an African American dying of prostate cancer. 
The 5-year survival rate for prostate cancer diagnosed in the United 
States between 1974 and 1985 was 62% for African Americans com-
pared with 72% for American whites. During the period 1983 to 1987, 
these percentages improved to 65% for black Americans and 78% for 
American whites, suggesting that both groups are diagnosed and treated 
on a comparable base. These data further indicate that the outcome for 
African Americans is worse than for American whites [22]. African 
Americans present with prostate cancer at a younger age, with a higher 
grade and later stage of the disease and generally have a greater delay in 
time to diagnosis [23, 53]. For example, Brawn et al. demonstrated, in 
close agreement with other studies, that 62% of American whites pres-
ented with localised prostate cancer compared with 35% of African 
Americans: metastatic disease was present in 53% of African Americans 
compared with 28% of American whites [22,54]. There is no evidence 
that stage for stage black men are treated differently than white men. 
Recently, Pienta et al. and the American College of Surgeons, taking into 
account stage-matched survival in African Americans compared with 
American whites with prostate cancer, confirmed a stage-for-stage 
survival disadvantage as an effect of age and race [55]. It is probable, 
therefore, that racial differences in prostate cancer survival may reflect 
differences in tumour biology. 
Japanese Americans show substantially higher mortality rates 
compared with mortality rates in Japan. A similar increase in prostate 
cancer mortality associated with immigration to a higher rate region has 
been seen for Polish immigrants in the United States. These geographical 
patterns of risk may suggest that the risk of disease is environmentally 
determined and that some change in culture or exposure accompanying 
migration may alter risk [15]. 
Familial Prostate Cancer 
Why has the incidence of prostate cancer in male relatives of 
patients with prostate cancer increased? Numerous case-controlled studies 
have attempted to address this question. 
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An early study in 1960 by Woolf on the Utah Mormon population, 
using vital statistics and death certificates, demonstrated a three-fold 
increase in risk in first degree relatives of men who died of prostate cancer 
[56]. In the 1980s, Meikle found that brothers of probands with prostate 
cancer diagnosed before the age of 62 years, had a four-fold relative risk 
of developing prostate cancer [57]. In a similar study around this time. 
Cannon et al. reported cases of prostate cancer in 2824 Utah men, and 
using computerised genealogy records found that the kinship coefficient 
for these prostate cancer cases was significantly higher than for controls 
[58]. 
The largest hospital-based case control study of 691 men with 
prostate cancer and 640 spouse controls to assess the risk of developing 
the disease in men with a family history of prostate cancer was reported 
by Steinberg et al. [59]. There was a trend of increasing risk in that men 
with two and three first-degree relatives affected had a five- and 11 -fold 
increased risk of developing prostate cancer, respectively. 
Men with a family history of prostate cancer have an age-depend­
ent significantly increased prostate cancer risk [60] and should be advised 
to have appropriate screening tests (fig. 8). It is advocated in the United 
States that men with a positive family history of prostate cancer, after the 
age of 40 years, should undergo a DRE and serum PSA monitoring yearly. 
No additional first-degree 
relatives affected 
One or more additional 
first-degree relatives affected 
и 
о 
JÉ 
S2 ir 
50 60 70 
Age at diagnosis of initial case 
'Reference group: Risk is set at 1.0 for comparison with other groups. 
However, men in this group may have elevated risk compared with the general population. 
Fig. 8. Estimated risk ratios for first-degree relatives of men with prostate cancer 
(adapted from Walsh 1994 [60]). 
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For familial clustering of prostate cancer two factors are important: 
early age at onset of the disease and the number of multiple affected 
family members. In the study by Steinberg et al. [59] the mean age of 
onset of the first prostate cancer occurred at an age of 54.9 years, in 
contrast to the mean age at diagnosis of 70 years in the general popula-
tion. Moreover, Carter et al. reported a relative risk of prostate cancer with 
one first-degree relative affected of 40% before the age of 53 years, 25% 
between the ages of 53 and 65 years, 14% after the age of 65 years and 
9% by the age of 85 years [61]. The relative risk of developing prostate 
cancer was calculated to be two times higher for persons with one first-
degree relative affected (father, brother); 1.7 for one second-degree 
relative affected (grandfather or uncle, paternal and/or maternal); and 8.8 
for one first- and second-degree relative affected. No differences were 
seen in maternal vs paternal origins suggesting that the susceptibility 
genes can be transmitted by women as readily as men. 
Prostate cancer may be seen as a multistep carcinogenesis and 
clustering can be explained by Mendelian inheritance. The estimated 
cumulative risk of developing prostate cancer is 88% for carriers compared 
with 5% for non-carriers. In an unselected Swedish twin population 
involving 4840 male twin pairs, 458 prostate cancers were identified and 
among these 16 monozygotic and six dizygotic twin pairs were concordant 
for prostate cancer [62]. It was concluded that genetic factors might be of 
importance in the development of prostate cancer [62]. Indeed, segrega-
tion analysis has revealed an autosomal dominant gene, a rare (q = 0.0030) 
high-risk allele, leading to an early onset of prostate cancer: and chromo-
somes 8p, 10q and 13q are frequently mutated or deleted [63]. 
Dietary Factors 
Based on epidemiological research and migrant studies it is pre-
sumed that the development of prostate cancer is associated with dietary 
components. Significant differences in the incidence of prostate cancer are 
well documented between West and East. For example, the age-adjusted 
rate of clinical prostate cancer for African Americans in California is 100 
and the rate for native Chinese in Shanghai is approximately 0.5 per 
100,000 men [64]. The diet of Japanese men is low in animal fat, and 
fibre (essentially vegetables and fruit) is high. This diet may relate to the 
lower incidence of clinical prostate cancer in the East compared with the 
West. Western and African American and American white men have a high 
animal fat intake but a low fibre intake [65, 66]. 
20 
Epidemiology of Prostate Cancer 
Laboratory studies have investigated the association between 
plasma lipid levels, particularly linolenic and alpha-linolenic acids. Linolenic 
acid is found predominantly in vegetable-oils, and alpha-linolenic plasma 
levels positively correlate with meat intake. Although low plasma levels of 
alpha-linolenic acids might be associated with a reduced risk of prostate 
cancer (independent of high meat intake), high linolenic plasma levels and 
marine fatty oils were not associated with increased risk. It is hypothe-
sized that the development of prostate cancer is 2-3 fold increased in men 
with high alpha-linolenic acid levels and low levels of linolenic acids [64]. It 
was therefore suggested that animal saturated fat intake: 1) may act as 
the environmental promoter responsible in part for the extreme variation in 
prostate cancer progression; 2) is positively associated with the number of 
deaths from prostate cancer world-wide; and 3) is linked to the changes in 
risk that follow migration [67, 68]. 
Studies on the migration of Japanese and Chinese people to Hawaii 
and then to the mainland of the United States support the concept that 
dietary factors influence disease aetiology and that the mortality rate for 
prostate cancer will increase towards that of indigenous Americans within 
a few generations. Moreover, there is a rising incidence of prostate cancer 
in the East with the diet becoming more Westernised [16]. 
The traditional Asian diet has a high legume content, particularly 
beans, soya, lentils and chick peas, these vegetables being considered as 
the major source of fibre. The health benefit is probably related to non-
nutrient components such as isoflavonoids and lignans, particularly found 
in soyabean, tofu, grains, flaxseed, rapeseed, whole cereals and aspara-
gus. These foods are metabolised by the normal gut microflora to produce 
diphenolic weak oestrogens such as the lignan enterolactone and the 
isoflavonoid genistein. Weak oestrogens have agonistic or antagonistic 
properties like the weakly oestrogenic tamoxifen used in the management 
of breast cancer. 
Supplementation of the Western diet could provide considerable 
health gain in the prevention of prostate cancer, as extra fibre might 
override the carcinogenic action of a high fat intake [66]. However, it is 
generally thought that a high fibre and low fat intake is more likely to 
protect men from prostatic cancer [49, 64, 69]. 
Vitamin A 
Vitamin A, and its precursor beta-carotene, are essential for normal 
epithelial cell proliferation and differentiation [70-72]. Vitamin A, present in 
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plants as beta-carotene, reduces the risk of prostate cancer in Japanese 
men who eat daily vegetables high in vitamin A content [69, 72-74]. 
There is, therefore, a strong indication that a diet rich in beta-carotene is 
protective. In contrast, vitamin A intake from animal sources increases the 
risk of prostate cancer [70]. 
In many studies the association between vitamin A and prostate 
cancer does not occur in certain age groups, mainly those over the age of 
70 years. However, in a prospective study of 84 elderly men who had 
developed prostate cancer the correlation was apparent [74]. 
Recent data suggest that individuals with low serum retinoid levels 
(a precursor of vitamin A) or low dietary intake of foods containing 
retinoids have an increased risk of prostate cancer [75]. Moreover, it has 
been demonstrated that retinoid acid mediates a downregulation of 
saturated fatty acid and an upregulation of unsaturated fatty acid in 
humans with prostate cancer [76]. 
Vitamin D 
The most important source of vitamin D is the photosynthetic 
reaction of 7-dehydrocholesterol with sunlight in the skin. To a lesser 
extent vitamin D is obtained in the diet, particularly from foods such as 
milk, fish or vitamin supplements. The possibility that progression of 
prostate cancer may be a result of vitamin D deficiency has been postu-
lated [77-79]. Investigators suggest that the protective effect of ultraviolet 
light may be mediated through vitamin D. This hypothesis is based on the 
fact that the excess risk among African Americans can be attributed to the 
inhibition by cutaneous melanin of vitamin D synthesis in the skin. African 
Americans absorb less ultraviolet light and have lower vitamin D levels 
[80]. Interestingly, ageing, a risk factor for prostate cancer, is typically 
accompanied by low serum levels of vitamin D. Also Asians, who have a 
low risk of prostate cancer, have a diet which is high in fish oils and is 
consequently rich in vitamin D. 
Vitamin D inhibits the growth of some prostate cancer cell-lines and 
causes LNCAP cells to increase their production of PSA. Prostate cancer 
cell-lines do vary in their rate of metabolising vitamin D and this may 
determine whether or not their growth is inhibited [80, 81]. 
Other studies, however, provide little support for the hypothesis 
that vitamin D metabolite levels are associated with subsequent risk for 
prostate cancer [82]. 
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Industrial Pollution, Occupation and Trace Elements 
Industrial pollution has been implicated in the aetiology of prostate 
cancer since it appears to be more common in urban than in rural popula-
tions [83]. Several industrial occupations are associated with a significant 
risk of prostate cancer. Among the high-risk groups the significance of 
mortality is greatest in rubber and tyre workers. These workers are faced 
with a wide variety of environmental hazards from the complex manufac-
turing processes involved in this industry [84]. Farming has also been 
consistently identified as moderately increasing the risk of prostate cancer 
[85], although pesticide exposure is only weakly implicated [86]. 
Exposure (or dietary intake) of trace elements such as zinc and 
cadmium plus radiation exposure directly correlate with mortality from 
prostate cancer, as well as cancer of the bowel and breast [87, 88]. Zinc 
is a necessary trace element in multiple intracellular metabolic pathways, 
for example, polymerases require zinc for the replication and repair of DNA 
and RNA [89]. In men with prostate cancer, prostate gland levels of zinc 
are significantly lower than in the normal prostate gland, whereas in the 
hyperplastic prostate gland elevated levels of zinc are found [90, 91]. 
Cadmium increases the risk for prostate cancer by interacting with zinc. 
In industrial areas there are marked racial differences in socio-
economic status and many studies have examined socio-economic factors 
and cancer incidence among American blacks and whites. The results of 
these studies are controversial although the African Americans have a 
higher incidence of prostate cancer [21 , 92, 93]. 
Hormones 
Since hormones are known to have stimulatory effects on the 
development and growth of prostate epithelium cells and small muscle 
cells it is presumed that they play an important role in the development of 
prostate cancer [94]. This hypothesis is based on: 1) eunuchs and cas-
trated men do not develop prostate cancer [95]; 2) the striking degression 
induced in many cases of prostate cancer by maximum androgen blockade 
[96, 97]; 3) the high rate of conversion of testosterone to 
dihydrotestosterone (DHT) and the unusually high uptake of testosterone 
by the prostate gland. Cell division in the prostate is controlled by testos-
terone after intracellular conversion, regulated by 5-alpha reductase to 
DHT [98]. The level of testosterone in neoplastic tissue has been found to 
be higher than in the hyperplastic prostate, although the levels of DHT 
were higher in the hyperplastic gland [99, 100]: and 4). The development 
of tumours in the dorsal prostate lobe has been demonstrated in NOBLE 
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rats following prolonged systemic stimulation with androgens [101, 102]. 
In reality, human studies have shown variability in circulating testosterone 
levels when measured against prostate cancer risk. 
It is noteworthy that African American men have higher testoster-
one levels than American whites, and serum androgen levels may be 
higher in African American women during pregnancy leading to a greater 
exposure of the foetus to androgen during the development of the prostate 
[103]. This androgen exposure in African Americans, which is higher than 
in other groups, is thought to result in increased cellular proliferation, 
leading to a higher risk of malignant transformation [104]. This might 
explain the 60-80% difference in prostate cancer rates between American 
blacks and whites [105]. 
Furthermore, African American and American white men have 
higher 5-alpha reductase enzyme levels compared with native Japanese 
and Chinese men. This difference may contribute to the lower incidence of 
prostate cancer observed in Japanese men [106, 107]. Low androgen 
levels are also found in Japanese and Chinese men, probably because total 
and free testosterone serum levels are generally decreased with high fibre 
and low fat diets [108]. 
Other hormones, especially prolactin and oestrogens, may also play 
a defined role in prostate metabolism [100, 109]. It has been demon-
strated in an autopsy study that there was a lower incidence of prostate 
cancer in cirrhotic (3.3%) than in non-cirrhotic (9.0%) patients, suggesting 
that prolonged exposure to high oestrogen levels could prevent or delay 
the development of prostate cancer [110, 111]. 
A possible drawback to endocrine studies in this field is that most 
have been carried out after the disease has been diagnosed, and it is 
probable that critical changes may have taken place many years before 
clinical symptoms appeared. 
Prostatic Hyperplasia and PIN 
An association between prostate cancer and benign prostatic 
hyperplasia (BPH) remains controversial [112, 113]. There are a number of 
similarities between prostate cancer and BPH: 1) the parallel increase in 
prevalence with age; 2) both require androgens for growth and develop-
ment and 3) both respond to antiandrogen treatment regimens. 
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In all age ranges, BPH is present in around 80% of patients with 
prostate cancer [72, 114, 115]. The age-adjusted death rate for prostate 
cancer is 3.7 times greater in BPH patients, and in a retrospective study 
the relative risk of developing prostate cancer was calculated as 5.1 in 
patients previously treated for BPH [11]. However, Greenwald et al. were 
unable to confirm these data in a prospective study, finding a relative risk 
of prostate cancer of 0.88 in BPH patients [113]. Bostwick has calculated 
from a review of the literature that the incidence of prostate cancer in 
patients with nodular hyperplasia is 2.96% [114]. 
Importantly, a recent Swedish study has confirmed previous studies 
that TUR of a clinically benign prostate does not promote the development 
of clinical prostate cancer [115]. 
In the pathogenesis of prostate cancer a number of steps can be 
identified by morphological and functional criteria. Bostwick differentiates 
between three putative pre-malignant lesions of the prostate: PIN 1, PIN 2 
and PIN 3, which have different morphological characteristics. During the 
step-by-step carcinogenesis it is not entirely clear whether transition from 
PIN to focal carcinoma, to infiltrating adenocarcinoma of the prostate 
occurs [116]. 
Meyers et al. have published results on the cellular distribution of 
the erbB-3 protein (P160 erbB-3) and the erbB-2 protein (P185 erbB-2) in 
various stages of prostatic adenocarcinoma [117]. Within benign glands 
immunostaining for P160 erbB-3 or P185 erbB-2 was strongest in the 
basal cells and was typically absent or weak in the luminal (secretory) 
cells: expression of both proteins was localised to the cell membrane. In 
PIN lesions immunostaining for P160 erbB-3 and P185 erbB-2 was strong 
and frequently within the cytoplasm and cell membrane of PIN luminal 
cells. High expression and subcellular distribution of both proteins was 
seen in malignant cells and represented early events in the development 
and progression of prostatic adenocarcinoma. 
Sterilisation and Circumcision 
Conflicting reports have been published regarding the potential 
contribution of vasectomy to prostate cancer risk. For example, Sidney 
reported in a large study a relative risk of 1.0 with respect to matched 
controls [118], whereas other smaller studies have indicated an increased 
relative risk of 1.4 to 1.7 for men reporting vasectomy up to 20 years 
before being diagnosed with prostate cancer [119, 120]. Recently, 
Giovannucci et al. confirmed in both a prospective study and a retrospec-
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tive study an association between years since vasectomy and prostate 
cancer: the relative risks were 1.85 and 1.65, respectively [121, 122]. 
Although controversy still exists regarding the significance of these 
findings and their long-term implications [123], the National Institute of 
Health has reviewed all of the published studies and concluded that the 
correlation is too weak, that detection bias cannot be ruled out and that 
there is insufficient evidence to recommend a change in clinical or public 
health practice at this time [124, 125]. 
Other Risk Factors 
A number of other risk factors have been reported in relation to 
prostate carcinoma such as lifestyle, religion and material status [126]. 
For example, in a case-controlled study in Southern California, a past 
history of venereal disease was associated with a high risk of prostate 
cancer in both blacks and whites: with relative risks of 2.3 and 1.7, 
respectively [65]. 
In addition, alcohol, tobacco and obesity have been reported to 
influence serum testosterone levels [35, 70, 127-129]. Alcohol has an 
acute depressant effect on testosterone levels and a small non-significant 
increase in prostate cancer risk is evident. Cigarette smokers have been 
reported to have higher testosterone levels than non-smokers but this has 
no effect on their risk status [119]. Obese men have been reported to have 
lower circulating testosterone levels than thin men but again no clear 
association has been found between various measures of obesity and 
prostate cancer risk in men [130]. 
Metastatic Versus Localised Prostate Cancer 
Over recent years there has been a very apparent change in the 
percentage of patients presenting with locally advanced and/or metastatic 
prostate cancer compared with localised disease. In the 1960s only 10% 
of all patients had localised disease yet at the beginning of the 1980s this 
percentage was about 15%. 
Since 1986, several local divisions of the Regional Institute for 
Cancer Registration in The Netherlands have registered all prostate cancer 
patients. In the Integrated Cancer Centre South (IKZ) 40% of prostate 
cancers registered were localised [131]. It was also noticed that the 
incidence of prostate cancer increased from 50 per 100,000 men in 1986 
to 60 per 100,000 in 1990, a rise mainly due to an increase in localised 
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(organ-confined) tumours (fig. 9). These findings concur with data pres­
ented in the United States [132, 133]. 
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Fig. 9. Trends in stage distribution (adapted from Coebergh et al. 1995 [13], source: 
Eindhoven Cancer Registry). 
In areas where screening has been performed the percentage of 
localised tumours has significantly increased, for example in New Mexico 
from 77.5% to 80.5% over a 5-year period [134]. Early detection pro-
grammes clearly improve lower stage distribution in contrast to less than 
10 years ago when a majority of prostate cancers were locally advanced 
and/or metastatic [28]. 
Interestingly, although the percentage of metastatic disease in the 
overall prostate cancer population has decreased during the past 15 years, 
there is still no apparent decrease in mortality from prostate cancer. It is 
obvious that the man with locally advanced and/or metastatic disease 
nowadays has a different soft and/or bone tumour load than the man 
suffering from the same disease 30 years ago. 
Conclusion 
Prostate cancer is an epidemic world-wide disease. The incidence 
of clinical prostate cancer has increased dramatically in past years due to 
greater awareness of the male population and increased use of screening 
tests. The most likely explanation for the wide divergence between the 
incidence rates in several global areas is a difference in diagnostic practice 
with regard to prostate cancer. In the United States the incidence and 
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mortality compared with The Netherlands was 165,000/35,000 and 
3,500/1,700, respectively, with incidence to mortality ratios of 4.7 and 
2 .1 , respectively. It is stated that: 'if the current trends continue in the 
United States, the death rate will increase by approximately 50% over the 
next 15 years as the incidence rate climbs in proportion to the average age 
of our population [14]. However, other investigators are convinced that the 
incidence of prostate cancer will 'level off! Although mortality rates from 
prostate cancer have risen slightly this rise is far behind the sharp increase 
in incidence observed in the past. 
It is widely assumed that latent prostate cancer occurs at a uniform 
frequency around the world. However, geographical variations in the 
incidence of clinical prostate cancer are considerable, with a 120-fold 
greater incidence in the United States than in China. Apart from age, race 
and possibly family history, few risk factors are related to clinical prostate 
cancer. The main environmental risk factors are linked with a Western 
lifestyle, for example a high intake of dietary fat, which is thought to play 
an important role in the multistep carcinogenesis of prostate cancer. If it is 
firmly established that fat intake plays a major role in the development and 
progression of prostate cancer it would explain the world-wide geographi-
cal variation in the incidence of prostate cancer. Such confirmation might 
lead to the development of low cost and low-risk interventions to reduce 
disease progression to clinical cancer among men with latent disease, and 
may improve survival among men with clinical disease. 
Nowadays the urologist is faced with an increasing incidence of 
less advanced prostate cancer. Whereas in the past the majority of 
prostate cancer patients presented with extensive soft tissue lesions and 
bone metastasis, more and more patients are now seen with less advanced 
disease. This trend is likely to continue if screening programmes are 
introduced in many countries. 
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Abstract 
Hormonal therapy represents first-line treatment for patients with 
advanced prostate cancer. Generally, surgical castration is viewed as the 
'gold standard' but carries with it a psychological effect. Medical alterna-
tives include LHRH analogues, antiandrogens, and oestrogens, though the 
last of these is associated with cardiovascular problems. For complete 
androgen ablation, it is generally believed that androgens of both testicular 
and adrenal origin need to be blocked. Combined androgen blockade (CAB) 
by the addition of an antiandrogen to castration (medical or surgical) may, 
therefore, be an appropriate treatment for advanced prostate cancer. 
Recent trials have shown that combined androgen blockade may have 
treatment advantages compared with castration alone, and these benefits 
are greatest in patients with minimal metastatic disease. For these patients 
CAB may now be considered as standard therapy. In the treatment of non-
metastatic disease, recent trends based on the experience gained in 
advanced prostate cancer, include the possible use of hormonal therapy in 
the neoadjuvant and adjuvant settings along with prostatectomy or 
radiotherapy. There is also growing interest in the use of intermittent 
rather than continuous hormonal therapy. New treatments offer an increas-
ing range of management options to help improve the quality of life of 
prostate cancer patients. 
Introduction 
Prostate cancer has become one of the most common malignancies 
in the male population world-wide and in many countries of the Western 
world it now represents the most common, newly diagnosed cancer in 
men. In the European Community, around 35,000 deaths were attributed 
to prostate cancer in 1990 and around 95,000 new cases are diagnosed 
each year [1]. In the United States the National Cancer Institute has 
estimated that 32,000 deaths were due to prostate cancer in 1991 [2]. In 
1994, more than 13% of all cancer deaths in the United States were due 
to prostate cancer and 200,000 new cases were diagnosed [3].Most cases 
of prostate cancer are diagnosed from the 6th decade of life; however, the 
incidence of the disease increases between 60 and 80 years of age [4]. 
Prostate cancer growth is stimulated by androgens, principally 
testosterone. Therefore, androgen deprivation is an essential component of 
a management strategy for prostate cancer. In 1941, using surgical 
castration or medical castration with oestrogens, Huggins and Hodges[5] 
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and Huggins et al.[6] were the first to demonstrate that androgen depriva-
tion produces a significant tumour response in most patients with prostate 
cancer. 
Since this pioneering work, the first-line treatment of advanced 
prostate cancer has been hormonal. Bilateral orchidectomy is still generally 
accepted as the 'gold standard' of hormonal treatment for prostate cancer, 
although it is unacceptable in up to 78% of patients primarily because of 
psychological problems [7,8]. The use of oestrogens has been limited, 
mainly due to their cardiovascular and feminising side effects, and newer 
drugs, such as LHRH analogues and antiandrogens, are now used in 
preference to them. LHRH analogues cause a down regulation of pituitary 
LHRH receptors, thus suppressing the release of androgen from the testes. 
The resultant medical castration is equivalent to surgical castration but 
avoids the psychological trauma of surgery [9]. 
Although castration (orchidectomy or LHRH analogues) causes a 
reduction of about 90% in serum testosterone concentrations, the 
androgen biosynthesis in the adrenals which contributes about 8-10% of 
the total amount of androgens is not affected. This explains why castra-
tion has less effect on the main mediator of androgenic action in prostatic 
tissue, the active testosterone metabolite dihydrotestosterone (DHT): the 
concentration of DHT remains at approximately 40% of that in uncastrated 
men [10]. This illustrates the potential extra benefit of blocking androgen 
production by the adrenals - to create a completely androgen-free milieu -
in addition to castration [11]. 
Combined androgen blockade (CAB) is not a new concept. This 
approach was first achieved by hypophysectomy or bilateral 
adrenalectomy in 1945 [12,13], and later by adrenal biosynthesis 
inhibitors, in patients who relapsed after castration [14]. The drawbacks of 
these treatments discouraged the widespread use of CAB. The advent of 
antiandrogens, however, has made this a more acceptable approach. 
Drugs such as flutamide (Eulexin™, Schering-Plough International), 
nilutamide (Anandron™, Roussel), and bicalutamide (Casodex™, Zeneca 
Ltd.) antagonise the effect of androgen on the receptor and may have an 
advantage over other methods of androgen deprivation in that they block 
both testicular and adrenal androgens. 
Steroidal antiandrogens were first used in combination therapy with 
oestrogens or with bilateral orchidectomy by Bracci [15] and Bracci and Di 
Silverio [16] in the 1970s. In 1982, Labrie et al. [17] reported promising 
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results in a small open study for the treatment of advanced prostate 
cancer using combination therapy, with a nonsteroidal antiandrogen as an 
antigonadotrophic agent in place of oestrogens and an LHRH analogue. 
Since then, further studies, comparative and placebo-controlled, have been 
conducted to verify the efficacy of CAB. 
This review sets out to examine current hormonal treatments for 
advanced prostate cancer, considering advances and trends in therapeutic 
approaches. 
Available Treatments 
Orchidectomy 
Orchidectomy produces symptomatic relief in 70-80% of patients 
with advanced prostate cancer [9]. Pain from bone metastases, if present, 
disappears in 80-90% of patients, and the size of the prostate tumour 
shrinks rapidly (within 4-6 weeks) [18]. This approach is, therefore, 
particularly effective in patients with secondary urinary outlet obstruction. 
Furthermore, orchidectomy represents the treatment of choice for immi-
nent spinal cord compression and bilateral hydronephrosis, two life-threat-
ening complications of prostate cancer [19]. 
Surgical castration is a relatively simple, safe, and inexpensive 
procedure, which can be performed on an outpatient basis, but it can 
cause psychological problems [8]. The subcapsular technique, where only 
the functional part of the testicle is removed, can be used to avoid the 
trauma of castration. Other disadvantages of surgical castration are the 
loss of libido and erectile function and its irreversibility especially in 
nonhormone responsive prostate cancer. Hot flushes may also be a 
distressing side effect in around 70% of patients [20], although these can 
be alleviated by cyproterone acetate or low dose oestrogen therapy [21]. 
Oestrogens 
The therapeutic effect of oestrogens is exercised indirectly, by 
suppressing the pituitary gland, inhibiting the release of luteinizing hor-
mone (LH), and so reducing the synthesis and secretion of testosterone by 
the testes. 
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Together with surgical castration, oestrogens such as diet-
hylstilboestrol (DES), ethinyloestradiol and conjugated oestrogens, were 
once thought to be the mainstay of primary hormonal therapy for prostate 
cancer. These oestrogens are orally active, inexpensive, and as effective 
as orchidectomy in lowering plasma levels of testosterone to castrate 
levels [22]. However, in clinical studies their use has been associated with 
mortality and morbidity due to cardiovascular complications, including 
increased incidence of thromboembolism and fluid retention, breast 
tenderness and gynaecomastia, gastric disturbances and impotence [22-
24]. 
Following their preliminary report that DES (1 mg/day) was as 
effective as DES (5 mg/day) but with less cardiovascular toxicity, the 
European Organisation for Research and Treatment of Cancer (EORTC) 
genito-urinary group compared the lower dose of DES with orchidectomy 
(EORTC 30805). DES (1 mg/day) was found to be as effective as 
orchidectomy and although it was associated with fewer deaths related to 
malignant disease than higher dose therapy, in this study DES (1 mg/day) 
was associated with slightly more deaths due to cardiovascular causes 
[25]. 
Recent clinical studies have assessed the use of DES in eliminating 
the flare reaction seen when treatment with LHRH analogues is started. 
Four weeks of pre-treatment with DES (0.1 mg daily) and cyproterone 
acetate (100 mg daily) can eliminate the initial acute increase in serum 
testosterone associated with administration of LHRH analogues [21]. It can 
also reduce 'menopausal' symptoms (hot flushes and sweats) following 
treatment with orchidectomy or LHRH analogues [26]. 
Parenteral administration may be important for oestrogen therapy. 
Recent results of a clinical study using polyoestradiol phosphate suggest 
that this route of administration could avoid the cardiovascular complica-
tions associated with oral administration [Ruutu, unpublished results]. 
LHRH Analogues 
LHRH analogues such as buserelin, leuprolide and goserelin acetate, 
represent medical alternatives to surgical castration. The efficacy of LHRH 
analogues with respect to response rate and survival is equivalent to both 
surgical castration and oestrogen therapy [9, 20, 27]. However, their use 
allows reversible castration, and they lack the cardiovascular problems 
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associated with oestrogens. A temporary worsening of symptoms, mainly 
bone pain, in up to 5% of patients is thought to be associated with the 
initial increase in circulating testosterone [27, 28]. Concomitant 
antiandrogen or simply a temporary increase in analgesic use can reduce 
the incidence of this phenomenon. Other side effects of LHRH analogues 
are comparable to orchidectomy, with similar loss of libido and impotence, 
and incidence of hot flushes [20]. Advantages of LHRH analogues include 
good tolerance and less psychological impact as compared with surgical 
castration. LHRH analogues are usually administered by monthly injections, 
however, 2- and 3-monthly formulations will become available shortly [29]. 
Antiandrogens 
Antiandrogens act by competitively blocking the binding of testos-
terone and its metabolite, DHT, to nuclear receptors in prostate cancer 
cells [24]. There are two classes of antiandrogens: steroidal and 
nonsteroidal. 
Steroidal antiandrogens 
Steroidal antiandrogens such as cyproterone acetate (CPA) have 
direct antigonadotrophic effects on the prostate gland, but also display 
systemic antiandrogenic properties due to their progestogenic effects [30]. 
Centrally, CPA exerts negative feedback on hypothalamic receptors, which 
leads to a reduction in the release of LH and FSH, and therefore, dimin-
ished production of testicular androgens [31]. Consequently, CPA has 
often been used as an oral monotherapy in advanced prostate cancer [32]. 
In comparative trials in patients with advanced prostate cancer, 
CPA (250 mg or 300 mg daily) was as effective as DES (3 mg daily) in 
terms of objective response, time to progression, and overall survival [32], 
and as effective as oestradiol undecylate in terms of clinical response and 
tumour regression [34]. 
Many of the side effects associated with CPA, such as increase in 
body weight, loss of body hair, reduction of adrenocortical function, and 
alteration of carbohydrate metabolism, are related to its progestational 
activity. Other side effects include hepatitis [34], hepatic tumours [35,36], 
alteration in hepatic function, gynaecomastia and thromboembolism [31]. 
Impotence and loss of libido also occur in 86% of patients, probably as a 
result of the reduced levels of serum testosterone in combination with 
pharmacological or surgical castration [33]. 
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Due to progestogenic activity of CPA patients rarely experience hot 
flushes. Therefore, patients undergoing pharmacological or surgical 
castration may be given CPA (150-300 mg daily) to prevent the develop-
ment of hot flushes [37]. The use of CPA should be questioned in patients 
with diabetes or with known cardiovascular risk. 
The optimal dose of CPA has not been established but patients are 
generally prescribed 200-300 mg daily. The problem of compliance with a 
multiple dosing regimen (2-6 tablets daily) should be considered in elderly 
men. 
Nonsteroidal antiandroqens 
Nonsteroidal antiandrogens such as flutamide, nilutamide, and 
bicalutamide show affinity for androgen receptors, but have no androgenic 
or progestational properties. 
The efficacy of the nonsteroidal antiandrogens flutamide and 
bicalutamide as monotherapy has been compared with that of 
orchidectomy, LHRH analogues or DES for patients with advanced prostate 
cancer [38-40]. The efficacy of nilutamide as monotherapy has only been 
investigated in small non-comparative studies [41]. Time to progression 
and overall survival were comparable with castration. 
As well as freedom from steroid-related side effects, nonsteroidal 
antiandrogens are less likely to interfere with sexual potency than steroidal 
agents. For example, libido and potency were maintained in 80-100% of 
advanced prostate cancer patients treated with flutamide or bicalutamide 
as monotherapy [42,43]. However, libido and potency are no longer 
maintained when nonsteroidal antiandrogens are used in combination with 
castration [44], which is the most common approach with current 
antiandrogens. 
Treatment with flutamide is associated with gastrointestinal 
disturbances, particularly diarrhoea, which may affect between 5 and 24% 
of patients [44-47] and lead to withdrawal from therapy in 6% of patients 
[47]. Flutamide can also cause hepatotoxicity. Wysowski et al. [48] have 
summarised all reports submitted to the FDA over a 3-year period of 
patients who had received flutamide in combination therapy and had 
developed hepatotoxicity. Of the 19 patients, 5 died of progressive hepatic 
disease. 
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Nilutamide is prescribed only in combination with castration. 
Treatment with nilutamide is reported to cause visual disturbances in up to 
30% of patients [41]. These manifest as delayed adaptation to darkness 
and impaired colour vision. Nilutamide causes mild nausea and vomiting in 
about 25% of patients, alcohol intolerance in 20-30% [41], and has been 
associated with interstitial lung disease (less than 2% of patients) [49,50]. 
Bicalutamide is associated with a low incidence of side effects 
apart from the expected pharmacological effects of gynaecomastia, breast 
tenderness, and hot flushes (these are reduced when combined with 
castration), which are associated with all nonsteroidal antiandrogens. In a 
double-blind comparative study, the incidence of diarrhoea was statistically 
significantly (p< 0.001) lower in bicalutamide patients (10%) than in fluta-
mide patients (24%) [47]. Fewer hepatic abnormalities were observed du-
ring treatment with bicalutamide than with flutamide and no cases of ful-
minant hepatic failure have been observed to date with bicalutamide [47]. 
Convenience of administration is an important consideration in an 
elderly population. Flutamide has a short half-life (5.2 h) and must be given 
three times daily. Bicalutamide and nilutamide have longer half-lives (1 
week and 56 h, respectively) which are compatible with once-daily treat-
ment. A simple once-daily dosing regimen has obvious advantages for 
enhancing compliance and maintaining consistent androgen blockade. 
Antiandrogen monotherapy is not currently available as standard 
therapy for advanced prostate cancer. As it offers the potential of conserv-
ing sexual potency, antiandrogen monotherapy may be useful in certain 
patients, for example, patients in whom retention of sexual potency is of 
overriding importance and a reduction in efficacy might be justifiable. 
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Combined androgen blockade 
Three large independent trials have shown significant benefits for 
CAB in terms of time to progression and survival, by comparison with 
castration (table 1) [44,51,52]. A meta-analysis of nilutamide trials 
involving 1,056 patients has also demonstrated a significant advantage for 
CAB, in time to progression and survival [53; Janknegt and De Géry, 
personal commun.]. A larger meta-analysis of over 5,000 patients (from 
trials of flutamide, nilutamide and CPA) has shown a trend towards a 
survival advantage for CAB compared with castration (5-year survival rates 
of 19.7% versus 16.7%) although the difference was not statistically 
significant [52]. Other trials (table 2) have failed to show any significant 
difference in either time to progression or survival between CAB and 
castration [25,37,46,55-67], but no study indicated that CAB was less 
effective than castration alone. 
Table 1. Randomised trials demonstrating and advantage for CAB 
Investigator 
Crawford et 
al. 1989 
Denis et al. 
1993 
Janknegt et 
al. 1993 
Bertagna et 
al. 1994 
Ref. 
No. 
44 
51 
52 
53 
Trial design 
leuprolide + flutamide 
versus 
leuprolide + placebo 
goserelin acet-
ate + flutamide 
versus 
orchidectomy 
orchidectomy + nilutamide 
versus 
orchidectomy + placebo 
orchidectomy + nilutamide 
versus 
orchidectomy + placebo 
η 
603 
310 
423 
1056 
Increased 
time to 
progression 
for CAB 
2.6 months 
(p = 0.039) 
12 months 
(p = 0.008) 
5.9 months 
(p = 0.005) 
16% 
(p = 0.05) 
Median survival 
advantage for 
CAB 
7.3 months 
(p = 0.035) 
overall 
7.3 months 
(p = 0.02| 
overall 
7.3 months 
(p = 0.041) 
prostate cancer 
NS 
NS = No significant difference. 
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Table 2. Randomised trials demonstrating no difference between combined 
androgen blockade and castration 
Antiandrogen 
/investigator 
Flutamide 
Junncic et al. 
1991 
Tyrell et al. 
1991 
Fourcade et 
al. 1992 
Boccardo et 
al. 1993 
Ferrari et al. 
1993 
Iversen et al. 
1993 
Ref. 
No. 
56 
46 
57 
58 
59 
60 
Trial design 
goserehn acetate + flutamide 
vs goserehn acetate 
goserehn acetate + flutamide 
vs goserehn acetate 
goserehn acetate + flutamide 
vs goserehn acetate + placebo 
goserelin acetate + flutamide 
vs goserelin acetate 
goserehn acetate + flutamide 
vs buserehn 
goserelin acetate + flutamide 
vs orchiectomy 
η 
50 
571 
245 
373 
96 
262 
Median 
time to 
progression 
or % of 
patients 
progressing 
NS 
25 vs 
31.7 mo. 
NS 
21 vs 
18 mo. 
NS 
24 vs 
18 mo. 
NS 
39 vs 
38% 
NS 
16.5 vs 
16.8 mo. 
NS 
Median 
survival 
NS 
34.9 vs 
34.9 mo. 
NS 
35 vs 
36 mo. 
NS 
34 vs 
32 mo. 
NS 
NH 
22.7 vs 
27.6 mo. 
NS 
Follow-up 
33 months 
(mean) 
24 months 
(median) 
48 months 
(median) 
24 months 
(median) 
19.8 vs 
20.2 mo. 
57 months 
(median) 
Nilutamide 
Bnsset et al. 
1987 
Knönagel et 
al. 1989 
Béland et al. 
1990 
Crawford et 
al. 1990 
LeDuc et al. 
1990 
Namer et al. 
1990 
61 
62 
63 
64 
65 
66 
orchiectomy + nilutamide 
vs orchiectomy + placebo 
orchidectomy + nilutamide 
vs orchidectomy + placebo 
orchidectomy + nilutamide 
vs orchidectomy + placebo 
leuprohde + nilutamide 
vs orchidectomy + placebo 
orchidectomy + nilutamide 
vs orchidectomy + placebo 
orchidectomy + nilutamide 
vs orchidectomy + placebo 
127 
51 
194 
333 
47 
125 
12-13 vs 
13 mo. 
NS 
53 vs 
85% SD 
p = 0.03 
12 vs 
12 mo. 
NS 
24.3 vs 
22.2 mo. 
NS 
22.7 vs 
36.8% 
NS 
NS 
22 vs 
24 mo. 
NS 
NS 
24.3 vs 
18 9 mo. 
NS 
NS 
NR 
NS 
NR 
12 months 
18-48 
months 
NR 
6 months 
36 months 
(minimum) 
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Antiandrogen Ref. 
/investigator No. 
Cyproterone 
acetate 
De Voogt et 37 
al. 1990 
Di Silvano et 55 
al. 1990 
Brewster et 67 
al. 1992 
Robinson 25 
1993 
Trial design 
buserelin + CPA 
vs orchiectomy 
goserelin acetate + CPA 
vs goserelin acetate 
goserelin acetate + CPA 
vs goserelin acetate 
orchidectomy + CPA 
vs orchidectomy 
η 
307 
328 
349 
221 
NS = No significant difference; SD = statistical difference; NR 
Median 
time to 
progression 
or % of 
patients 
progressing 
NS 
12.4VS 
12.7 mo. 
NS 
NS 
NS 
Median 
survival 
NS 
NS 
NS 
NS 
= data not reported 
Follow-up 
12 months 
(median) 
9-5Θ 
montns 
NR 
48 months 
(median) 
What is the balance of evidence on the benefit of CAB? The 
survival advantage for CAB in the positive trials is 7.3 months. These 
studies included between 300 and 600 patients and the median follow-up 
ranged from 3 to 5 years. The study designs varied: LHRH analogue or 
orchidectomy was the form of castration in one or both arms, and only 
two trials were double-blind. Two studies showed a particular advantage 
for patients with minimal disease, although the numbers of patients with 
minimal disease were small. There is an on-going double-blind study by the 
South West Oncology Group (SWOG), involving more than 1,300 M + 
patients with minimal disease and good performance status, comparing 
orchidectomy with flutamide versus surgical castration alone. The results 
of this large study should help determine the balance of evidence on the 
benefit of CAB. 
The studies that demonstrated equivalence for CAB and castration 
involved between 47 and 571 patients, with a minimum follow-up in the 
range of 12-57 months. Although there is no obvious reason why these 
two sets of studies provide different results, it is pertinent to focus on the 
meta-analyses when assessing the benefit of CAB. A trend to a survival 
advantage for CAB was demonstrated in the meta-analysis of 21 trials 
involving over 5,000 patients. A further update of this analysis including 
trials with longer follow-up periods and the inclusion of the 1,200 patients 
of the SWOG trial is expected. 
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In CAB studies, the incidence of disease 'flare' in association with 
LHRH analogues was consistently reduced in the combination arms, when 
evaluated [44]. However, the importance of disease 'flare' with respect to 
final objective endpoints is controversial. In most of the CAB studies 
assessing disease flare the reduced incidence did not relate to improved 
objective endpoints compared with LHRH analogue monotherapy. The 
South West Oncology Group trial may, however, clarify the association 
between disease 'flare' and ultimate clinical response, since it employs 
surgical castration in both arms. 
The meta-analysis of different antiandrogen trials indicates that the 
choice of agent may influence outcome [54]. Grouping the trials by the 
type of antiandrogen showed a reduction in annual death hazard ratios 
(flutamide 10%, nilutamide 6% and CPA 0%). If this finding is confirmed 
in the updated meta-analysis, the efficacy and tolerability of antiandrogens 
will be important factors in the choice of combination therapy. 
Only one study has compared antiandrogens in the setting of 
combination therapy. A total of 813 patients with metastatic prostate 
cancer were randomised to receive either bicalutamide (50 mg once daily) 
plus LHRH analogue or flutamide (250 mg three times daily) plus LHRH 
analogue therapy and were followed for at least 6 months [47]. The 
primary endpoint was time to treatment failure which took account of 
objective progression, mortality and tolerability (stopping randomised 
therapy because of adverse events). The antiandrogens were given double-
blind, and the results demonstrated that bicalutamide was more effective 
than flutamide, when used in combination with castration, with respect to 
time to treatment failure (p = 0.005). The data are currently too immature 
for a survival analysis. 
The survival data from this trial may well help in choosing which 
antiandrogen is best suited for use in combination therapy in patients with 
advanced prostate cancer. 
Other Approaches 
5o-reductase inhibitors 
The enzyme 5a-reductase is responsible for the conversion of 
testosterone to 5o-DHT), the active androgen which binds to the nuclear 
receptor. In placebo-controlled studies of prostate cancer, 5a-reductase 
inhibitors decreased serum prostate specific antigen (PSA) concentrations 
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by 50% after 3-6 months of treatment, but resulted in a 25-30% decrease 
in prostatic volume and no effect on serum testosterone, prostatic acid 
phosphatase or bone scans [68]. The decrease in serum PSA suggests that 
δσ-reductase inhibitors have an effect in patients with prostate cancer 
which is less than that seen with medical or surgical castration [68,69]. 
The use of 5o-reductase inhibitors in combination with the antiandrogen 
flutamide has been investigated in a small pilot study of 10 sexually active 
patients with advanced prostate cancer [70]. Early results suggest that 
combination treatment can cause disease regression. However, the results 
are too immature to draw any conclusions on long-term efficacy. 
Chlormadinone acetate 
Chlormadinone acetate (CMA) is a steroidal antiandrogen, similar in 
structure to CPA, which has been evaluated for the treatment of prostate 
cancer both as monotherapy and in combination with chemotherapy [71]. 
The clinical use of CMA is largely restricted to Japan. 
Comparison of CMA monotherapy with flutamide monotherapy in 
patients with stage С or D prostate cancer has shown similar decreases, in 
serum PSA in both treatment groups, and comparable objective response 
rates [72]. Both treatments were generally well tolerated, although both 
were associated with reports of diarrhoea and hepatic toxicity, and both 
treatments were equally effective in maintaining libido and potency. 
As with CPA, the use of CMA is associated with steroid-related 
side effects. Dosage reduction may be required for troublesome side 
effects, such as hair loss, change in body weight, fatigue, gynaecomastia, 
and alteration of hepatic function. 
Suramin 
Suramin is a trypanocidal drug which also has a cytostatic effect 
on prostate cancer cell lines [73-75]. In the human cell lines PC3 and 
DU 145, suramin exerts its cytostatic effect by inhibiting the binding of 
growth factors to cell surface receptors [73]. It also reduces the specific 
binding of transforming growth factor-σ to PC3 and DU 145 cells as well as 
increasing the percentage of cells in the S-phase of the cell cycle. 
In t w o androgen-independent prostate cancer cell lines [74], 
suramin alone resulted in a cytostatic effect on cell growth whereas 
administration of suramin after a course of radiotherapy enhanced the 
cytotoxic effect of the irradiation. 
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The clinical use of suramin in combination with mitomycin С has 
been investigated in 32 patients with hormone-refractory prostate cancer 
[77]. Disease stabilised in 15 patients, 6 had a partial response, and 1 a 
complete response. The median survival time was 209 days. However, 
combination treatment was associated with significant toxicity: patients 
developed a range of haematological changes, neurotoxicity, proteinurea, 
in addition to nausea, vomiting, gastrointestinal intolerance, and elevation 
of liver enzymes. 
Suramin monotherapy has been investigated in 35 patients with 
metastatic, hormone-refractory prostate cancer and resulted in major 
antitumour activity in 6 of the 12 patients with measurable disease [76]. 
Treatment also reduced serum levels of PSA by more than 50% in 24 
patients and pain in 20 patients. However, dose-limiting toxicity, ranging 
from malaise, lethargy and fatigue to reduction in creatinine clearance and 
neuropathy, was reported in up to 9 0 % of the patients. 
Cytostatic agents such as suramin may have a role in the treatment 
of hormone-refractory prostate cancer although toxicity is a significant 
problem. 
Imidazole derivatives 
Imidazole derivatives, such as R75251, have been investigated in 
vivo in different androgen dependent and independent Dunning rat prostate 
tumours. A 60-70% decrease in median tumour volume was seen when 
R75251 was applied as a dietary admixture. By oral gavage a 9 0 % 
reduction in median tumour volume was observed in androgen independent 
tumours AT-6 sq (at 60 mg/kg twice daily) [77,78]. In relapsed, hormone-
resistant prostate cancer patients, objective partial responses and subjec­
tive responses have been found in almost half of the patients [79]. The 
precise mode of action of the drug is unclear. It is, however, known that 
R75251 inhibits cytochrome P450-dependent steroid biosynthesis and the 
hydroxylation of retinoid acid to its polar metabolites. Retinoid acid is 
known to be the key molecule in cellular proliferation and differentiation 
and has shown anticarcinogenic and antitumoural effects. R75251 
enhances, dose-dependently, the retinoid acid concentration in serum and 
tumours [78]. 
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Early Intervention 
In considering the advances made to date in the hormonal treat-
ment of advanced prostate cancer, it is important to ask the question: 
How can we best optimise the existing approaches? One possibility is to 
use hormonal therapy at an early stage. The outcome for patients with 
cancers localised to the prostate gland is generally good and survival in 
excess of 10-15 years is common in patients treated with initial conserva-
tive management and delayed hormonal therapy [80,81]. 
Debate and controversy continue on the need to intervene early in 
the management of non-metastatic prostate cancer and the choice of 
treatment modality for early intervention. Treatment options are influenced 
by the age and general condition of the patient, the need to preserve 
sexual function, and the stage and grade of the disease. These options 
include radical prostatectomy, radiotherapy, and hormonal treatment, 
either alone or in combination, or watchful waiting. 
Hormonal therapy can be used in the neoadjuvant setting prior to 
localised therapy or as adjuvant therapy after localised treatment. With the 
exception of neoadjuvant therapy, hormonal treatment is generally given 
continuously until either clinical progression occurs or the patient dies. 
Neoadjuvant Therapy 
The use of hormonal therapy in a neoadjuvant setting is gaining 
increasing interest. The aims of pre-surgical androgen deprivation are to 
achieve a downstaging and downgrading of the tumour, an increase in 
local control, a reduction in surgical morbidity and operative sequelae, a 
reduction in time to progression, and a favourable impact on survival. 
Treatment regimens vary but include LHRH analogues, with or without 
antiandrogens, given for 2-6 months prior to radical prostatectomy. 
Most studies on the benefit of neoadjuvant therapy have been small 
and non-randomised, and have provided equivocal results in terms of 
downgrading and pathological downstaging [82-85]. There is a clear need 
for large, prospective, randomised studies to define the place of 
neoadjuvant therapy in the management of patients with prostate cancer. 
Labrie et al.[86] recently published preliminary results of a randomised trial 
comparing neoadjuvant hormonal treatment prior to radical prostatectomy 
versus direct radical prostatectomy in patients with localised prostate 
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cancer. An advantage in the neoadjuvant group with respect to negative 
margins and stage reductions was noticed. However, these early results 
have to be confirmed by other randomised trials which are ongoing. Two 
randomised trials comparing neoadjuvant hormonal therapy prior to radio­
therapy have also been conducted. One of these randomised trials, has 
recently been published [87]. Patients (455) with locally advanced prostate 
cancer were randomised to receive goserelin acetate and flutamide before 
and during radiotherapy, or to radiotherapy alone. With radiotherapy alone 
the expected rate of local tumour regrowth (39% over 4 years) was 
observed, but this was reduced to 2 2 % for neoadjuvant therapy (p<0.01). 
The incidence of development of distant metastases was also reduced 
with the neoadjuvant therapy, falling from 42 to 25% (p = 0.03). 
Adjuvant Therapy 
Adjuvant hormonal ablation or tamoxifen has a highly significant 
effect on both tumour recurrence and mortality in breast cancer [88]. 
Extrapolating this experience to the analogous setting of hormonally 
sensitive prostate cancer provides a rationale for the use of adjuvant 
antiandrogen therapy following radical prostatectomy. Early studies in 
patients with stage С or D1 prostate cancer have indicated possible 
beneficial effects with adjuvant treatment (orchidectomy and/or radiation) 
[89]. Again there is a need for large, randomised, prospective studies to 
define the role of adjuvant therapy in the management of non-metastatic 
prostate cancer. 
Intermittent Therapy 
There is preclinical and clinical evidence to suggest that intermit­
tent androgen withdrawal could lead to a prolongation of androgen sensi­
tivity at the tumour [90,91]. This would permit repeated courses of 
androgen-withdrawal therapy and could delay either clinical progression of 
the disease or death of the patient. 
With the introduction of reversible LHRH analogues and well-
tolerated antiandrogens, intermittent therapy is achievable. It may have 
benefits for the patient in terms of quality of life and preservation of sexual 
function. The relative merits of continuous and intermittent androgen 
withdrawal on clinical outcome require further investigation. 
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Patient Choice 
What factors influence patients in deciding between surgical and 
medical castration? With regard to response rate and survival, there is no 
difference in efficacy between the two approaches [92]. Although quality-
of-life considerations favour medical castration, because of its reversibility, 
the burden of side effects is comparable for medical castration and 
orchidectomy, with similar loss of libido and potency [93]. 
In a United States study designed to investigate patient choice, 
78% of patients selected medical castration with the LHRH analogue 
goserelin acetate and 22% orchidectomy. The main reasons for choosing 
medical castration included avoidance of surgery (36%), success of the 
treatment (18%), and convenience of drug treatment (10%). Patients 
selected surgery because of convenience of the surgical procedure (32%) 
and success of treatment (29%) [7,8]. A similar European study revealed 
that patients preferred goserelin acetate to orchidectomy for cosmetic 
reasons and because of a fear of surgery [94]. Factors influencing the 
patients' decision are shown in table 3. 
Table 3. Castration: advantages and disadvantages of surgical and medical approaches 
Surgical Medical 
Advantage 
Disadvantage 
Assured compliance 
Rapid removal of androgens 
Complications to surgery 
Psychological impact 
Hot flushes 
Loss of potency and libido 
No operation 
Efficacy equivalent to 
surgery 
Reversibility (especially inter-
mittent therapy) 
Initial rise in testosterone 
Hot flushes 
Loss of potency and libido 
The new clinical approach of intermittent therapy is directed at 
improving patients' quality of life during periods off treatment. For intermit-
tent hormonal therapy, using combination therapy, the patient does not 
have a choice as medical castration is essential. As more treatments 
become available, further choice is available to patients and they are likely 
to become increasingly involved in decisions about treatment. 
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Summary 
The incidence and mortality of prostate cancer are rising faster than 
can be explained by the increasing proportion of elderly in the population 
[2]. The reasons for this are unclear but may be due partly to changes 
associated with a Western lifestyle, for example, dietary changes such as 
high fat intake [95]. 
Increasing awareness of prostate cancer amongst both the medical 
profession and lay community has led to an increase in the detection of 
the disease and presentation of patients at an earlier stage of disease. The 
introduction of national screening programmes for prostate cancer would 
lead to a continuation of this trend. 
There is a hypothesis that prostate cancer cells represent a hetero-
geneous population of cells with differing sensitivities to androgens [96]. 
Disease progression after castration may result from increased growth of 
androgen-insensitive cells due to remaining intracellular DHT promoting 
tumour resistance. Since the aim of CAB is to neutralise androgens from 
testicular and adrenal origins, it may be the most appropriate treatment for 
patients with advanced cancer of the prostate. 
The choice of components for CAB is increasing and there is a 
trend towards the use of LHRH analogues and nonsteroidal antiandrogens, 
in preference to surgery and steroidal antiandrogens, as they fulfil the 
requirements of patient preference and improved tolerability. CAB may 
have advantages over monotherapy in slowing disease progression and 
increasing the duration of survival. There are, however, many unanswered 
questions about its use: when should treatment start and for how long 
should treatment continue? To answer these questions more trials of CAB 
are needed, involving longer follow-up periods and larger subgroups of 
patients, such as those with minimal disease, who are characterised prior 
to trial initiation. 
Clinical trials are also needed to assess the value of approaches 
such as the use of hormonal therapy used intermittently or in the 
neoadjuvant or adjuvant setting. 
In patients with advanced prostate cancer, there are factors that 
affect survival, such as performance status, haemoglobin, alkaline 
phosphatase, and number of bone lesions [97,98]. These prognostic 
factors can be used to identify three distinctive groups of patients. Those 
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patients with a good performance status, normal alkaline phosphatase, 
minimal central metastatic osseous metastases, and whose PSA levels 
decrease to normal during the first 3-6 months of CAB therapy are likely to 
have a good prognosis and should continue with CAB. Patients with a poor 
performance status, high alkaline phosphatase, central metastatic osseous 
metastases and whose PSA levels do not normalise during the first 3-6 
months of CAB therapy are likely to have a poor prognosis: in these 
patients other additional treatments should be considered such as chemo-
therapy, or only palliation should be encouraged. In patients who fall into 
the intermediate category, with respect to these prognostic factors, the 
determining factor should be the response in PSA levels to CAB therapy, 
for example those showing normalisation of PSA could be treated further 
as the good prognostic group. For this category of patients and the good 
prognostic category, CAB using medical or, if it is the patient's preference, 
surgical castration and a nonsteroidal antiandrogen could now be con-
sidered as standard hormonal therapy. 
Advances in the treatment of advanced prostate cancer do now 
offer increased options for therapy, enabling physicians to make choices 
on the most suitable therapy for given patients. 
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Introduction 
Prostate cancer is the second most common malignant disease in 
men and the most common cancer in men older than seventy years of age 
of whom approximately 70-80 percent will present with advanced disease. 
In 1941 Huggins and Hodges reported that prostate cancer was 
responsive to oestrogen therapy or castration which provided temporary 
control of the disease in 70-80 percent of previously untreated patients 
who had androgen-sensitive tumours [1]. Even half a century after this 
pioneering publication, many urologists still regard orchidectomy as the 
treatment of choice for advanced prostate cancer hoping that it will slow 
down progression of the disease and perhaps lead to longer survival [2]. 
As a result, orchidectomy has become the gold standard against which all 
other treatment must be compared, especially in clinical trials. 
The neuroendocrine control of gonadotropin secretion was firmly 
established by the experiments of Harris in 1955 [3]. Schally et al. ident-
ified the key neuroendocrine mediator, luteinizing hormone-releasing 
hormone (LH-RH), and from that moment, the hypothalamic-pituitary 
gonadal axis became a significant target for pharmacological manipulation 
aimed at testicular androgen ablation [4] 
As LH-RH has only a short duration of action, several LH-RH 
agonist analogues with vastly improved potency and duration of action 
have been introduced into clinical practice. However, if LH-RH analogues 
are to compete with castration as another treatment option for patients 
with advanced prostate cancer, their performance in terms of clinical 
efficacy and tolerability must be at least as good as that of castration. One 
LH-RH analogue is goserelin acetate (Zoladex) [5,6,7]. Ahmed argued that 
suppression of basal testosterone concentration by Zoladex was due to 
inhibition of pituitary luteinizing hormone secretion [8] rather than direct 
inhibition of Leydig cell function [9]. 
In a phase I clinical study, subcutaneous administration of Zoladex 
was shown to effectively reduce plasma levels of luteinizing hormone (LH), 
follicle stimulating hormone and testosterone and produce clinical improve-
ment [10]. For the patients, however, the gain was negligible as they had 
to make a daily clinic visit to receive treatment from a healthcare worker 
as opposed to the once-only event of castration. 
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Therefore, the development and clinical investigation of a depot 
formulation of Zoladex that required subcutaneous injection every 28 days, 
rather than daily administration, was of immense practical significance 
[11]. An additional advantage to the patient was the cosmetic and psycho-
logically more acceptable presentation of this first-line treatment. 
During the 1980s more than 3,500 patients with prostatic cancer 
have used the one-month depot formulation of Zoladex. The results from 
some of these patients have been reported in studies by Furr [7]; Walker et 
al. [11]; Peeling et al. [2]; and Debruyne et al. [12]. All demonstrated a 
subjective and objective response rate, comparable to that seen after 
standard endocrine therapy (castration). The most frequently reported side-
effects were reduced libido and the development of reversible hot flushes. 
Minor skin rash or skin irritation was noted in some patients. No prolonga-
tion of overall survival has been demonstrated with these analogues. 
Zoladex has now become established as a valuable and effective alterna-
tive to orchiectomy in the management of advanced prostate cancer. 
In 1994, Shaheen reported that 44 percent of patients missed one 
or more one-month depot injections and 24 percent had a delay of more 
than two weeks after the scheduled date for another one-month depot 
injection [13]. Walsh pertinently stated that: "Compliance is a major factor 
to consider when choosing among the various forms of hormonal therapy 
that are available" [13]. 
Many patients are not anxious to remind themselves to have a 
painful monthly injection. Hence, the availability of an extra long-acting 
Zoladex depot of at least three months was desirable to improve conveni-
ence to patients and healthcare workers, provide well-tolerated androgen 
ablation with improved compliance, and a reduced overall cost. 
The first pharmacokinetic and pharmacodynamic study with a 
Zoladex three-month depot started in 1988. To optimise the investigation, 
the protocol consisted of two studies with different but complementary 
objectives: 
1. An open study to define: 
a) the release profile and the duration of effect of the three-month 
depot formulation of Zoladex in suppressing serum testosterone 
compared with surgically castrate levels in patients with advanced 
prostatic carcinoma. 
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b) the safety and the tolerability of the three-month depot formulation 
of Zoladex. 
2. An open, randomised, parallel-group study was performed to determine 
whether: 
a) one three-month depot injection of Zoladex was pharmaco-dynami-
cally equivalent to three consecutive one-month injections and to 
assess the safety, tolerability and probability of accumulation of 
this longer-acting depot, when administered repeatedly. 
b) patients could be transferred successfully from the one-month to 
the three-month depot formulation of Zoladex. 
3. The Clinical Efficacy and Endocrine Profile. 
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Summary 
A new depot formulation of the LHRH analogue Zoladex® (goserelin 
acetate) has been developed which releases the drug over a period of at 
least 3 months as judged by measurement of drug content in depots at 
intervals after insertion in male rats and by the suppression of oestrogen 
secretion and oestrus in female rats. This formulation is based on the 
lactide/glycolide polymer system used for the standard 1-month Zoladex® 
depot, but the dose has been increased to 10.8 mg and the characteristics 
have been modified to enable a longer release of drug to be achieved. 
Thirty-eight patients with histologically proven, locally advanced 
(stage T3 or T4) and/or metastatic prostate cancer were treated with this 
new longer acting LHRH analogue depot formulation containing 10.8 mg 
Zoladex®. After initial increase of serum testosterone in the first week of 
therapy, castration levels were reached in all patients after 4 weeks and 
this was maintained for more than 14 weeks. At the time of depot exhaus-
tion, when escape from castration levels of androgen occurred, all patients 
received a single injection of a standard 1-month depot containing 3.6 mg 
Zoladex® which restored castration levels of androgen thus showing that 
the pituitary gland was again suppressed. The tolerance and acceptability 
of the longer-acting depot is high and comparable to the 1-month depot. 
Taking into account social and psychological factors, patients with 
advanced prostate carcinoma will soon be able to be treated with a longer 
acting LHRH depot formulation every 3 months an alternative of the 1-
month depot now widely used clinically. 
Introduction 
The studies of Huggins and Hodges [1,2] in 1941 first established 
the value of castration and oestrogen administration as endrocrine therapy 
for patients with advanced carcinoma of the prostate. Nowadays, 
androgen withdrawal by castration is the only well accepted treatment for 
patients with advanced prostate cancer. Oestrogen therapy is no longer 
used because of substantial cardiovascular mortality. Furthermore surgery 
is unacceptable to some patients, is irreversible and is associated with a 
high incidence of psychological morbidity. 
Induction of a potentially-reversible medical castration with LHRH 
analogues has provided a radical new approach to the treatment of 
hormone-dependent prostate cancer. 
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There are two distinct phases in the induction of castration by 
LHRH analogues. In the initial phase the LHRH analogue stimulates the 
pituitary-gonadal axis causing a transient rise of serum LH and testoster-
one during the first two weeks. After this period there is a downregulation 
of pituitary LHRH receptors and the pituitary gland becomes refractory and 
so the serum LH concentration decreases. This causes a reduction in 
testosterone biosynthesis and serum androgens decrease to castration 
values. 
Pharmacological data show the goserelin acetate (Zoladex®), D-
Ser(But)6, Azgly10-LHRH, a synthetic analogue of luteinizing hormone-
releasing hormone is a potent LHRH agonist when given parenterally but 
has low potency when dosed orally. To avoid the need for daily parenteral 
administration of this peptide analogue a biodegradable, biocompatible 
depot formulation was developed which released the drug continuously 
over 1 month [3]. The first clinical study of Debruyne et al. [4] in patients 
with advanced prostate cancer showed that this depot induced a fall in 
serum androgen to castrate values and that these were maintained by 4-
weekly depot administration. 
Recently, a new longer acting depot formulation of Zoladex has 
been developed. In order to achieve continuous release over not less than 
3 months, injectable depot delivery systems, in the form of cylinders 
having the dimensions approximately 1.5 mm diameter by 1.8 cm length, 
containing 10.8 mg Zoladex were prepared. These biodegradable depots 
were based on a poly(c/,1-lactide-co-glycolide) polymer having a high 
lactide content. 
For clinical studies the longer-acting depot was presented as a 
white-cream coloured cylindrical rod in which 10.8 mg Zoladex is dis-
persed in a matrix of tf,1,-lactide-glycolide co-polymer having a high lactide 
content. 
The aims of the study were to define the release profile and 
duration of action of this new 10.8 mg Zoladex depot in suppressing 
serum testosterone to surgically castrate levels and to assess its safety, 
tolerance and acceptability. 
When serum testosterone had risen to twice castration values (on 
two consecutive occasions) following exhaustion of the depot, it was 
important to establish that the pituitary gland was still capable of being 
suppressed and so all patients received a single injection of a standard 28 
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day depot containing 3.6 mg Zoladex at the time to evaluate the response. 
Patients and Methods 
A consecutive group of 38 patients entered this open study. 
Approval for the study was obtained from the Ethical Committees of the 
participating hospitals. At entry, all patients had untreated, histologically-
proven, advanced carcinoma of the prostate (stage T3, T4 Nx MO or TO to 
T4 Nx M1) with a life expectancy of more than 3 months. All patients 
gave informed consent. 
The drug was administered as a subcutaneous injection into the 
abdominal wall from a preloaded syrige with a 14 gauge needle. Local 
anaesthetic was not used. 
The study was in two parts: 
(a) Patients received a single injection of the new longer-acting depot 
formulation of 10.8 mg Zoladex. After castrate levels of serum 
testosterone were reached, the patients were followed until on two 
consecutive occasions serum testosterone values were at least 
twice the upper limit of the surgically-castratc range (2 nmol/l). 
(b) When serum testosterone values were at least twice the upper limit 
of the surgically-castrate range, patients received a single injection 
of a standard one month depot of 3.6 mg Zoladex and were fol-
lowed for a further 29 days to confirm that the pituitary-gonadal 
axis was again suppressed. 
Blood samples were taken from every patient for monitoring the 
endocrinological response and pharmacokinetics of the drug, pretreatment, 
after day 3, at week 1 and every week thereafter until serum testosterone 
values reached twice the surgically-castrate level. 
Haematological and biochemical parameters, including blood counts 
and liver and kidney function were monitored on day 1, week 12 and at 
withdrawal. Any possible adverse events were documented. 
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Results 
All patients satisfied the selection criteria. The average age was 
72.5 yr (range 51-90 yr). Eight patients were withdrawn from the study. 
Five due to progression, two due to death from cardiac arrest and one 
patient refused further follow-up. 
Endocrine response 
After an initial increase in serum LH and testosterone during the 
first week after Zoladex depot administration, there was a decrease in 
serum testosterone and castration levels were obtained within 28 days in 
all patients. 
Mean serum testosterone and LH levels at initiation of therapy were 
13.1 nmol/l (range 8.0-25.2) and 5.4 ug/1 (range 1.8-18.9) respectively. 
Serum testosterone values for all patients are shown in Fig. 1. 
The first increase in serum testosterone to twice surgical-castration 
values, indicating exhaustion of the 3-month depot, was seen after 14 
weeks. When the serum testosterone had risen to twice the surgical 
castration value, an injection of a standard 3.6 mg Zoladex depot gave an 
immediate decrease in serum testosterone to castration values in all 
patients. The mean value for the medical castration levels is shown in Fig. 
2 for all patients. 
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Fig. 1. Serum testosterone (a) and serum LH (Ы concentrations following a single sc 
injection of the new longer-acting 10.8 mg Zoladex depot to patients with 
advanced prostate cancer. The values for all 38 patients are shown. 
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Pharmacokinetics 
The concentrations of Zoladex in serum samples were determined 
by radioimmuno-assay [5]. Peak concentrations were seen after 7 days 
with a continuous, but declining, release of the drug to very low or 
undetectable serum concentrations over the remainder of the study. 
Serum Zoladex concentrations are shown in Fig. 2. It is remarkable 
that a concentration of Zoladex in serum as low as 0.05 ng/ml manages to 
maintain castrate serum testosterone concentrations. Serum testosterone 
only increases above castrate values when serum Zoladex concentrations 
fall to below the detection limit (0.05 ng/ml) of the assay. 
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Fig. 2. Mean serum testosterone and Zoladex values _+ SD for all 38 patients with 
advanced prostate cancer given a single depot of the net, longer-acting depot 
containing 10.8 mg Zoladex 
Tolerance and acceptability 
The depot was well tolerated systemically in all patients. No local 
intolerance was observed at the injection site in any patient. 
Pharmacological effects related to the reduction of serum testoster­
one, such as loss of libido and impotence, were present in most of the 
patients: breast tenderness was seen in one patient. Hot flushes were 
noticed in 10 patients and transient worsening of symptoms in four 
patients. No haematological or biochemical toxicity was observed. One 
patient had papillomatous exanthema on both legs which disappeared 
spontaneously and was considered to be unrelated to treatment; one 
patient had thrombosis of one leg, 2 weeks after a TUR. 
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Discussion 
The new extra long acting depot formulation of 10.8 mg Zoladex 
dispersed in a biodegradable biocompatible matrix of lactide-glycolide co-
polymer seems to be very effective at suppressing serum testosterone to 
surgically castrate values in patients with advanced prostate cancer. The 
duration of action appears to be at least 14 weeks making 3 monthly 
administration feasible. 
After an initial increase of serum LH and serum testosterone in the 
first week after initiation of therapy, a decrease of serum testosterone to 
surgically castrate values occurs within 4 weeks and there is no variability 
in serum testosterone thereafter up to 14 weeks. 
Medical castration levels are induced by serum drug concentrations 
at the limit of detection of the assay (0.05 ng/ml). Increase of serum 
testosterone is only seen when serum Zoladex concentrations fall below 
this value. 
A second s.c. injection of the standard one month 3.6 mg Zoladex 
depot, given at the time when serum testosterone had reached twice 
surgical castration levels, caused an immediate resuppression of serum 
testosterone into the castrate range, confirms that the pituitary gland is 
still capable of being suppressed. 
Tolerance and patient acceptability are very high and the 3-month 
depot may be preferable to a 1-month depot for some patients for social 
and psychological reasons. Local anaesthetic was given since experience 
with the 1-month depot showed this to be unnecessary; the acceptability 
of this was confirmed in this study. 
In summary, we conclude that, like the experience with the stan-
dard 1-month depot, the longer acting (3-monthly) 10.8 mg Zoladex depot 
is well tolerated both locally and systemically. Serum testosterone levels 
remain at castrate values in all patients for at least 14 weeks. When the 
depot becomes exhausted of drug and the serum testosterone concentra-
tions begin to increase again, the pituitary gland remains responsive and 
can be suppressed again after as second depot injection. 
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Abstract 
A new longer-acting depot formulation containing 10.8 mg Zoladex 
administered every 12 weeks was compared to the 3.6-mg Zoladex depot 
administered every 28 days, in a randomised trial in patients with 
advanced prostatic carcinoma in which pharmacodynamic efficacy and 
safety were assessed. Effective induction of mean serum testosterone 
suppression into the surgically castrate range by 21 days and maintenance 
of suppression for the duration of therapy was achieved with both the 3.6-
mg and the 10.8-mg depot formulations. The Zoladex 10.8-mg depot was 
well tolerated both locally and systemically. This new formulation which is 
equivalent to three successive 3.6-mg depots will provide a more conveni-
ent dosing regime for both patient and doctor in this indication. 
Introduction 
Since the publication of Huggins et al. [1] in 1941, the influence of 
testicular androgen deprivation on the growth of androgen-dependent 
prostate carcinoma cells has been well recognised. 
Until recently, the initial choice of therapy for patients with 
advanced prostate cancer has been orchidectomy as the alternative means 
of suppression of testosterone using oestrogens has been shown to be 
associated with an unacceptably high incidence of cardiovascular side-
effects [2-4]. However, surgical castration is unacceptable to some 
patients, is irreversible and is associated with psychological morbidity. 
Suppression of testicular androgens using luteinizing-hormone-
releasing hormone (LHRH) analogues is now a widely accepted alternative 
treatment to orchidectomy. Debruyne et al. [5] have shown that the LHRH 
analogue Zoladex, when administered subcutaneously as a 3.6-mg depot 
every 28 days, is well tolerated and effective in suppressing serum 
testosterone to castrate levels. Parmar et al. [6,7] and Kaisary et al. [8] 
have also shown in two randomised controlled studies that once monthly 
LHRH analogue depots produce equivalent objective and subjective 
responses and overall survival to that obtained following orchidectomy. A 
new longer-acting depot containing 10.8 mg Zoladex which is administered 
every 12 weeks has been developed. Data from an open phase II clinical 
trial using the Zoladex 10.8-mg depot has shown effective suppression of 
serum testosterone and maintenance of suppression for at least 12 weeks 
[9]. 
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The aim of this study was to assess the pharmacodynamic efficacy 
and safety of a Zoladex 10.8-mg depot compared to that of the 3.6-mg 
depot formulation in a phase III randomised clinical trial. 
Patients and Methods 
A consecutive group of 80 patients entered this open, randomised, 
multicentre study in the Netherlands. Approval for the trial was obtained 
from the Ethics Committees of the participating hospitals. At entry all 
patients had histologically proven, previously untreated, locally advanced 
and/or metastatic prostate cancer. A life expectancy of more than 6 
months and written informed patient consent were requisites at entry. 
Pretreatment serum testosterone values were to be within the normal 
range of the local hospital laboratory. 
Patients were randomised to one of two treatment arms: half the 
patients received a subcutaneous injection of the Zoladex 3.6-mg depot 
formulation every 28 days, then after three administrations proceeded.to 
receive injections of the Zoladex 10.8-mg depot formulation every 12 
weeks for the 48-week duration of the trial; the other half of the patients 
received the Zoladex 10.8-mg depot formulation throughout the trial. 
The Zoladex 10.8-mg depot consists of a biodegradable, biocom-
patible matrix of lactide-glycolide copolymer containing 10.8 mg goserelin 
and administered subcutaneously. 
Serum testosterone and Zoladex concentrations were measured 
before treatment and at intervals of no more than 2 weeks during the first 
24 weeks of the study, then at weeks 36 and 48. Both testosterone and 
Zoladex levels were measured at central laboratories. Haematology and 
biochemistry assessments were performed before treatment and at weeks 
12 and 24. All adverse events occurring during the trial were fully docu-
mented. 
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Results 
Of the 80 patients who entered the study, 42 were randomised to 
start treatment with the Zoladex 3.6-mg depot and 38 with the 10.8-mg 
depot. The mean age was 73 years (range 56-89 years) in the 3.6-mg 
group and 72 years (range 55-86 years) in the 10.8-mg group. During the 
48 week study period, 6 patients in the 3.6-mg group and 3 in the 
10.8-mg group were withdrawn, of whom 7 were withdrawn due to 
disease progression and 2 patients died. 
Table 1. Patients reporting adverse events with incidence > 5% 
Adverse event 
Hot flushes 
Pain 
Urinary tract 
infection 
Within the first 12 weeks 
3.6-mg depot 
(n=43) 
1 9 (44%) 
1 (2%) 
2 (5%) 
10.8-mg depot 
(n = 39) 
12 (31%) 
3 (8%) 
1 (3%) 
Weeks 12-48 
10.8-mg depot 
(n = 80) 
41 (51%) 
19 (21%) 
5 (6%) 
Efficacy 
After an initial increase in mean serum testosterone levels during 
the first week after the Zoladex depot administration, there was a 
decrease to within the surgical castrate range (0-2.5 nmol/l) in all patients 
in both treatment arms by day 2 1 . Mean serum testosterone levels in the 
3.6-mg and 10.8-mg treatment arms at initiation of therapy were 18.5 and 
17.2 nmol/l, respectively. These values decreased to 1.6 and 1.4 nmol/l 
following 21 days of treatment and remained suppressed throughout the 
48-week treatment period. There was no statistically significant difference 
in serum testosterone values at week 4 (p = 0.59), week 8 (p = 0.21) or 
week 12 (p = 0.17) between patients randomised to either the 3.6-mg or 
the 10.8-mg depot. Patients randomised to the 3.6-mg depot were trans-
ferred to the 10.8-mg depot following 12 weeks of treatment. Serum 
testosterone levels remained suppressed in these patients for the duration 
of the trial. Figure I shows the mean serum testosterone levels throughout 
the 48 weeks of treatment. 
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Pharmacokinetics 
The concentrations of Zoladex in serum samples were determined 
эу radio-immunoassay [10]. In those patients randomised to start treat-
nent with the Zoladex 10.8-mg depot, peak serum concentrations were 
seen at about 2 h after dosing followed by a continuous release of the 
drug over the 12-week dosing period (fig. 2). 
Tolerance 
During the 48-week study period, a total of 346 Zoladex 10.8-mg 
depots and 125 Zoladex 3.6-mg depots were administered. Forty-six 
ïercent of patients randomised to the 10.8-mg depot and 67% of those 
andomised to receive the 3.6-mg depot experienced at least one adverse 
îvent within the first 12 weeks of therapy (table 1). The most common 
îvent was hot flushes, an expected pharmacological side-effect of LHRH 
jgonist therapy. 
Patient group 
10 θ depot 
3 6 depot 
Number of patients assessed at each sampling point 
before Day 
treatment 8 15 22 29 43 57 71 85 Θ9 112 127 141155 169 253 337 
36 37 37 33 35 32 34 34 33 31 28 30 29 29 25 20 14 
37 41 39 39 39 40 35 31 31 33 30 31 29 31 27 20 20 
Upper castrate limit 
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The reports of pain occurred following long-term therapy and were 
usually associated with progression of metastatic disease. Two cases of 
bone pain were reported within the first 4 weeks of therapy in the 10.8-
mg depot group; however, in both cases the condition resolved following 
continuation of therapy. No patient was withdrawn from the trial because 
of an adverse event. 
Two patients died during the study. One patient died of a 
myocardial infarction 16 weeks after the start of therapy, and 1 patient 
died of active euthanasia 27 weeks after the start of therapy. This patient 
had severe bone pain associated with disease progression prior to death. 
In both cases, the investigator considered that death was unrelated to trial 
therapy. There were no reports of local reactions at the site of injection 
and no local anaesthetic was administered to patients in either treatment 
arm prior to the Zoladex injections. 
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Discussion 
The value of LHRH analogues in the treatment of patients with 
advanced prostate cancer is now firmly established. From a psychological, 
social and even economic perspective, a longer-acting LHRH agonist such 
as the Zoladex 10.8-mg depot might be preferable to surgical castration. 
In this randomised open study, the Zoladex 3.6-mg depot adminis-
tered every 28 days was compared to the newly developed Zoladex 10.8-
mg depot administered every 12 weeks. The results show that the 10.8-
mg depot is equally effective in inducing suppression of mean serum 
testosterone levels to within the castrate range by 21 days and maintain-
ing these levels for the 12 week duration of therapy. The pharmacokinetic 
profile indicates that Zoladex is continually released over the 12-week 
period. The 10.8-mg depot formulation is well tolerated both locally and 
systemically and has a similar safety profile to that seen with the 3.6-mg 
depot. 
The results have confirmed that the Zoladex 10.8-mg depot is 
pharmacodynamically equivalent to three consecutive administrations of 
the Zoladex 3.6-mg depot. Continued suppression of serum testosterone 
occurs both following transfer of patients from the 3.6-mg to the 10.8-mg 
depot and with repeated dosing for up to 48 weeks. 
The availability of a 12-weekly depot formulation will offer a more 
convenient dosing regime for both patient and doctor in the treatment of 
patients with prostate cancer. 
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Abstract 
Purpose 
To assess the pharmacodynamic equivalence of the new 10.8 mg. 
goserelin depot with the current 3.6 mg. depot 3 studies were performed 
in patients with advanced prostate cancer. 
Materials and Methods 
In 2 comparative studies 160 patients were randomized for dosing 
every 12 weeks using the 10.8 mg. depot or every 4 weeks using the 3.6 
mg. depot. In the noncomparative study 35 patients received the 10.8 mg. 
depot. Blood sampling for serum testosterone and evaluation of toxicity 
was done during the 48-week study period. 
Results 
Serum testosterone profiles of the 10.8 and 3.6 mg. goserelin 
depots were similar with testosterone levels decreasing into the castrate 
range by day 21 after depot administration. The safety profile of 10.8 mg. 
goserelin is comparable to that of the current monthly depot with the main 
side effects related to androgen deprivation. 
Conclusions 
The new long acting depot was pharmacologically equivalent, and 
well tolerated locally and systemically, and will offer added convenience to 
patients and health care personnel. 
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Introduction 
Prostate cancer is now the most common newly diagnose malig-
nancy in men in the United States with an estimated 200,000 new 
diagnoses and 38,000 deaths in 1994.' It predominantly affects the 
elderly male population, which has contributed to an increasing incidence 
in recent years. The established mode of treatment of advanced disease is 
androgen deprivation. The development of luteinizing hormone releasing 
hormone analogues has offered an effective and well tolerated pharmaco-
logical alternative to orchiectomy, while the availability of depot formulati-
ons has contributed to the rapid establishment of this class of compounds 
in the treatment of this disease. 
Currently available depot formulations of luteinizing hormone-
releasing hormone analogues require administration by injection subcutane-
ously or intramuscularly on a monthly basis, which usually involves a clinic 
visit by a patient or a home visit by health care personnel. A longer acting 
depot formulation would reduce the frequency of injections and offer 
improved convenience to patients and health care personnel. The luteini-
zing hormone-releasing hormone analogue, goserelin, § is currently available 
as a depot containing 3.6 mg. goserelin acetate administered by subcuta-
neous injection every 28 days. A new 10.8 mg. formulation has been 
developed based on modifications of the lactide: glycolide copolymer 
carrier of the current 3.6 mg. dose, containing 10.8 mg. goserelin acetate 
designed to be administered every 12 weeks. We performed 1 noncompa-
rative and 2 comparative studies with this depot in patients with prostate 
cancer to assess its pharmacodynamic equivalence with the current 3.6 
mg. depot. 
Materials and Methods 
Population 
Between January 1989 and July 1992, 195 patients with advan-
ced prostate cancer were entered by the Dutch South East Cooperative 
Urological Group into the 3 studies, including 80 into each of the 2 
comparative studies and 35 into the noncomparative study. Patients with 
histological confirmation of prostate cancer, locally advanced (T3 to T4) or 
metastatic (M1) disease, pretreatment serum testosterone within the 
normal range and life expectancy of more than 6 months were eligible for 
entry into the study and those previously treated with orchiectomy or 
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hormonal therapy were excluded. All patients provided informed consent. 
After study entry patients were withdrawn because of a serious adverse 
event, disease progression requiring change of treatment, unwillingness or 
inability to continue in the study or investigator decision in the interest of 
the patient. 
Design and assessments 
Multicenter comparative studies 1 and 2 were of an identical open, 
parallel group design with a 48-week study period. Patients were randomi-
zed to receive treatment with a single 10.8 mg. goserelin depot or 3 
consecutive monthly 3.6 mg. goserelin depots during weeks 0 to 12. 
Following this period all patients received treatment with a single goserelin 
10.8 mg. depot every 12 weeks. Blood sampling for serum testosterone 
was performed before randomization, at weekly intervals for the first 4 
weeks, then every 2 weeks until week 24, and at the end of weeks 36 
and 48. On days when sampling coincided with depot administration 
samples were taken before the depot was given. Samples were analyzed 
centrally at the laboratories of University Hospital, Nijmegen. Patients in 
noncomparative pharmacokinetic study 3 received a single 10.8 mg. 
goserelin depot. Blood sampling for serum testosterone was performed 
before treatment on day 1, then on days 2, 3, 5 and 8, followed by 
weekly sampling until 2 consecutive samples had been obtained with 
serum testosterone levels exceeding at least twice the upper limit of 
castrate range (0 to 2.5 nmol./l.). 
Response criteria 
The primary objective of the studies was to assess pharmacody-
namic equivalence of the 10.8 mg. goserelin depot with the current 3.6 
mg. depot. Therefore, the main end point was the surrogate end point of 
serum testosterone. In the comparative studies this end point was as-
sessed in 2 ways. Mean testosterone levels achieved during weeks 4 to 
12 and at the end of weeks 4, 8 and 12 were statistically compared 
between the 10.8 and 3.6 mg. treatment groups. In addition, serum 
testosterone levels of individuals were assessed according to criteria for 
induction, as defined by testosterone levels decreasing into the castrate 
range within 28 days of first administration, and maintenance, as defined 
by serum testosterone levels remaining within the castrate range throug-
hout a 12-week dosing period. 
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Table 1. Demographic details 
Comparative 
Study 1 
Depot (mg.) 
No. pts. 
Mean age (range) 
Mean kg. wt. (range) 
Depot (mg.) 
No. pts. 
Mean age (range) 
Mean kg. wt. (range) 
Depot (mg.) 
No. pts. 
Mean age (range) 
Mean kg. wt. (range) 
10.8 
38 
72 (55-86) 
80 (53-100) 
10.8 
39 
73 (49-88) 
74 (57-105) 
3.6 
42 
73 (56-89) 
76 (48-105) 
Comparative 
Study 2 
3.6 
41 
71 (52-86) 
77 (54-108) 
Noncomparative 
Study 3 
10.8 
35 
72 (53-86) 
73 (45-91) 
Statistical methods 
Analysis of variance was done to compare mean testosterone 
levels among weeks 4 to 12 of the 2 comparative studies separately and 
pooled. Possible sources of variation of study, center within study, treat-
ment, and study and center by treatment interaction were considered. 
Induction and maintenance data were summarized in terms of numbers of 
patients meeting the criteria. Successful induction required that at least 1 
sample value be within the castrate limit within 28 days of the first depot 
administration. For successful maintenance all patients who received at 
least 1 depot were required to have no sample levels outside of the 
castrate range within 84 days of depot administration, excluding the 
induction period for the first depot. A 95% confidence interval was derived 
for the difference in percent maintenance rates between the 2 treatment 
groups to assess the precision of comparison. Induction and maintenance 
success results of the noncomparative study were analyzed similarly. 
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Results 
Demography 
Patients in each of the comparative studies were comparable in age 
and weight (table 1). There were 3 protocol deviatore in study 2. Two 
patients randomized to the 3.6 mg. group received a 10.8 mg. depot in 
error at week 8. The testosterone data from week 8 were excluded from 
efficacy analysis, while they were included in the 10.8 mg. group during 
this period for safety assessments. One patient randomized to the 10.8 
mg. depot received a 3.6 mg. depot in error at week 0 and no further 
depots until week 12. This patient was excluded from efficacy analysis 
but was included in the 3.6 mg. depot group for safety assessment during 
this period. 
Mean serum testosterone levels 
In studies 1 and 2 mean testosterone levels during weeks 4 to 12, 
and 4, 8 and 12 were within the castrate range with no significant diffe-
rences between the 10.8 and 3.6 mg. treatment groups. Pooling data from 
the 2 studies indicated that there were no significant differences in mean 
testosterone levels achieved by the 2 depot formulations (table 2). The 
figure shows the mean serum testosterone profile achieved in the 2 
treatment groups pooled from both comparative studies. Between weeks 0 
and 12 the profiles relate to the 10.8 and 3.6 mg. depots, while between 
weeks 12 and 48 patients in both treatment groups received 10.8 mg. 
goserelin depots. The achieved profiles were similar with testosterone 
levels decreasing into the castrate range by day 21 after administration of 
the first depot in each group, and then remaining within the castrate range 
for the remainder of the period, ending at week 12. On repeat dosing of 
10.8 mg. goserelin beyond week 12 testosterone levels in both groups 
were maintained within the castrate range (see figure). 
In the comparative studies all patients receiving either depot had 
successful induction. Following induction a similar maintenance of suppres-
sion of testosterone levels occurred in patients treated with the 10.8 and 
3.6 mg. depots. As expected with this drug class, the most common 
adverse events were related to the pharmacological action of testosterone 
deprivation. The incidence of such events during the comparative studies 
is shown in table 3. The most commonly reported event was hot flashes, 
followed by gynecomastia (3 patients in the 10.8 and 1 in the 3.6 mg. 
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group), breast pain (2 and 1, respectively), impotence (2 in the 10.8 mg. 
group) and bone pain (2 in each group). The incidence of these events 
during treatment with 10.8 mg. goserelin was comparable to that after 
treatment with the 3.6 mg. goserelin depot. The incidences beyond week 
12 reflect the differences in the periods of observation and recording of 
events that persisted beyond week 12. 
20 τ 
—•—10.8 mg depot 
-•••3.6 mg depot 
12 \ 
Mean io \ 
Testosterone \ 
8 \ 
6 \ 
4 \ Upper castrate limit 
2 \ ^ 
0 1 2 3 4 6 8 10 12 14 16 18 20 22 24 36 48 
Nominal Study Week 
Fig. 1. Mean serum testosterone levels during 48 weeks in studies 1 and 2 
Only 1 patient had an adverse event that led to study withdrawal. 
In study 2, 1 patient had mild pruritis from paraneoplastic dermatitis 
unrelated to goserelin use. No patient was withdrawn from the study due 
to an adverse event related to treatment. The incidence of early worsening 
of signs and symptoms was similar for patients treated with 10.8 and 3.6 
mg. goserelin depots. Pain/bone pain increased in 4 % of patients in each 
treatment group and there was 1 case of spinal cord compression in each 
group. One patient had medullary compression 8 days after the first 3.6 
mg. goserelin depot, while 1 had spinal cord compression on the day of 
the first 10.8 mg. goserelin depot, which was considered by the clinician 
to be related to disease progression. Three cases of urinary retention in the 
3.6 mg. group were treated successfully with urinary catheterization, and 
there were no such cases in the 10.8 mg. group. No deaths were conside­
red related to treatment. Depots of 10.8 mg. goserelin were well tolerated 
locally, and only 2 of the 614 depot administrations (0.3%) in the compa­
rative studies were associated with local reactions (hematomas not 
requiring specific management). 
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Table 2 . 
Study 1 wks: 
4 to 12 
4 
8 
12 
Study 2 wks: 
4 to 12 
4 
8 
12 
Pooled data 
(wks 4 to 12) 
Table 3. 
Depot (mg.) 
No. pts. 
Mean 
10.8 
Mg. 
Depot 
(nmol/l 
0.559 
0.822 
0.672 
0.753 
0.681 
0.776 
0.653 
0.786 
0.639 
serum 
No. 
Pts. 
) 
37 
35 
34 
33 
39 
38 
36 
36 
76 
testosterone levels ¡ 
3.6 
Mg. 
Depot 
(nnmol/l) 
0.632 
1.101 
0.531 
0.564 
0.743 
0.782 
0.721 
0.664 
0.686 
Adverse events 
% Adverse events: 
Hot flashes 
Gynecomasti 
Breast pain 
Impotence 
Bone pain 
¡a 
10.8 
78 
47 .4 
3.8 
2.6 
2.6 
2.6 
Wks. 
No. 
Pts. 
42 
39 
36 
36 
38 
37 
36 
35 
80 
O t o 12 
3.6 
84 
47 .6 
1.2 
1.2 
0 
2.4 
in comparative studies 
Estimated 
Difference 
(nmol./l) 
-0.033 
-0.279 
0.140 
0.189 
-0.062 
-0.006 
-0.068 
0.121 
-0.047 
95% 
Confidence 
Interval 
-0.294-0.228 
-1.312-0.755 
-0.083-0.364 
-0.086-0.464 
-0.199-0.075 
-0.118-0.176 
-0.257-0.122 
-0.139-0.381 
-0.193-0.099 
Wk. 12 
Onward 
10.8 
157 
63.7 
8.3 
4.5 
1.3 
5.7 
P-
Value 
0.8043 
0.5919 
0.2143 
0.3704 
0.9456 
0.4763 
0.3550 
0.5264 
Discussion 
Randomized comparative studies on the use of luteinizing hormone-
releasing hormone analogues in patients with advanced prostatic carcino-
ma have clearly established that these substances suppress serum testos-
terone into the castrate range. This suppression is maintained on repeat 
dosing, and is associated with clinical responses and survival times similar 
to those achieved with orchiectomy and estrogens.2-3 Luteinizing hormone-
releasing hormone analogues are now generally accepted as a medical 
alternative to orchiectomy. 
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It is important to discuss with every patient the best way in which 
testosterone suppression can be achieved. The major point of discussion is 
whether surgical or medical castration should be performed. The choice of 
medical or surgical castration should not depend solely on economic 
reasons. The psychological impact and consequences of surgery should 
also be considered, in addition to the irreversibility of the intervention. 
There exist only limited prospective data in regard to patient 
preference and it is surprising how little attention has been given to patient 
attitude in this respect. Chadwick et al. concluded that with equally 
effective treatments a fully informed patient should be encouraged to 
participate in deciding the treatment (surgical or medical castration) he 
should receive.4 The study indicated that inpatients were more inclined to 
elect surgical castration, whereas outpatients preferred luteinizing hormo-
ne-releasing hormone therapy. In a Norwegian study patients clearly 
preferred luteinizing hormone-releasing hormone depot therapy, which was 
also the treatment that Norwegian urologists would prefer for themselves.5 
Cassileth et al. suggested that luteinizing hormone-releasing hormone 
depot therapy may be superior to surgical castration in terms of long-term 
improvement of quality of life and psychological distress,6 although a 
significant statistical difference in quality of life parameters was not 
demonstrated in the study of Parmar et al.7 
The administration of luteinizing hormone-releasing hormone analo-
gues evolved from daily intranasal or subcutaneous application to monthly 
depot injections, which are considered more convenient for patients. An 
initial depot preparation was the 3.6 mg. goserelin subcutaneous depot, 
which is administered monthly and has proved to be effective in suppres-
sing testosterone in all patients with advanced prostatic cancer.8 However, 
even a monthly depot preparation requires frequent visits by patients, 
which for some elderly individuals can be embarrassing and cumbersome. 
Therefore, it would be advantageous for patients and physicians or other 
health care personnel if a longer acting luteinizing hormone-releasing hor-
mone depot preparation were available with an administration frequency 
that coincided with regularly scheduled treatment for advanced metastatic 
prostate cancer. In general, a 3-month depot preparation was considered 
the most appropriate formulation. 
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Conclusions 
We evaluated the pharmacological equivalence of a new 3-month 
10.8 mg. goserelin depot with the current 3.6 mg. depot, as demonstrated 
by a similar testosterone profile. Induction and maintenance rates during 
the prolonged dosing period of 12 weeks were comparable to those of the 
current 3.6 mg. depot, which is given at 28-day intervals. The safety 
profile of the new depot was also similar to that of the current depot with 
a similar incidence of pharmacologically related adverse events. The depot 
was well tolerated with no patient study withdrawals related to treatment. 
There was also a similar incidence of early worsening of signs and symp­
toms in some patients shortly after administration of the first depot. The 
new depot will provide a significant reduction in the number and frequency 
of injections, which should lead to improved convenience for patients and 
health care personnel with potential reductions in costs of depot administ­
ration. 
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Abstract 
Objectives 
To compare the pharmacodynamics and tolerability of the new 
goserelin acetate 10.8-mg depot with the 3.6-mg depot in patients with 
advanced prostate cancer during the first 3 months of therapy. 
Methods 
One hundred and sixty patients were randomized in two com-
parative studies to receive either the 10.8-mg goserelin acetate depot 
every 12 weeks or the 3.6-mg goserelin acetate depot every 4 weeks for 
12 weeks and then the 10.8-mg depot every 12 weeks, thereafter. Data 
for pharmacodynamic assessments were collected prospectively, whereas 
clinical response data were collected retrospectively. 
Results 
Serum testosterone profiles of the 10.8-mg goserelin acetate depot 
and the 3.6-mg goserelin acetate depot were similar; testosterone levels in 
both groups fell below castrate levels by Day 21 after administration. 
Decreases in serum PSA after 3 months of therapy were also similar in 
both groups; 94% with the 10.8-mg depot and 92.5% with the 3.6-mg 
depot. For all patients, the median time to progression was 152.7 weeks 
and the median time to death was 213.6 weeks. The safety profile of the 
10.8-mg goserelin acetate depot was similar to that of the 3.6-mg depot; 
hot flashes was the most common adverse event. The incidence of 
injection site reactions was very low (2 [0.3%] of 614 administrations). 
Conclusions 
The new 10.8-mg depot was pharmacologically equivalent to the 
current 3.6-mg depot and was well tolerated both locally and systemically. 
The observed time to progression and survival were as expected in this 
patient population. The 10.8-mg goserelin-acetate depot provided a dosing 
schedule that was convenient for the patient and the physician, and has 
the potential to reduce health care costs while maintaining the quality of 
life in patients being treated for advanced prostate cancer. 
100 
Goserelin Acetate: Clinical Efficacy and Endocrine Profile 
Introduction 
Since their introduction over a decade ago as a treatment for 
advanced prostate cancer, luteinizing hormone-releasing hormone (LHRH) 
agonist analogues have displaced estrogens as the leading alternative to 
orchiectomy for patients undergoing monotherapy,1 and have emerged as a 
component of combination therapy with antiandrogens in patients receiv-
ing combined androgen blockade.2,3 Because the commercially available 
depot formulations of LHRH analogues for prostatic cancer require adminis-
tration every 4 weeks, development of a convenient, longer-acting depot 
formulation has long been desirable. 
A new longer-acting, 3-month depot formulation of the LHRH 
analogue goserelin acetate implant (Zoladex, Zeneca Pharmaceuticals, 
Wilmington, Del and Macclesfield, Cheshire, UK) was recently evaluated in 
clinical trials conducted in patients with advanced prostatic cancer. In a 
phase II study, effective suppression of serum concentrations of testoster-
one was achieved and maintained for at least 12 weeks following adminis-
tration of the 10.8-mg depot formulation.4 In two phase III studies,5,6 the 
pharmacodynamics, efficacy, and tolerability of the new 10.8-mg formula-
tion were compared with the standard 3.6-mg formulation. Effective 
suppression of serum testosterone below the castrate level within 3 weeks 
and maintenance of suppression for the duration of therapy was achieved 
with both the 10.8-mg and 3.6-mg depot formulations. The 10.8-mg depot 
was well tolerated both locally and systemically.5,6 In this report, we 
update the pharmacodynamic and safety results of these two phase III 
studies and present an analysis of prostate-specific antigen (PSA) 
response, time to progression, and survival. 
Material and Methods 
Patient selection 
Patients with histological confirmation of prostate cancer, either 
locally advanced (T3, T4) or metastatic (M1) disease, with pretreatment 
serum testosterone within the normal range and a life expectancy of more 
than 6 months were eligible for entry. Patients previously treated with 
orchiectomy or hormonal treatment were excluded. All patients provided 
written informed consent and the study was approved by the appropriate 
Institutional Review Boards. 
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Study design 
The two multicenter, comparative studies (0001 and 1805) were of 
an identical, open, parallel-group design with a 48-week study period. 
Patients were randomized to one of two treatment groups: one group 
received the 10.8-mg depot formulation at 84-day intervals throughout the 
study; the other group initially received a subcutaneous injection of the 
3.6-mg depot formulation of goserelin acetate, and, after three administra-
tions at 28-day intervals, they received subcutaneous injections of the 
10.8-mg depot formulation at 84-day intervals throughout the remainder of 
the study. 
Testosterone assessments 
The primary objective of these studies was to compare the 
pharmacodynamics of the 10.8-mg and 3.6-mg goserelin acetate depots. 
The mean testosterone levels achieved during Weeks 4 to 12 and at the 
end of Weeks 4, 8, and 12 were compared between the 10.8-mg and the 
3.6-mg treatment groups. In addition, the serum testosterone levels of 
individual patients were assessed according to secondary criteria for 
induction (defined as testosterone levels falling below the castrate level 
after the first administration) and maintenance (defined as serum testoster-
one levels remaining below the castrate level throughout a 12-week 
administration period). 
Serum testosterone analyses were performed in a central labora-
tory, the Urological Research Laboratory (URL), at the University of 
Nijmegen, Nijmegen, The Netherlands. Total serum testosterone was 
assessed using a Diagnostic Products Corporation (DPC) radioimmuno-
assay kit (Los Angeles, California, USA). This kit was previously tested 
against three other methods of testosterone measurement (a radioimmuno-
assay manufactured by Amersham, a fluorescence immunoassay manufac-
tured by DELPHIA system [LKB-Pharmacia], and a paper chromatographic 
analysis [Endocrinology - KN]). These assays were compared using a series 
of testosterone levels from two sets of control sera (NMS I, II, and III and 
Lyphocheck [Biorad] I, II, and III). The results of the comparisons showed 
that, in the range of low testosterone levels, the variability with the DPC 
kit was lowest, approximately 20% (2.46 ± 0.46 nmol/L). Serum testos-
terone assay results from URL were also compared with results obtained 
from Endocrine Sciences Laboratory, Ine (ESL), Calabasas Hills, CA (ESL 
used a column chromatographic assay). The comparison was made using 
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samples obtained from 15 patients at the Nijmegen University Hospital 
who were being treated with LHRH analogues; these patients were not 
enrolled in the two studies that compared the 10.8-mg and 3.6-mg 
goserelin acetate depots. 
In the current studies that compared the two depots, serum testos-
terone levels were measured before treatment, weekly for the first 4 
weeks, then every 2 weeks until Week 24, and at Weeks 36 and 48 (the 
day of administration of the first depot was defined as Day 1). On days 
when sampling coincided with depot administration, samples were taken 
before administration of the depot. Serum testosterone was recorded as 
the mean value from duplicate assessments of the testosterone level of 
the sample. Internal quality control samples (NMS and Lyphocheck) were 
included each time samples were assessed. When recorded results on any 
study day were greater than 2 nmol/L, the assessment was repeated and 
the new result was recorded as the testosterone value for that day, 
regardless of whether the new result was higher or lower than the original 
result. This castrate level was defined by using testosterone values in the 
castrate range from 10 patients in a previous study with the goserelin 
acetate 10.8-mg depot (1802). The mean testosterone value (0.95 nmol/L) 
obtained from these patients plus two standard deviations (2 X 0.55 
nmol/L) was used to arrive at the castrate level of 2.0 nmol/L. 
Efficacy evaluations 
Data for PSA, time to progression, and survival were collected 
retrospectively by the Trialbureau Urology in Nijmegen and verified against 
hospital records. PSA results were compared between the 3.6-mg and 
10.8-mg depots but only up until 3 months of therapy, because after that 
point all patients received the 10.8-mg depot. Results for time to pro-
gression and survival were combined for the two treatment groups to give 
an overview of disease outcome for these patients. 
Changes in serum PSA alone were not considered evidence of disease 
progression. However, increases in PSA levels with subjective evidence of 
progression was considered evidence of progression. 
Any one of the following was considered progression: 
• an increase greater than 50% in the value obtained when the larges 
diameter in one or more measurable lesions is multiplied by its 
longest perpendicular diameter; 
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• new soft tissue metastasis; 
• new osteolytic lesions or an increase of 25% or more in the size of 
existing osteolystic metastases; 
• new "hot spots" on bone scintigraphy. 
For changes in PSA levels, stabilization was defined as an increase of 
greater than or equal to 50% of the baseline level confirmed by 2 assess-
ments not less than 2 weeks apart. A PSA increase was defined as an 
increase greater than 4 ng/ml in patients who previously had a complete 
response, or an increase greater than 50% of the baseline level in patients 
who previously had a partial response, each confirmed by 2 assessments 2 
weeks apart. 
Any of the following was considered evidence of subjective progression: 
• cancer-related decrease of greater than 25% of the hemoglobin 
measurement or the need for more than 2 blood transfusions a 
month; 
• A cancer-related weight loss greater than 15%; 
• A cancer-related increase in the performance-pain-analgesic-per-
formance score. 
Safety evaluations 
All patients who received study treatment were included in the 
safety evaluation. Adverse events were recorded at each visit until 
patients completed their randomized therapy. Patients were solicited 
indirectly for adverse events; prompted by a question, each patient 
described anything that had bothered him since his last visit. In addition, 
any event considered by an investigator to be an adverse event was 
recorded. 
Statistical analysis 
Mean testosterone level was the primary endpoint and was ana-
lyzed statistically between Weeks 4 to 12 and at the end of Weeks 4, 8, 
and 12. Analysis of variance (ANOVA) was used to compare mean testos-
terone levels between the 10.8-mg depot and the 3.6-mg depot for each 
of the two studies separately; the results were then pooled. One hundred 
and fifty six patients were analyzed using the intent-to-treat approach. 
Possible sources of variation of study, center within study, treatment, 
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study by treatment interaction, and center by treatment interaction were 
taken into account. 
Successful induction required at least one sample value being 
below the castrate level after the first depot. For successful maintenance, 
all patients administered at least one depot were required to have no 
sample levels above the castrate level within 84 days of a depot adminis-
tration, excluding the induction period for the first depot. A 95% confi-
dence interval was derived for the difference in the percentage mainten-
ance rates between the two treatment groups to assess the precision of 
this comparison. 
The percent fall in PSA from the baseline value after 3 months of 
study treatment was calculated. The number and percentage of patients 
whose PSA values were elevated ( > 4 ng/ml) at baseline and fell to within 
the normal range at Month 3 were tabulated and compared between the 
two treatment groups. 
Time to progression and time to death were estimated using the 
methods of Kaplan and Meier. Time to progression was defined as the 
number of days from the administration of the first goserelin acetate depot 
to the date of documentation of progression or death without progression. 
The time to death was defined as the number of days from the time of 
administration of the first goserelin acetate depot to the date of death for 
any cause. Data from patients who neither progressed nor died were 
censored at the time of their last visit to the clinic. 
Results 
Demography and Patient Characteristics 
The age and body weight of patients from both treatment groups in 
both studies were similar at entry (Table I). Of the 80 patients entered into 
each study, between 10 March 1990 and 8 July 1992, 67 (84%) patients 
in Study 0001 and 66 (83%) patients in Study 1805 were over 65 years 
of age. 
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Table 1. 
Age (yr) 
Mean 
Range 
Weight (kg) 
Mean 
Range 
Demographic 
Stage (TMN classification) 
To 
T, 
Ъ 
Тэ 
т4 
т
ж 
м0 
M, 
M, 
G, 
G2 
G3 
G. 
details 
3.6-mg depot 
(η = 83) 
72 
52-89 
76 
48-108 
0 
0 
7 
46 
26 
4 
28 
43 
12 
15 
38 
26 
4 
Treatment group 
10.8 mg depot 
(η = 77) 
73 
49-88 
77 
53-105 
2 
2 
21 
38 
11 
3 
25 
44 
8 
9 
38 
26 
4 
Table II. Testosterone level suppression (nmol/U* 
Weeks of treatment Treatment group 
3.6-mg depot 
(n = 83) 
10.8-mg depot 
In = 77) 
WeekO 
Week 4 
WeekS 
Week 12 
17.91 .+ 6.99 
(n = 75) 
1.05 +. 2.04 
(n = 76) 
0.60 +. 0.39 
(n = 70) 
0 . 6 0 ^ 0 . 3 6 
(n = 65) 
18.48 +.6.35 
(n = 75) 
0.92 +. 0.47 
(n = 73) 
0.62 +. 0.49 
(n = 70) 
0.73 +.0.69 
(n = 69) 
* mean + standard deviation 
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Testosterone Assessments 
Mean testosterone levels between Weeks 4 to 12 and at the end of 
Weeks 4, 8, and 12 were below the castrate level; there were no signifi­
cant differences between the 10.8-mg and 3.6-mg treatment groups 
(Table II). 
Figure 1 illustrates the mean serum testosterone profile achieved in 
the two treatment groups. The profiles were similar for both groups, with 
testosterone levels falling below the castrate level by Day 21 and then 
remaining below the castrate level until Week 12. Beyond Week 12, when 
both groups were receiving the 10.8-mg depot, levels achieved in both 
groups were maintained below the castrate level. 
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Figure 1. Mean serum testosterone levels over 48 weeks 
Adequate suppression of testosterone was maintained in 99.4% of 
the patients. Only one (0.6%) patient did not have adequate suppression 
during therapy; the patient received the 10.8-mg depot. In eight other 
patients, a transient elevation in testosterone levels above the castrate 
limit (2.0 nmol/L) was followed by a return within 14 days to levels within 
the castrate range. The clinical outcome for these patients was similar to 
that observed for the rest of the patients in these studies. 
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Figure 2 shows the results of the comparison of assay results from 
URL and ESL. URL reported higher testosterone levels for all samples 
indicating a clear difference between the two testosterone assays. 
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Figure 2. Comparison of serum testosterone levels reported by URL and ESL 
Efficacy 
PSA results were available at baseline and at 12 weeks for 54 of 
77 patients in the 3.6-mg group and 54 of the 83 patients in the 10.8-mg 
group. The percentages of patients with PSA values that fell to within the 
normal range following 3 months of study treatment were similar between 
treatments: 26 (48.2%) of 54 patients treated with the 3.6-mg depot and 
28 (51.9%) of 54 patients treated with the 10.8-mg depot. The median 
percentage fall in serum PSA was also similar in both groups: 92.5% for 
the 3.6-mg depot and 94.0% for the 10.8-mg depot. 
One-hundred and five (66%) of the 160 patients had progressed at 
the time of this analysis. The median time to progression was 152.7 
weeks. The Kaplan-Meier probability of progression is presented in Figure 
3. Eighty-three (52%) of 160 patients had died at the time of this analysis. 
Fifty-three (64%) of 83 patients who had died did so as a result of pros­
tate cancer alone, 25 (30%) died as a result of other causes, and 5 (6%) 
died as a result of unknown causes; the observed causes of death were 
not unexpected in this patient population and none of the deaths were 
attributed to treatment. The median time to death was 213.6 weeks. The 
Kaplan-Meier probability of death is presented in Figure 4. 
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Figure 3. Kaplan-Meier probability of progression 
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Safety 
During the comparative phase (Weeks О through 12), the only 
adverse event reported in greater than 5% of patients was hot flashes, 
with an incidence of 4 7 % in the 10.8-mg group and 4 8 % in the 3.6-mg 
group. Adverse events occurring in greater than 5% of patients during the 
noncomparative phase (Weeks 12 through 48) are presented in Table III. 
Only one patient had an adverse event that led to withdrawal; the patient 
had mild pruritus from paraneoplastic dermatitis while he receiving the 
10.8 mg depot preparation of goserelin. The adverse event was considered 
unrelated to therapy with goserelin 10.8 mg. Tumor flare was reported in 
6 patients, including 4 in the 3.6-mh treatment group and 2 in the 10.8-
mg treatment group. One patient in each group had a spinal cord compres­
sion: one patient had medullary compression 8 days after receiving the 
first goserelin 3.6-mg depot; another patient had spinal cord compression 
on the same day as the first administration of the 10.8-mg goserelin 
depot. Both events were considered by the investigator to be related to 
disease progression. Only 2 (0.3%) of 614 administrations of the 10.8-mg 
depot resulted in local reactions; both were hematomas and did not require 
specific management. A local anesthetic was not required in 597 (97%) 
occasions out of 614 administrations of the 10.8-mg depot. 
Table III. Adverse events reported in greater than 5% of patients during the 
noncomparative phase, Weeks 12 to 48 
Adverse event 10.8-mg depot 
(n=157) 
n_(%) 
Hot flashes 100(64) 
Pain 22(14) 
Gynecomastia 13 (8) 
Pelvic pain 10(6) 
Bone pain 9 (6) 
Comment 
The combined results from the two studies, which include data 
from a total of 160 patients, demonstrate that the 10.8-mg depot formula­
tion of goserelin acetate is pharmacodynamically equivalent to three 
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consecutive administrations of the 3.6-mg depot, with regard to induction 
and maintenance of serum testosterone suppression. Adequate sup-
pression of serum testosterone was maintained in 99.4% of the patients. 
During treatment, nine patients had at least one serum testosterone value 
above the castrate level of 2.0 nmol/L, eight of which were transient and 
isolated; however, the clinical outcome of these patients, as measured by 
time to progression and survival, was no different from that of the rest of 
the patients in these studies. Only one patient was considered to have 
failed initial treatment with goserelin acetate for part of the treatment 
period; the resultant failure rate of 0.6% (1 of 160) was considered 
acceptable. Ultimately, with the continued administration of goserelin 
acetate during the follow-up period, this patient's serum testosterone level 
was adequately suppressed and the clinical course of his disease was 
considered by the investigator not to have been adversely affected. 
The difference in results between the URL and ESL testosterone 
assays underline the importance of defining the castrate limit using the 
local patient population and assay. It also suggests that choosing a 
different castrate limit (e.g. from literature references), may lead to 
different conclusions depending on the actual assay used. 
The median time to progression (152.7 weeks) and median survival 
time (213.6 weeks) with the 10.8-mg depot were longer than those 
previously reported with the 3.6-mg depot. Kaisary7 reported a median 
time to treatment failure of 26.9 weeks and a median survival time of 110 
weeks while Vogelzang, et al.8 reported median times to treatment failure 
and survival of 52 and 119 weeks, respectively; both used the 3.6-mg 
depot. The differences between the previously published reports and the 
current studies may be due to different patient populations; while the 
previous reports studied mainly patients with metastatic prostate cancer, 
the current studies included patients with both locally advanced and 
metastatic disease. 
The adverse event profile of the 10.8-mg goserelin depot was 
similar to that of the 3.6-mg depot. The 10.8-mg depot was well tolerated 
and the incidence of injection site reactions was low (0.3%). Tumor flare 
was reported in 6 patients, (4 in the 3.6-mg group and 2 in the 10.8-mg 
group), but none of the patients withdrew because of this adverse event. 
It is possible that co-administration of antiandrogen therapy with LHRH-A 
therapy could have prevented or lessened the severity of tumor flare in 
these patients. 
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The 10.8-mg goserelin-acetate depot is an acceptable and effective 
method for suppressing serum testosterone levels, providing a dosing 
schedule that is convenient for the patient and the physician and which 
coincides with the routine care of patients with advanced prostate cancer. 
The 10.8-mg depot also has the potential to reduce health care costs by 
reducing the number of health care provider contacts, while maintaining 
the quality of life of patients being treated for advanced prostate cancer. 
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Introduction 
The growth and function of the normal and prostatic carcinoma 
cells are largely dependent upon androgens. The primary source of 
androgens resides in the testis, but a small contribution comes also from 
the adrenals. The main androgens of adrenal origin, which account for 
about 10 percent of the total amount of circulating androgens, are 4-
androstenedione and dehydro-epiandrosterone [1]. These steroids undergo 
metabolic conversion to testosterone which is further converted to 
dihydrotestosterone (DHT) by the enzyme 5-alpha reductase. The receptor-
DHT complex binds to acceptor sites on cellular chromatin, this activates 
the transcription process, and results in formation of messenger RNA and 
increased protein synthesis [2]. 
Huggins and Scott, and Harrison, first used maximal androgen 
blockade (MAB) by castration and bilateral surgical adrenalectomy as a 
second-line form of endocrine management for patients with progression 
after castration or oestrogen therapy [3,4]. The average objective response 
was 34 percent with a duration of 2.5 months, and subjective response 
was 74 percent. Chemical adrenalectomy by aminoglutethimide and 
glucocorticoids produced similar results with objective and subjective 
responses of 23 percent and 65 percent, respectively [5,6]. The duration 
of response ranged from eight months to two years. 
Later, Geller reported that intra-prostatic levels of DHT after castra-
tion or 1 mg diethylstilbestrol per day resulted in prostatic DHT tissue 
concentrations of 1.6 (1.2 - 2.3) and 3.38 (0.2 - 4.4) ng/g, respectively 
[7]. The same author reported that there was a considerable range of DHT 
levels in various prostatic cancer tissues at the time of relapse following 
orchidectomy which suggested a positive correlation between higher levels 
of DHT and response to treatment [8]. 
Several early studies demonstrated the importance of suppressing 
androgens of extra-testicular origin in the prostate. 
MAB can be achieved by combined androgen blockade: castration 
or luteinizing hormone-releasing hormone (LH-RH) analogue in combination 
with an anti-androgen. Anti-androgens block the receptor that forms part 
of the DHT-receptor complex and thus inhibit the translocation of hor-
mone-receptor complex into the prostate cell nucleus. Anti-androgens are 
classed as steroidal (cyproterone acetate, CPA) and non-steroidal or pure 
(flutamide, nilutamide, bicalutamide). Steroidal anti-androgens have 
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progestational and anti-gonadotrophic properties [9], whereas pure anti-
androgens only neutralize the action of androgens (from all sources) and 
thus, theoretically, represent an ideal form of therapy [10]. A summary of 
the results of studies in which MAB has been used to treat advanced 
prostate cancer follows. 
Labrie reported the results of a non-randomised, open study of 10 
patients combining an LH-RH agonist (buserelin) and a pure anti-androgen 
(nilutamide) to treat patients with stage С and D prostate cancer [11]. Nine 
patients had positive bone scans and four had elevated serum acid 
phosphatase. Bone pain, clinical signs and symptoms of prostatism, and 
general well-being were improved by 60-90 percent within one month. 
After t w o months, minimal bone pain remained in only one patient. Bone 
scans demonstrated a 70-90 percent decreased uptake and in three out of 
four patients acid phosphatase levels were reduced by 60-90 percent after 
two months of treatment. 
In 1985, the same authors reported the results of 87 previously 
untreated patients with stage D2 prostate cancer [12]. Seventy-seven 
patients received combination therapy (Tryptal or buserelin alternated with 
flutamide) and 10 patients had an orchidectomy plus flutamide. Twenty 
out of 87 patients randomly received either flutamide or nilutamide; 
however, the occurrence of visual disturbances in 70 percent of the 
patients receiving nilutamide thereafter led to the substitution of nilutamide 
with flutamide. A 100 percent objective response (National Prostatic 
Cancer Project [NPCP] criteria) was observed in all cases [12]. Pain 
disappeared in all patients within one month and performance status 
became normal in all patients within four months. After a period of 
remission, progression was observed in eight patients; only one patient 
died from prostate cancer. The probability of continuing response and 
survival at two years for those patients receiving combination therapy was 
81 and 91 percent, respectively [12]. 
Combined treatment with LH-RH agonist and pure anti-androgen 
produced a remission of 60-80 percent in a group of 30 patients with 
advanced prostate cancer [13]. Of these only one has died after two years 
compared with the 40-54 percent death rate observed after castration 
alone. 
While the results of Labrie seem to be favourable, the data should 
be considered as very preliminary on the basis of the small number of 
patients and the short follow-up. To address this problem, a randomised 
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EORTC study was started to investigate the possible advantages of the 
addition of an anti-androgen (CPA) to medical castration with an LH-RH 
analogue [14]. During the 1980s, many randomised have been developed: 
for example, an LH-RH analogue plus an anti-androgen vs LH-RH analogue 
plus placebo [15,16]. 
In 1984, the US National Cancer Institute (NCI) sponsored a large 
randomised, controlled, multicenter, inter-group study (NCI INT 0036) to 
evaluate combined therapy. The results, reported in 1989, showed a three-
month difference in the median progression-free survival and a 7.1-month 
difference in survival suggesting that combined therapy (1 mg subcu-
taneous leuprolide per day and 250 mg flutamide three times a day) offers 
some advantage over monotherapy in the treatment of advanced prostate 
cancer. After stratification, treatment with leuprolide and flutamide was 
found to be superior to leuprolide alone, particularly in men with minimal 
disease and a good performance status [17]. 
Similarly, following a re-assessment of EORTC study 30853 
(Zoladex and flutamide vs bilateral orchidectomy, first reported by 
Keuppens et al [18].), Denis noted that there was a statistically significant 
increase in time to subjective and objective progression in favour of the 
combination treatment [19,20]. 
However, not all studies have reported such positive findings with 
the use of MAB [6,21,22,23,24]. These investigations did not show any 
superiority for total androgen withdrawal over testicular suppression alone 
in terms of subjective and objective responses, or survival. In these 
studies, combined treatment was associated with more side-effects. 
Further investigations into the role of MAB in advanced prostate 
cancer were conducted from June 1986 until February 1988 in a double-
blind, randomised, multicenter trial (protocol FF/86/908/01). This study 
compared total androgen blockade, using nilutamide in combination with 
orchidectomy, vs orchidectomy alone and evaluated: 
1. objective and subjective responses including survival 
2. safety and tolerance of treatment. 
The investigation was followed by an extended treatment period: 
3. to evaluate the long-term safety and tolerance and the significance 
of early normalization of prostate specific antigen (PSA). 
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Urologists still face the challenge of how best to select appropriate 
advanced prostate cancer patients to receive combination therapy. A 
retrospective analysis of patients with disseminated prostate cancer has 
therefore been performed to: 
4. establish the importance of prognostic factors and categorise 
patients into risk groups. 
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Abstract 
The efficacy and tolerance of the nonsteroidal antiandrogen nilutamide in 
the treatment of prostatic cancer were studied in a large double-blind clinical trial 
initiated in 1986. Patients with metastatic prostatic cancer without prior 
endocrine manipulation underwent orchiectomy and were randomized to 1 of 2 
groups receiving nilutamide (225 patients) or placebo (232). Nilutamide and 
placebo were evaluated for efficacy in 207 and 216 patients, respectively. 
Progression-free survival was significantly longer in the nilutamide group 
(median time to progression 20.8 months on nilutamide and 14.9 months on 
placebo, ρ = 0.005). Median time to death from prostatic cancer was 30.0 
months in the placebo group and 37 months in the nilutamide group. Objective 
regressions were higher in the nilutamide group (41 %) than in the placebo group 
(24%). Significant differences in favor of the nilutamide group were found at 
several intervals for bone pain, prostatic acid phosphatase, prostate specific 
antigen, alkaline phosphatase and bone scan isotope uptake. 
Nilutamide and orchiectomy constitute a more effective treatment for 
metastatic prostatic cancer than orchiectomy alone, and the adverse effects of 
nilutamide, usually minor, are outweighed by the significant improvements in 
most disease measures and progression-free survival. 
Introduction 
For nearly 50 years suppression of testicular androgens has been the 
cornerstone of treatment for advanced prostatic cancer. It has been achieved 
with surgical castration, estrogens1 and more recently luteinizing hormone-
releasing hormone agonists.2 None of those methods impairs the secretion of 
adrenal androgens, which are responsible for substantial amounts of the active 
androgen 5a-dihydrotestosterone remaining in the plasma and prostatic tissue.3 , 4 
Surgical or chemical adrenalectomy, as a second-line treatment in relapsing 
castrated patients, has been used to obtain total androgen ablation but with 
disappointing results.6 
The simultaneous removal of all active androgens through the 
combination of an antiandrogen with surgical or chemical castration as first 
hormonal treatment of advanced prostatic cancer was studied in open trials.6 , 7 
The authors reported that response rate and survival were better than those 
obtained with ablation of testicular androgens alone. The first double-blind trials 
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of orchiectomy plus a nonsteroidal antiandrogen versus orchiectomy plus a 
placebo showed a significant beneficial effect of the combination treatment as 
judged by best objective response, which was the main efficacy criterion studied, 
and several secondary criteria, including pain and disease markers.8,9 Those 
studies, however, included relatively small numbers of patients and would have 
allowed the detection of only large differences in interval to progression or 
survival. 
To confirm the beneficial effect of the combination treatment on response 
rate and to study its effect on time to progression, a large study to compare 
orchiectomy and the antiandrogen nilutamide with orchiectomy and placebo was 
instituted. Orchiectomy was chosen because it remains the standard treatment 
for metastatic prostatic cancer. It leaves plasma testosterone concentrations 
predictably low and not dependent on patient compliance, as might be the case 
with use of luteinizing hormone-releasing hormone agonists or estrogens. 
Testicular androgens are suppressed immediately after orchiectomy. In contrast, 
with the administration of luteinizing hormone-releasing hormone agonists the 
decrease in testosterone is preceded by a peak with a possible flare-up of the 
disease. A beneficial effect of the antiandrogen might be related to the 
prevention of the early flare-up rather than to the long-term blockade of the 
action of adrenal androgens. 
The nonsteroidal antiandrogen nilutamide was chosen for several reasons. 
Its potent antiandrogenic activity was demonstrated not only in animals10, but 
also in human studies. The drug is effective in blocking androgen activity in 
male-to-female transsexuals11 and in preventing luteinizing hormone-releasing 
hormone agonist-induced flare-up.12 The long half-life of 56 hours13 allows for a 
convenient once-a-day dosage and ensures permanent saturation of androgen 
receptor sites, thus preventing more effectively the access of adrenal androgens 
to androgen dependent tumor cells. The dosage of nilutamide was based on the 
kinetics profile and on the results of a dose-ranging double-blind study that 
compared nilutamide at 150 and at 300 mg. per day, and a placebo.8 
Nilutamide is known to be an effective component in the treatment of 
prostatic cancer in combination with orchiectomy. Double-blind studies 
comparing orchiectomy and nilutamide with orchiectomy and placebo had shown 
a higher response rate, more frequent pain improvement and normalization of 
markers in the nilutamide groups. However, a study with at least 200 patients 
per treatment group was needed to evaluate the efficacy of the combination on 
interval to progression and survival. 
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Materials and Methods 
Patients and protocol design 
The study wasamulticenter, double-blind, randomized, placebo-controlled 
trial in which 66 investigators in 15 countries participated. It began in June 1986 
and the planned number of patients was reached in March 1988. To be eligible 
patients had to be 40 to 85 years old, have histologically documented carcinoma 
of the prostate with évaluable and measurable distant metastases (M+), have an 
anticipated survival of at least 3 months, accept imminent orchiectomy and give 
informed consent to participate in the study. Patients were excluded if they had 
received any hormonal treatment or chemotherapy for the prostatic cancer, had 
another neoplasm other than nonmelanomatous skin cancer, had severe hepatic 
or renal dysfunction unrelated to prostatic cancer, or were receiving any 
medication that could interfere with the interpretation of efficacy. Previous 
radiation for the primary tumor was allowed. 
We enroled a total of 457 patients: 225 in the orchiectomy plus 
nilutamide group and 232 in the orchiectomy plus placebo group. The main 
patient and disease characteristics are shown in table 1. No difference was found 
between the 2 groups at inclusion. A total of 34 patients who did not fulfil the 
inclusion criteria was excluded from the efficacy analysis. The numbers and 
reasons for exclusion are given in table 2. Therefore, the numbers of évaluable 
patients were 207 in the nilutamide group and 216 in the placebo group. 
After pretreatment evaluation patients underwent orchiectomy and were 
randomly assigned to receive, starting the day after orchiectomy, either 300 mg. 
nilutamide orally once a day for 1 month and 150 mg. once a day thereafter or 
identical placebo tablets. Randomization was centralized, stratified by center and 
balanced by blocks of 4. Before the onset of treatment a medical history was 
obtained and a complete physical examination was performed. The 
characteristics recorded were metastatic pain on a 5-point rating scale (with 
analgesic consumption taken into account), performance status (Karnofsky 
seals), dimensions of primary tumor (according to rectal examination) and urinary 
obstruction. Radiological evaluations included a bone scan followed by 
roentgenography of areas displaying abnormal uptake, chest roentgenography 
and excretory urography or nephrography. Laboratory tests performed by the 
local institutions included a hematological profile; measurements of platelets, 
haptoglobin, prothrombin time and Coombs antibodies; blood chemical 
measurements; uringlysis, and measurement of plasma alkaline phosphatases and 
prostatic acid phosphatase (PAP). In addition, PAP, prostate specific antigen 
(PSA), testosterone and nilutamide were assayed at a central laboratory. 
126 
Orchiectomy and Nilutamide or Placebo for Metastatic Prostate Cancer 
Table 1. Characteristics of évaluable patients in treatment groups before enrollment 
Characteristics 
Orchiectomy Plus 
Nilutamide (207 pts) 
Orchiectomy Plus 
Placebo (216 pts) 
Mean yrs. age (range) 
White pts. (%) 
Median mos. of stage D2 diagnosis 
(range) 
Historical finding, Gleason grade 
8-10(%)* 
Impaired performance status. 
Karnofsky scale 70 or less (%) 
Metastatic pain (%) 
Wt. loss more than 10% (%) 
Extensive bone involvement (%)" 
Soft tissue metastases (%)' 
Hydronephrosis (%) 
Prior radiotherapy of prostate (%) 
Hemoglobin less than 12 gm./dl. (%) 
PSA: i 
Upper normal value or less (%) 
Greater than upper normal value 
and 100 or less times upper normal value 
(%) 
Greater than 100 times upper normal value 
and 1,000 or less times upper normal value 
(%) 
Greater than 1,000 times upper 
normal value (%) 
PAP: 
Upper normal value or less (%) 
Greater than upper normal value 
and 10 or less times upper normal 
value (%) 
Greater than 10 times upper normal 
value (%) 
Alkaline phosphatase: 
Upper normal value or less (%) 
Greater than upper normal value 
and 4 or less times upper normal 
value (%) 
Greater than 4 times upper normal 
value (%) 
Mean ng./dl. testosterone (range) ! 
71.0(50-85) 
90 
0.50 (0-90) 
41 
35 
68 
20 
70 
13 
25 
10 
26 
2 
37 
50 
11 
25 
48 
27 
35 
43 
22 
380.6 
(16-1,051) 
72.0 (46-86) 
92 
0.53 (0-59) 
42 
37 
61 
17 
73 
12 
19 
12 
30 
4 
37 
52 
27 
50 
23 
31 
49 
20 
382.8 
(17-1,084) 
* Central review pathology slides (Prof. D.J. de Ruiter, St. Radboud Hospital Nijmegen, The 
Netherlands), " More than 2 lesions, ' With or without bone or lymph node involvement, 
§ Central laboratory: nilutamide 134 patients and placebo 133 patients 
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Table 2. 
Reason for E 
Patients excluded from efficacy analysis 
ixclusion 
No. 
Orchiectomy Plus 
Nilutamide 
Pts. Excluded 
Orchiectomy Plus 
Placebo 
Age more than 85 years 
Stage С or D1 
Previous hormonal therapy 
Previous radiotherapy 
Use of antiandrogenic drugs 
History or presence of another Ca 
Severe hepatic or renal dysfunction 
Concomitant Paget's disease 
Drug started more than 12 days after 
orchiectomy 
Totals 
0 
4 
0 
0 
5 
3 
2 
4 
0 
18 
1 
0 
1 
1 
5 
3 
3 
0 
2 
16 
Patients were excluded only from the analyses of objective response, best response to 
treatment, progression of prostatic cancer and bone scan isotope uptake. 
Clinical and laboratory evaluations, except that of plasma testosterone, 
were repeated after 1, 3 and 6 months, and every 6 months thereafter. 
Radiological examinations (bone scan and/or computerized tomography, and bone 
and chest roentgenography) were performed at 6 months, every 6 months 
thereafter and whenever a patient had subjective progression. 
Objective response was assessed according to National Prostatic Cancer 
Project criteria, which were modified to be more strict for objective progression. 
The category of subjective progression was used when a disease-related 
deterioration was not accompanied by objective evidence of progression. A 
patient was said to have subjective progression if he had 1 of the following 
conditions: cancer related deterioration in Karnofsky index by at least 1 general 
category, weight loss of 10% or greater or increase in metastatic pain evidenced 
by the need for increased analgesia. 
When there was objective and subjective progression the event that 
occurred first was considered for the analysis of interval to objective or 
subjective progression. The main efficacy criteria were best objective response 
to treatment, interval to progression and survival. 
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Individual response criteria, such as metastatic pain, performance status, 
amount of isotope uptake on bone scan and tumor markers, were also analyzed. 
Patients continued taking the study drug until they had objective progression or 
intolerance, or withdrew consent. When progression occurred the patients who 
had been in the nilutamide group could continue on an open-label basis; patients 
who had been on placebo were not given nilutamide so as to permit a 
comparison according to the initial randomization. In any case, patients were 
followed until death. 
The safety of the drug was evaluated at each visit by questioning patients 
in a general manner to determine whether any clinical adverse experience had 
occurred and by monitoring laboratory values. All clinical or laboratory adverse 
events were recorded, regardless of the relationship to treatment. 
Statistical methods 
On the basis of assumption that patients treated with orchiectomy and 
placebo had an interval to progression of 65 weeks, it was calculated that with 
200 patients per group the study would provide a 94% chance of detecting a 
3 8 % improvement in the median progression-free survival from 65 weeks to 90 
weeks at the 0.05 level of significance. Demographic and pretreatment 
characteristics were compared with analysis of variance for continuous variables 
and the Cochran-Mantel-Haenszel test for the categorical variables. For objective 
response and best response to treatment (modified National Prostatic Cancer 
Project criteria), the percentages of patients with regression and progression of 
prostatic cancer were compared with the Cochran-Mantel-Haenszel test. When 
patients were withdrawn for safety they were censored at the date of 
discontinuation of treatment and they were included in the intent-to-treat analysis 
of interval to progression and interval to death. 
Progression-free and survival actuarial rates were computed with the 
Kaplan-Meier estimate. The survival distribution of the 2 treatment groups was 
subjected to the log-rank test. For all individual efficacy variables, changes from 
pretreatment evaluations in the 2 treatment groups were compared at each visit 
with the Cochran-Mantel-Haenszel test. For weight, blood pressure and 
laboratory results analyzed for safety, treatment groups were compared with 
analysis of variance on differences from pretreatment values. All reported ρ 
values are based on 2-sided tests; differences are reported as statistically 
significant if ρ is < 0 . 0 5 . 
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Results 
At the time of data Collection of all patients (May 3 1 , 1990) the median 
follow-up was 35 months and 388 patients had been discharged from the study: 
190 in the nilutamide group (including 112 because of progression and 39 
because of intercurrent or adverse events) and 198 in the placebo group 
(including 140 because of progression and 24 because of intercurrent or adverse 
events). 
Compliance 
Close accountability of drug consumption and central assay of plasma 
nilutamide at all study points confirmed the good compliance with treatment. 
Table 3. Best response of évaluable patients to treatment at any time during treatment 
Reason for Exclusion 
Response: 
Complete objective regression 
Partial regression 
Objectively stable disease 
Subjective progression® 
Objective progression 
Not classified 
No. classifiable pts.: 
Regression 
Stable plus progression 
Regression plus stable 
Progression 
Orchiectomy 
Plus 
Nilutamide 
(184 pts.C 
14(8) 
58 (32) 
64 (35) 
10(5) 
29(16) 
9(5) 
175 
72(41) 
103(59) 
136 (78) 
39 (22) 
No. Evaluable Pts. (%) 
Orchiectomy 
Plus 
Placebo 
(191 pts.)* 
9(5) 
35 (18) 
72 (38) 
15(8) 
51 (27) 
9(5) 
182 
44 (24) 
138(76) 
116 (64) 
66 (36) 
Ρ Values 
< 0.001 
0.002 
§ 
@ 
Excluded 35 patients (18 nilutamide and 17 placebo) with no National Prostatic 
Cancer Project data and 13 patients (5 nilutamide and 8 placebo) with pretreatment 
bone scan missing or not performed at right time (3 months before to 2 weeks after 
entry). 
Based on Cochran-Mantel-Haenszel test. 
Without evidence of objective progression. 
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Best response to treatment 
If only regression (complete and partial) was considered as a response to 
treatment, the percentage of response was 41 % in the nilutamide group and 
24% in the control group (table 3, ρ < 0.001). If regression and stabilization of 
the disease were considered as responses to treatment, the percentage of 
response was 7 8 % in the nilutamide group and 64% in the placebo group (p = 
0.002). The percentage of patients who neither improved nor stabilized for at 
least 6 months and who, therefore, had progression as the best response to 
treatment was 2 2 % in the nilutamide group and 3 6 % in the placebo group. 
Interval to progression 
The progression-free actuarial rates were consistently higher (p = 0.005) 
in the nilutamide group than in the placebo group. The median interval to 
objective progression was 20.8 months with nilutamide and 14.9 months with 
placebo (fig. 1). With respect to interval to objective or subjective progression, 
the between group difference was also significant (p = 0 . 0 4 1 , fig. 2). 
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Fig. 1. Progression-free actuarial rate: objective progression (évaluable patients). 
, orchiectomy plus nilutamide (ANANDRON) group, 202 patients at risk, 118 with 
progression, median time 20.8 months. - - -, orchiectomy plus placebo group, 208 
patients at risk, 145 with progression, median time 14.9 months. 
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Fig. 2. Progression-free actuaría/ rate: objective or subjective progression (évaluable 
patients). , orchiectomy plus nilutamide (ANANDRON) group, 202 patients at risk, 
133 with progression, median time 18.1 months. , orchiectomy plus placebo 
group, 208 patients at risk, 153 with progression, median time 13.8 months. 
Survival 
The cutoff date for survival data analysis was January 3 1 , 1991, by 
which time 313 of the 457 patients had died: 145 (64%) in the nilutamide group 
and 168 (72%) in the placebo group. Among them, 104 nilutamide patients and 
132 placebo patients were reported as having died of prostatic cancer. For 
évaluable patients interval to death from all causes was longer in the nilutamide 
group: the median survival time was 27.3 months with nilutamide and 24.2 
months with placebo. In regard to deaths from cancer, the median interval to 
death was 37.0 months in the nilutamide group and 30.0 months in the placebo 
group (p = 0 .071, fig. 3). 
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Fig. 3. Prostate cancer survival actuarial rate (évaluable patients). , orchiectomy plus 
nilutamide (ANANDRON) group, 207 patients at risk, 98 deaths, median time 37.0 
months. - - -, orchiectomy plus placebo group, 216 patients at risk, 121 deaths, 
median time 30.0 months. 
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Intent-to-treat analyses performed on all patients for death from any 
cause yielded results similar to those based on évaluable patients. However, for 
death from prostatic cancer the difference between the 2 groups was statistically 
significant in favor of nilutamide (p = 0.041). The median interval to death was 
37.1 months in the nilutamide group and 29.8 months in the placebo group. 
Pain 
Significantly more patients in - the nilutamide group than in the placebo 
group had a decrease in pain at 1 month (74% versus 68%, ρ = 0.046), 
3 months (85% versus 7 0 % , ρ = 0.007) and 6 months (78% versus 6 5 % , 
ρ = 0.030). 
Performance status (Karnofsky scale) 
No significant differences in changes in performance status were noted 
between the 2 groups for patients with a pretreatment Karnofsky index of 70 or 
less. Improvement occurred in 69% versus 68% at 1 month, 8 3 % versus 7 2 % 
at 3 months and 7 1 % versus 76% at 6 months in the nilutamide and placebo 
groups, respectively. At 6 months among patients with a Karnofsky index of 80 
or more before treatment 16 of 108 nilutamide patients and 26 of 112 placebo 
patients had worsened. 
Bone scan 
A semiquantitative evaluation of areas with increased isotope uptake for 
each body site was done. The extent of areas with increased isotope uptake at 
each visit was compared with baseline values in a blind manner and classified on 
a 6-point scale (table 4). The percentages of patients who had improved were 
significantly higher in the nilutamide group than in the placebo group: 5 2 % 
versus 3 9 % at 6 months and 52% versus 3 7 % at 12 months (p = 0.01 and 
ρ < 0 . 0 0 1 , respectively). 
Tumor markers 
PAP values, which were abnormal before treatment, normalized more 
rapidly in the nilutamide group. At 1 month 5 1 % of previously abnormal PAP 
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values in the nilutamide group had become normal, compared with only 3 2 % in 
the placebo group (p = 0.027). At 6 months similar percentages had normalized 
in the 2 groups (60% and 5 7 % , respectively). PSA, which was abnormal before 
entry in 9 8 % of the patients on nilutamide and 9 6 % on placebo, had become 
normal in 17% and 14%, respectively, after 1 month. A significant difference 
was apparent in favor of nilutamide at 3 and 6 months, with normalization of 
5 7 % and 2 8 % in the nilutamide and placebo groups, respectively, at both times. 
At both times the ρ value was < 0.001. Alkaline phosphatase normalized in more 
patients in the nilutamide group than in the placebo group: 2 6 % versus 12% at 
3 months (p = 0.005), 41 % versus 28% at 6 months (p = 0.039) and 4 8 % 
versus 25% at 12 months (p = 0.002). 
Table 4. Change from pretreatment in bone scan isotope uptake (évaluable patients! 
No. Pts. at 6 Mos. (%) 
Uptake Change 
Disappeared 
Decreased by 50% to less than 100% 
Decreased by less than 50% 
Unchanged 
Decreased, with new area(s) 
Increased, with new area(s) 
Orchiectomy 
Plus 
Nilutamide 
(155 pts.) 
11 (7) 
37 (24) 
32 (21) 
42 (27) 
12(8) 
21 (14) 
Orchiectomy 
Plus 
Placebo 
(153 pts.) 
6(4) 
23 (15) 
30 (20) 
58 (38) 
10(7) 
26(17) 
No. Pts. at 12 Mos. (%) 
Ρ Value* 
0.010 
Uptake Change Orchiectomy 
Plus 
Nilutamide 
(124 pts.) 
Orchiectomy 
Plus 
Placebo 
(111 pts.) 
Ρ ValueS 
Disappeared 
Decreased by 50% to less than 100% 
Decreased by less than 50% 
Unchanged 
Decreased, with new area(s) 
Increased, with new area(s) 
13(10) 
25 (20) 
27 (22) 
32 (26) 
13(10) 
14(11) 
7(6) 
14(13) 
20(18) 
31 (28) 
8(7) 
31 (28) 
<0.001 
Patients with pretreatment bone scans more than 3 months old were not included in analysis. 
* Blind comparison with baseline. 5 Based on Cochran-Mantel-Haenszel test. 
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Safety 
All patients included in the study were analyzed for safety. Totals of 
15.5% of the patients in the nilutamide group and 9% in the placebo group were 
prematurely withdrawn from the study because of adverse or intercurrent events. 
All adverse or intercurrent events were recorded, so that a large number of 
patients in each group had 1 or more events: 188 (84%) in the nilutamide group 
and 182 (78%) in the placebo group. The most frequent adverse events are 
listed in table 5. 
Table 5. Most frequent clinical and laboratory adverse events 
Events 
Hot flushes 
Visual disturbance 
Nausea 
Dyspnea 
Gynecomastia 
Alcohol intolerance 
Liver enzyme increase 
Anemia 
Respiratory disorders, regardless of relationship with study medication, 
occurred with similar frequency in the 2 groups and were the cause of 
withdrawal from the study of 7 (3.1 %) nilutamide and 1 (0.4%) placebo patients. 
Among the 7 nilutamide patients 1 had interstitial lung disease after 2.5 months 
in the study. The symptoms and chest roentgenogram improved after drug 
discontinuation. One patient had increased lung markings discovered on a chest 
roentgenogram but no respiratory symptoms. The other 5 patients either had 
dyspnea with no other sign or symptom of interstitial lung disease or had 
unrelated respiratory events. 
Digestive problems consisted mainly of nausea. The visual disturbances 
were lengthening of light-to-dark adaptation or blurred vision, resulting in 
withdrawal of 5 patients from treatment. The body hair loss and scalp hair 
growth reported in some nilutamide patients as intercurrent events were related 
to the antiandrogenic activity. Apart from the increases in liver enzymes, which 
were transient in 16 of 18 patients, laboratory adverse events were the same in 
both groups. 
Orchiectomy Plus 
Nilutamide 
(225 pts.) 
62 (28) 
61 (27) 
22(10) 
13(6) 
9(4) 
11 (5) 
18(8) 
9(4) 
No. Pts. (%) 
Orchiectomy Plus 
Placebo 
(232 pts.) 
50 (22) 
6(3) 
13(6) 
15(7) 
13(6) 
1 (0.4) 
9(4) 
16(7) 
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Discussion 
Orchiectomy is regarded as the standard first line hormonal treatment for 
metastatic prostatic cancer. Although it has not been proved to prolong 
survival,14 it is widely acknowledged to lead to disease regression and improved 
quality of life. In recent studies the rates of disease regression after orchiectomy 
alone ranged from 209 to 57%,8 median interval to progression from 7.715 to 
18.516 months and median overall survival from 1615 to 35.58 months. Results 
might differ with severity of the disease or because some measures, such as pain 
and urinary symptoms, are subjective and others, such as improvement in bone 
scan isotope uptake, are objective. 
In our trial ablation of testicular androgens was achieved through 
orchiectomy in both groups, and the combined treatment (with nilutamide or 
placebo) was randomized and doubleblind. As verified on the basis of many 
individual demographic and prestudy disease characteristics, including sample 
pathological review and centrally assayed testosterone, PAP and PSA, the 2 
groups were comparable on entry into the study. 
Because of the blindness of evaluation the comparison between the 
groups was reliable for subjective and subjectively assessed measures, as well 
as for objective measures, such as tumor markers and overall survival. At the 
time of data cutoff all patients had a potential followup of at least 26 months, 
and more than half of them had objective progression or died. Estimation of the 
median intervals to progression and death was, therefore, reliable. For 2 of the 
3 main efficacy measures, best objective response and progression-free rates, 
treatment with orchiectomy and nilutamide was more effective than treatment 
with orchiectomy alone. Although the between group difference for survival did 
not reach statistical significance, the increase in median survival in the nilutamide 
group paralleled the increase in median interval to objective progression. A similar 
coherence in the differences in favor of nilutamide was observed for individual 
measures. After 6 months of treatment pain had improved more often and 
worsened less often, tumor markers had become normal in more patients and 
bone scan isotope uptake had improved more frequently in the nilutamide group. 
When this study began no validated method of evaluating quality of life 
in patients with prostatic cancer was available. We used pain, the Karnofsky 
index and interval to objective or subjective progression as indirect indicators of 
quality of life. The treatment related differences were significantly in favor of 
nilutamide for pain and interval to objective or subjective progression; changes 
in the Karnofsky index were similar in the 2 groups. Treatment related adverse 
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events should also be considered in the evaluation of quality of life. The transient 
visual disturbances that occurred at entrance into a dark area were troublesome 
to only 5 of 225 patients and most often they were considered mild. 
This large controlled clinical trial confirmed the beneficial effects of the 
combination treatment of orchiectomy and nilutamide compared with 
orchiectomy alone on best objective response, pain, PAP and alkaline 
phosphatase that were obtained in studies done with the same design and the 
same antiandrogen by Beland9 and Knönagel15 et al., and Brisset.6 The first of 
those studies, performed in Canada, included 208 patients and a long followup 
that allowed for comparison of interval to progression and survival. The 
differences in favor of nilutamide for progression-free survival and overall survival 
were similar to those reported in our study, although they did not reach statistical 
significance in prior studies, possibly because of the smaller patient numbers. 
Although to our knowledge no other reported long-term, large, double-
blind study has compared an antiandrogen with placebo in combination with 
orchiectomy, such studies have used a luteinizing hormone-releasing hormone 
agonist as the means of testicular androgen removal. Crawford et al. reported no 
significant difference in response rate but a longer interval to progression and 
survival in the group treated with leuprolide and flutamide than in the group 
treated with leuprolide and placebo in a large multicentric study.17 Another large 
study reported a significantly better objective response rate, improvement of pain 
and normalization of tumor markers with leuprolide and nilutamide than with 
leuprolide and placebo.18 However, there was no difference between groups in 
interval to progression and survival because possibly few patients had 
progression or died at the time of analysis. Sufficient duration of followup is 
important. 
Fourcade et al. recently reported a difference in interval to progression 
favoring goserelin and flutamide over goserelin and placebo,19 whereas results 
reported previously did not show such a difference.20 Other large studies with 
long followup have been randomized and comparative but not double-blind. They 
include comparisons of orchiectomy with orchiectomy and cyproterone acetate,21 
goserelin with goserelin and flutamide, 22,23 orchiectomy with goserelin and 
flutamide,16,24 and goserelin with goserelin and cyproterone acetate.25 Differences 
in some measures were found in several studies but not in others. Without a 
double-blind design, however, it is difficult to be sure of the comparability of 
groups at entry and to eliminate investigator bias. Moreover, it is difficult to rely 
on results regarding measures that are not strictly objective. 
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Without generalizing to all means of castration or all antiandrogens, we 
conclude from this large, well controlled and carefully monitored study that the 
combination of orchiectomy and nilutamide is more effective than orchiectomy 
alone as a first line hormonal treatment in patients with metastatic prostatic 
cancer in alleviating metastasis related pain, normalizing tumor markers, 
increasing objective response rate and prolonging the interval to objective or 
subjective progression. It might also prolong survival. The clear-cut efficacy 
markedly outweighs the inconvenience of adverse events seen with nilutamide. 
Although there was no pretreatment stratification according to disease severity, 
an analysis is planned to try to determine whether some groups of patients will 
derive a greater benefit from the combination treatment than others. 
PSA, PAP, testosterone and nilutamide assays were performed at Cerba, Cergy-
Pontoise, France. 
Additional participants included Prof. Leon Bernstein-Hann, Hospital Israelita Ezrah and 
Dr. Jorge Schiappapietra, Hospital Italiano, Buenos Aires, Argentina; Dr. Eike Dittel, Ao 
Krankenhaus, Krems Donau and Prof. Julian Frick, Landeskrankenanstalten, Salzburg, Austria; 
Prof. Luc Baert and Dr. Hendrik Van Poppel, Universitair Ziekenhuis, Leuven, and Dr. G. 
Legraive, Centre Hospitalier Bracops and Prof. Claude C. Schulman and M. Vanden Bossche, 
Hôpital Erasme, Bruxelles, Belgium; Prof. Joseph L. Chin, University Hospital, London, Ontario, 
Prof. Mostafa M. Elhilali, Royal Victoria Hospital, Montreal, Quebec, Dr. Ernest W. Ramsey, 
Healih Sciences Center, Winnipeg, Manitoba and Dr. Peter Venner, Cross Cancer Institute, 
Edmonton, Alberta, Canada; Prof. Clement С Abbou and Dr. Dominique Chopin, Centre 
Hospitalier Universitaire Henri Mondor, Creteil, Dr. Henry Botto, Hôpital Foch, Suresnes, Dr. 
Jean-Marie Brisset, Clinique Medico Chirurgicale de la Porte de Choisy, Paris, Dr. Roland 
Jorest, Centre Hospitalier de Creil, Creil, Dr. Ilya Savatovsky, Centre Hospitalier General R. 
Ballanger, Aulnay-Sous-Bois and Prof Gérard Serment, Hotel Dieu, Marseille, France; Prof. 
Tullio Lotti, Universita di Napoli, Napoli, Prof. Michelangelo Rizzo and Dr. Ricardo Bartoletti, 
Università di Firenze, Firenze, and Dr. Filiberto Zattoni, Università di Padova, Padua, Italy; Prof. 
N.F. Dabhoiwala and Dr. Th.M. de Reijke, Academisch Medisch Centrum, Amsterdam Zuid-
Oost, Prof. F.M.J. Debruyne and Dr. P. Fernandez, Radboud University Hospital, Nijmegen, Dr. 
G.A. Dijkman, Ignatius Ziekenhuis, Breda, Dr. H. Groenewold, Streekziekenhuis, Almelo, Dr. 
R.P. Heybroek, Vereniging "Het Ziekenhuis", Velp, Prof. R.A. Janknegt and Dr. J.G. 
Fernandes, Groot Ziekengasthuis, 's-Hertogenbosch, Dr. G.S.S. Khoe, Ziekenhuis "de 
Stadsmaten", Enschede, Dr. M. Kiewiet de Jonge, Rode Kruis Ziekenhuis, Den Haag, Dr. 
W.L.R. Knol, Ziekenhuis Rivierenland, Tiel, Dr. J.G. Lardenoye, Maria Ziekenhuis, Tilburg, Dr. 
J. Plasman, StFranciscus Ziekenhuis, Roosendaal, Dr. J.C. Scheepers, St Maartens Gasthuis, 
Venlo, Dr. J. Wagenaar, Lichtenberg Ziekenhuis, Amersfoort, and Dr. E.H.J. Weil, St Annadal 
Ziekenhuis, Maastricht, The Netherlands; Dr. Fernando Calais Da Silva, Hospital Desterro, 
Lisbon, Dr. Manuel De Sousa, Hospital Distrital de Viseu, Viseu and Dr. Joao Lino Dos Santos, 
Centro Hospitalar, Funchal-Madeira, Portugal; Dr. Hermann Becker, Marienkrankenhaus, 
Hamburg, Prof. Hans J. Peters and Dr. Kipping, St Elisabeth Hospital, Köln, and Dr. Elias 
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Papadopoulos, Klinik of the С Albrechts University, Kiel, Federal Republic of Germany; Prof. 
Dionisius J. Du Plessis, University of Pretoria, Pretoria and Prof. Louis Goedhals, Orange Free 
State University, Bloemfontein, South Africa; Prof. Georg Rutishauser and Dr. Franz J. Hering, 
Urologische Klinik, Basel, Prof. D. Hauri and Dr. Harmut Knönagel, Universitätsspital, Zürich, 
Dr. Hans Neuenschwander, Ospedale Civico, Lugano, and Dr. Edgar Senn and Dr. H. Alioth, 
Kantonsspital, St Gallen, Switzerland; Prof. Hjalmar Jansen and Dr. A. Paradis, Central 
Lasarett, Karlskrona, Sweden; Prof. Geoffrey Chisholm and Mr. Christopher M. Goodman, 
Western General Hospital, Edinburgh, Mr. Nairn В. Farah, Central Middlesex Hospital, London, 
Prof. John M. Fitzpatrick and Mr. James M. Smith, Mater Misericordiae Hospital, Dublin, Mr. 
Michael Hehir, Stirling Royal Infirmary, Livilands Stirling, Mr. David Kirk, Western Infirmary, 
Glasgow, Mr. John R. Logic, Raigmore Hospital, Inverness, Mr. John R. Macfarlane, Victoria 
Hospital, Kirkcaldy, Mr. James R. Rhind, General Hospital, Hartlepool, Mr. Brian Richards, York 
District Hospital, York, Mr. Michael F. Smith, Law Hospital, Carluke, Prof. Philip H. Smith, 
Huddersfield Royal Infirmary, Huddersfield and Mr. John Wightman, Royal Hospital, 
Chesterfield, United Kingdom; Dr. Vicente Ferla, Hospital Maciel, Montevideo, Uruguay; Dr. 
Bruce Bracken, Medical Center, Cincinnati, Ohio; Dr. E.D. Crawford, University of Colorado 
Health Sciences Center, Denver, Colorado; Dr. Om. P. Khanna, Hahnemann University 
Hospital, Philadelphia, Pennsylvania; Dr. P.O. Madsen, William S. Middleton Memorial Veterans 
Hospital, Madison, Wisconsin; Dr. R.P. Nelson, Jr., Medical University of South Carolina, 
Charleston, South Carolina, and Dr. J. Rajfer, Harbor-UCLA Medical Center, Los Angeles, 
California. 
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Subjective Improvement by Total Androgen Blockade 
Abstract 
Patients with advanced prostate cancer have a beneficial effect from 
maximal androgen blockade in terms of the subjective and objective delay of 
progression and median duration of survival, although side effects do occur more 
often in the combination treatment than in testicular suppression alone. Sig-
nificant improvement or delayed deterioration in subjective parameters such as 
metastatic pain, performance status and urinary disorders strongly suggest (in 
the absence of validated questionnaires of quality of life at the time of this study) 
that orchiectomy plus nilutamide improves the quality of life as assessed by the 
subjective delay of progression, according to NPCP criteria, to an extent which 
outweighs the majority of adverse events. 
Introduction 
The aim of hormonal treatment in metastatic prostate cancer is to prolong 
life where possible while maintaining its quality [1-3]. If prolonging survival is not 
a realizable goal, the aim should then be to maximize the patient's quality of life 
by improving the subjective parameters until the disease takes its course. 
A recent approach to achieving these goals has been to combine 
testicular hormonal deprivation, either by orchiectomy or administration of a 
luteinizing hormone-releasing hormone (LHRH) agonist, with adrenal blockade by 
a nonsteroidal anti-androgen to produce maximal androgen blockade (MAB) [4-7]. 
Several large studies have tried to show that MAB compared to castration leads 
to lengthening of time to subjective and objective progression and to increased 
survival time [8-10]. 
However, these trials have rarely considered the patient's comfort as an 
endpoint for assessment. Furthermore, not all studies demonstrated an overall 
benefit with MAB, nor have they reported on the subjective benefits experienced 
by the patient. Quality of life is not, of course, a new concern, but until recently 
no appropriate scoring system had been available and/or validated at the time of 
most studies in the mid 1980s. This situation has now been rectified by 
Aaronson et al. and the EORTC Study Group [11] who produced a questionnaire 
which addresses the subjective aspects of cancer. With the use of such tools, 
future trials will be able to give quality of life issues their due weight. 
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As a first effort, a recently started quality of life assessment, EORTC 
30835, needs regular réévaluation on the one hand, and on the other doctors 
must gain confidence in the value of this part of clinical trials, and realize that 
these subjective parameters are not separate from objective criteria [11]. In the 
meantime, there is much to learn from investigations initiated before the new 
subjective evaluative techniques became available. 
The aim of the present paper is to reassess the results of one large, 
randomized, placebo-controlled study of complete androgen blockade with 
orchiectomy plus nilutamide that was initiated in 1986 and recently published 
[12]. Although the authors clearly demonstrated clinically and statistically 
significant benefits in the objective delay of disease progression, due to the lack 
of a validated tool few conclusions were drawn with regard to the subjective 
improvement. Comparison with other contemporary studies was not possible 
because of the subjective parameters chosen [13,14]. 
To elucidate this aspect of the investigation, special attention is given in 
this paper to the symptoms of advanced prostate cancer which interfere most 
with a patient's well-being, thereby adversely affecting his quality of life. Thus, 
pain, performance status, disease-related weight loss, urinary impairment and 
subjective progression will be considered. In addition, because no treatment of 
such a serious disease is free of side effects, drug-related adverse events were 
weighed against the gains in quality of life improvement. 
Patients and Methods 
A total of 457 patients with stage D-11 metastatic prostate cancer were 
initially enroled into a multicenter, double-blind, randomized, placebo-controlled 
study. 66 investigators in 15 countries participated. To be eligible, subjects had 
to be aged between 40 and 85 years and have histologically documented 
carcinoma of the prostate with évaluable and measurable distant metastases, but 
had not previously received hormonal treatment or chemotherapy. After informed 
consent was obtained, subjects were randomized to receive orchiectomy plus 
either the nonsteroidal anti-androgen nilutamide (Anandron) or placebo. Patients 
randomized to receive nilutamide (n = 225) were given 300 mg daily for 1 month, 
starting 1 day after surgery, followed by 150 mg daily thereafter. Those in the 
control arm (n = 232) received matching placebo. 
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Disease characteristics which have a bearing on the quality of life were: 
pain; performance status; weight loss; urinary symptoms, and subjective 
progression. Patients were evaluated prior to treatment, at 1, 3 and 6 months, 
and then at least every 6 months. 
Pain was assessed on a 5-point rating scale: no pain; pain not requiring 
analgesics; pain requiring occasional use of analgesics; pain requiring and 
controlled by analgesics, and pain uncontrolled by analgesics. Performance status 
was assessed using the Karnofsky scale divided into 3 categories: category 1 
(80-100%); category 2 (50-79%), and category 3 (0-49%). 
Cancer-related weight loss of 10% or more was significant. Urinary 
symptoms were assessed as absent, mild, moderate, severe, or severe requiring 
an indwelling catheter. 
Subjective progression was considered to have occurred whenever there 
was a disease-related deterioration not necessarily accompanied by objective 
progression. Changes (compared to baseline) considered to represent subjective 
progression were a deterioration in Karnofsky performance status by at least one 
general category: a cancer-related weight loss of at least 10%, and an increase 
in metastatic pain requiring analgesia. For most patients subjective progression 
occurred before objective progression and the event that occurred first was taken 
into account for analysis. 
Intercurrent events recorded at all clinical investigations were either 
reported spontaneously by the patient or given in response to the standard 
question: 'Did the treatment upset you in any way?'. These data were then 
compared with the percentage of adverse events. 
Statistical Methods 
Changes from pretreatment values in individual variables were compared 
at each timepoint using the Cochran-Mantel-Haentzel test. Subjective 
progression-free rates were computed using Kaplan-Meier estimates. The 
distributions of the two treatment groups were compared using the log-rank test, 
ρ < 0.05 was taken as significant. 
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Results 
Of a total of 457 patients, 423 patients were évaluable for efficacy (207 
in the nilutamide arm, and 216 in the placebo arm). The characteristics of the 
évaluable patients are given in table 1. 
Metastasis-related pain was present in 68 % of the nilutamide patients 
and in 61 % of placebo patients prior to treatment. Pain at entry decreased 
subsequent to treatment in significantly more nilutamide patients than placebo 
patients: 74 vs. 68% at 1 month (p = 0.046); 85 vs. 70% at 3 months 
(p = 0.007), and 78 vs. 65% at 6 months (p = 0.030; fig. 1). Of those patients 
without pain at entry, worsening was similar in both groups, and of those with, 
pain at entry, worsening was seen in 8% in the nilutamide group vs. 15% in the 
placebo group at 6 months. 
Table 1. Summary of demographic and pretreatment characteristics (évaluable patients) 
Orchiectomy + 
nilutamide 
(n = 207) 
71.0 (50-85) 
1.9 (0-90) 
35 
68 
20 
30 (62/207) 
10(21/207) 
41 
70 
25 
Orchiectomy 
placebo (n = 2 
72.0 (46-86) 
1.8 (0-59) 
37 
61 
17 
35 (76/216) 
9 (20/216) 
42 
73 
19 
-Mean age, years (range) 
-Median time from stage D-ll diagnosis prior 
to treatment, months (range) 
-Impaired performance status, 
Karnofsky scale <70 , % 
-Metastatic pain, % 
-Weight loss > 10%, % 
-Urinary obstruction, % 
None 
Severe 
-Histological finding, Gleason grade 8-10, % 
-Bone lesions > 2 , % 
-Hydronephrosis, % 
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Fig. 1. Percentage of patients with metastasis-related pain upon entry who had an 
improvement in pain after 1, 3 and 6 months of treatment. 
Performance status clearly improved in both groups at 3 and 6 months 
compared with baseline. Among patients in Kamofsky category 1, 23% of the 
placebo group worsened compared with 15% of the nilutamide group. The 
cancer-related weight loss of 10% or more compared to baseline was similar in 
both treatment arms. 
Urinary obstruction also improved similarly in both groups but, among 
patients who had no signs of obstruction before treatment, 1 of 57 (2%) 
worsened with nilutamide compared with 10 of 69 (14%) taking place at 1 
month. Hydronephrosis was present in 25 % of nilutamide patients and 19% of 
placebo patients prior to treatment. At 6 months hydronephrosis was present in 
only 6% of the nilutamide patients compared with 12% of the placebo patients. 
The median interval to subjective progression was consistently (31 %) and 
significantly (p = 0.011) longer, 18.1 months in the nilutamide group compared 
with 13.8 months in the placebo group, and paralleled the gain in time to 
objective progression and death (fig. 2). 
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12 15 IB 21 24 27 30 33 36 39 42 
Months 
— Nilutamide 
— Placebo 
Median time 
n=202 18 1 months 
n=208 13 8 months 
Fig. 2. Time to first objective or subjective progression rates (évaluable patients) with 
orchiectomy plus nilutamide (202 patients at risk, 133 with progression, median time 
18.1 months) and orchiectomy plus placebo (208 patients at risk, 153 with 
progression, median time 13.8 months, ρ = 0.011). 
Overall, side effects were reported in 84% of nilutamide patients and 
7 8 % of placebo patients (NS). Because of adverse or intercurrent events, 15.5% 
(p = 0.155) of the patients in the nilutamide group and 9.0% in the placebo group 
were prematurely withdrawn from the study. More patients in the nilutamide 
group experienced nausea (10 vs. 6 % ) , impaired adaptation to seeing in the dark 
(13 vs. 1%) and interstitial pneumonitis (0.4 vs. 0%), all completely reversible 
on treatment discontinuation. These experiences occurred early during treatment, 
and in most cases resolved following the scheduled dose reduction at 1 month. 
More patients given placebo experienced adverse events likely to be related to 
disease progression, for example, asthenia, anemia (11 vs. 5 % ) , peripheral 
edema (7 vs. 4%) and urinary symptoms or signs (16 vs. 10%; table 2). 
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Table 2. Adverse events (%, all patients) 
Orchiectomy + Orchiectomy + 
nilutamide placebo 
(n = 225) (n = 232) 
-Nausea 
-Adaptation dark 
-Interstitial pneumonia 
-Asthenia/anemia 
-Peripheral edema 
-Urinary symptoms 
-Gynecomastia 
-Dyspnea 
-Hot flushes 
-Alcohol intolerance 
10 
13 
0.4 
5 
4 
10 
4 
6 
28 
5 
6 
1 
0 
11 
7 
16 
6 
7 
22 
0.4 
Discussion 
The hypothesis that MAB by castration and an antiandrogen leads to a 
better outcome for patients with advanced prostate cancer than castration alone 
is gaining acceptance [6]. 
During the 1980s many double-blind trials for the management of these 
patients were started. At the time of these studies, none of the randomized trials 
contained a validated quality of life assessment. In the EORTC protocol 30853, 
Calais da Silva [15] warned that the data presented should be considered with 
caution and that the currently used questionnaires were still under investigation 
and should be reevaluated regularly. 
In our study [16], testicular deprivation was performed by surgical 
castration, being the cornerstone of treatment and leading to a maximal patient 
compliance. Although castration alone is not free of adverse events (psychologi-
cal resistance from the patient, impotence, mild gynecomastia, hot flushes and 
small surgical risk), prompt relief of the most damaging symptoms of the disease 
(pain) is seen. 
Another major consideration of surgical castration versus medical 
castration with an LHRH agonist was to avoid initial flair reactions (8-32%) 
noticed by increased bone pain and symptoms of outlet obstruction. Of particular 
clinical concern are risks of spinal cord compression [16,17]. Furthermore, hot 
flushes are more frequent and intense (44-56%) and a discomfort for the patient. 
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Initial studies with MAB, published by Labrie et al. [18,19], showed a 
statistically significant improvement in the delay of objective progression and 
overall survival. These studies were mainly done with leuprolide plus flutamide 
versus placebo [18,19]. However, many other studies [20-25] could not confirm 
these data. Therefore, subjective improvement became an important factor. In 
another study with leuprolide and flutamide [13], a statistically significant 
difference in the progression-free overall survival was observed favoring a MAB 
of 35.6 vs. 28.3 months (p = 0.035). Crawford et al. [13] found a survival 
advantage of 7.3 months. After stratification of the patient's disease severity, 
the outcome was much more pronounced for minimal disease. Also, the objective 
median progression-free survival time was 16.5 months for patients in the 
leuprolide plus flutamide arm and 13.9 months for the leuprolide plus placebo 
arm (p = 0.039). Exact subjective data were not given. 
In a final follow-up analysis of an EORTC trial, Denis et al. [14] reported 
that subjective progression was highest in the pain score, with 3 7 % of the 
patients having an increase of 2 or more categories after 6 months. The median 
time to first subjective progression occurred at 78 weeks in the combining 
therapy arm vs. 52 weeks in the orchiectomy arm (p = 0.009), and the median 
time to subjective or objective progression was 71 vs. 46 weeks for combined 
therapy and castration, respectively (p = 0.002). The median duration of survival 
difference in favor of the MAB treatment is 7 months, as shown by the study of 
Crawford et al. [13], EORTC 30853 [14] and the nilutamide study. 
Intercurrent or adverse events are more common in patients receiving a 
nonsteroidal anti-androgen as compared with those undergoing castration alone. 
For flutamide these side effects are mainly diarrhea (13.6 vs. 4.9 %; ρ < 0.001), 
reversible hepatic toxicity with mild elevation in serum glutamic oxaloacetic 
transaminase and lactic dehydrogenase levels in 9 vs. 5% (NS, ρ = 0.07), 
gastrointestinal disturbances with vomiting and nausea, gynecomastia (19 vs. 
8%) and hot flushes (68 vs. 58%) [13,23,25]. 
For nilutamide side effects (table 2) were vision disturbances (dark 
adaptation) in 13%, alcohol intolerance in 5%, and reversible acute interstitial 
pneumonitis in 0.4%. 
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In this study, analysis of the subjective parameters shows that a pain 
decrease was significantly greater at 1-6 months in the nilutamide group vs. the 
placebo group. The median time to subjective or objective progression was 18.1 
months in the nilutamide group and 13.8 months in the placebo group. 
With respect to performance status, weight loss and symptoms of urinary 
obstruction, there was only a slight difference, which was not statistically 
significant, in favor of the group of patients treated with nilutamide. 
Subjective improvement was also reported by Béland et al. [26] who 
found significant (p< 0.005) improvements in bone pain in the nilutamide 
recipients (86%) compared with the placebo recipients (68%). Brisset et al. [27] 
found that a significantly greater proportion of patients given nilutamide (71-
94%) experienced release of bone pain than those given placebo (44%). 
In a 6-month double-blind, placebo-controlled trial including patients with 
pain associated with metastases. Le Duc et al. [28] showed that greater 
improvements in pain were experienced by nilutamide patients (90.5%) 
than placebo patients (70.5 %) at 6 months. This was paralleled by a reduction 
in the requirement for analgesics by nilutamide patients compared with placebo 
patients, reaching statistical significance at 3 months (p = 0.001) and maintained 
until 6 months. 
Recently Bertagna et al. [29] published the results of a meta-analysis of 
7 randomized, comparable, double-blind trials (1,056 patients) and reported that 
48% of the nilutamide patients experienced improvement in pain at 6 months, 
compared with 34% of placebo patients, and that combining castration with 
nilutamide results in a statistically significant reduction (16%; p = 0.050) in risk 
of progression and a 10% reduction in the risk of death, which was not 
significant. 
The subjective responses on MAB with nilutamide do not enable a 
comparison with the studies by Crawford et al. [13] and the EORTC trial [14] due 
to differences in trial design. 
To our knowledge no other reported long-term, large, double-blind study 
has compared the subjective improvement of an anti-androgen versus placebo in 
combination with castration. 
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Conclusion 
At the time of our study there was no validated quality of life 
questionnaire. However, the overall significant benefit on subjective improvement 
of 31 % (pain, urinary symptoms and delayed subjective progression) observed 
when nilutamide (Anandron) was administered in combination with castration is 
likely to improve the quality of life of patients with advanced prostate cancer, 
outweighing the related adverse events. 
References 
1. Huggins C, Stevens R-E Jr, Hodges CV: Studies on prostatic cancer. II. The effects 
of castration on advanced carcinoma of the prostate gland. Arch Surg 1941 ; 43:209-
223. 
2. Blackard CE, Byar DP, Jordan WP, the VARURG Group: Orchiectomy for advanced 
prostatic carcinoma: A revelation. Urology 1973; 6:553-560. 
3. Byar DP: VARURG studies on prostatic cancer and its treatment; in Tannenbaum M 
(ed): Urologie Pathology: The Prostate. Philadelphia, Lea & Febiger, 1977, pp 241-
267. 
4. Huggins C, Scott W: Bilateral adrenalectomy in prostatic cancer: Clinical features and 
urinary excretion of 17 ketosteroids and estrogens. Ann Surg 1945; 122:1031-1041. 
5. Robinson MR: Aminogentethamide: Medical adrenalectomy in the management of 
carcinoma of the prostate: A review after 6 years. Br J Urol 1980; 52:328-329. 
6. Labrie F, Dupont A, Belanger A, et al.: New hormonal therapy in prostatic carcinoma: 
Combined treatment with an LHRH agonist and an anti-androgen. Clin Invest Med 
1982; 5:267-275. 
7. Crawford ED: Combined androgen blockade. Urology 1989; 34(suppl 4):22-26. 
8. Labrie F, Dupont A, Belanger A: Complete androgen blockade for the treatment of 
prostate cancer: in Devita VT Jr., Hellerman S, Rosenberg SA (eds): Important 
Advances in Oncology. Philadelphia, Lippincott, 1985, pp 193-217. 
9. Robinson MRG, Denis L, Newling DWN, Sylvester R, de Pauw M: EORTC protocol 
30853. Orchidectomy versus Zoladex plus flutamide in the management of metastatic 
carcinoma of the prostate. Interim statistical analysis of the side effects of treatment. 
Cancer 1990; 66(suppl 5): 1022. 
10. Schröder FH: Total androgen suppression in the management of prostatic cancer. A 
critical review; in Schröder FR, Richard В (eds): Therapeutic Principles in Metastatic 
Prostatic Cancer. New York, Liss, 1985, pp 307-317. 
1 1 . Aaronson NK, Ahmedzai S, Bullinger M, et al.: The EORTC core quality of life 
questionnaire: Interim results of an international field study; in Osoba D (ed): Effect 
of Cancer on Quality of Life. New York, CRC Press, 1991, pp 185-202. 
154 
Subjective Improvement by Total Androgen Blockade 
12. Janknegt RA, Abbou CC, Bartoletti R, et al.: Orchiectomy and nilutamide or placebo 
as treatment of metastatic prostate cancer in a multinational double-blind randomized 
trial. J Urol 1993; 149:77-83. 
13. Crawford ED, Eisenberger MA, McLeod DG, et al.: A controlled trial of leuprolide with 
and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321:419-424. 
14. Denis JL, Whelan P, Carneiro de M our a JL, Newling D, et al.: Goserelin acetate and 
flutamide versus bilateral orchiectomy: A phase III EORTC trial (30853). Urology 
1993;42:119-130. 
15. Calais da Silva F: Quality of life in prostatic cancer patients. Cancer 1 993; 72:3803-
3806. 
16. Debruyne FMJ, Denis L, Lunglmayr G, et al.: Long term therapy with a depot 
luteinizing hormone-releasing analogue (Zoladex) in patients with advanced prostatic 
carcinoma. J Urol 1988; 140:775-777. 
17. Mahler C: Is disease flair a problem? Cancer 1993; 72:3799-3802. 
18. Labrie F, Dupont A, Belanger A, et al.: New approach in the treatment of prostate 
cancer: Complete instead of partial withdrawal of androgens. Prostate 1 983; 4:579-
594. 
19. Labrie F, Dupont A, Belanger A, et al.: New hormonal treatment in cancer of the 
prostate: Combined administration of an LHRH agonist and anti-androgen. J Steroid 
Biochem 1983; 19: 999-1007. 
20. Schröder FH, Lock TMTW, Chadra DR, et al.: Metastatic cancer of the prostate 
managed with buserelin versus buserelin plus cyproteron acetate. J Urol 1987; 
137:912-918. 
2 1 . Robinson MRG: A further analysis of European Organization for Research and 
Treatment of Cancer Protocol 30805. Cancer 1993; 72(suppl 1 2):3855-3857. 
22. de Voogt HJ, Klijn JGM, Studer U, et al.: Orchidectomy versus buserelin in 
combination with cyproterone acetate, for 2 weeks or continuously, in the treatment 
of metastatic prostatic cancer. Preliminary results of EORTC trial 30843. J Steroid 
Biochem Mol Biol 1990;37: 965-999. 
23. Iversen P, Christensen MG, Friis E, et al.: A phase III trial of Zoladex and flutamide 
versus orchiectomy in the treatment of patients with advanced carcinoma of the 
prostate. Cancer 1990; 66:1058-1066. 
24. Keuppens F, Denis L, Smith P, Pinto Cavalho A, Newling D, Bond Sylvester R, de 
Pauw M, Vermeylen К, Ongena Ρ: Zoladex and flutamide versus bilateral orchiectomy. 
Cancer 1990; 66:1045-1057. 
25. Crawford ED, Blumenstein BA, Goodman PJ, et al.: Leuprolide with and without 
flutamide in advanced prostate cancer. Cancer 1990; 66: 1039-1044. 
26. Béland G, Elhilali M, Fradet Y, et al.: Total androgen ablation: Canadian experience. 
Urol Clin North Am 1991; 18:75-82. 
27. Brisset J-M, Boccon-Gibod L, Botto H, et al.: Anandron (RU 23908) associated to 
surgical castration in previously untreated stage D prostate cancer: A multicenter 
comparative study of two doses of the drug and of a placebo; in Murphy G, Khoury 
S, Kuss R, Châtelain С, Denis L (eds): Prostate Cancer. Part A: Research, Endocrine 
Treatment, and Histopathology. New York, Liss, 1987, pp 411-422. 
155 
Chapter 4-3 
28. Le Duc A, Ballanger R, Cariou G, Coloby P, et al.: Comparaison de l'efficacité du 
nilutamide (Anandron) à un placebo sur les douleurs des métastases osseuses du 
cancer de la prostate. Prog Urol 1992; 2(suppl):24-30. 
29. Bertagna C, de Géry A, Hucher H, et al.: Combination of anandron (nilutamide) with 
orchiectomy in metastatic prostate cancer. A meta-analysis of seven randomized 
double-blind trials (1,191 patients). Br J Urol 1994; 73: 396-402. 
156 
Chapter 4-4 
Long-Term Efficacy and Safety of Nilutamide 
plus Castration in Advanced Prostate Cancer, and the 
Significance of early Prostate Specific Antigen Normalisation 
Gerhard A. Dijkman, Rudi A. Janknegt, 
Theo M. de Reijke and Frans M.J. Debruyne 
for the International Anandron Study Group 
The Journal of Urology 1996: In press 
Efficacy and Safety of Nilutamide plus Castration 
Abstract 
Purpose 
To study the long-term efficacy and tolerability of nilutamide, a non-
steroidal antiandrogen, in combination with orchiectomy in patients with 
advanced prostate cancer. 
Materials and Methods 
Patients were entered into a large double-blind trial (N = 457), and 
randomized to receive either nilutamide or placebo following orchiectomy. 
Results 
In this eight and half-year follow up, significant benefits were found for 
both parameters (progression and survival) in favor of patients receiving 
nilutamide and orchiectomy. In addition, normalized prostate specific antigen 
(PSA) levels at three months (from the start of therapy) were found to be 
predictive of good long-term outcome. Moreover, combined androgen blockade 
with nilutamide increased the chance of patients having normal PSA levels at 
three months. Nilutamide was well tolerated in the long-term with no increase 
in the incidence of drug-specific adverse events. 
Conclusions 
With long-term follow up of patients with advanced prostate cancer, the 
combination of nilutamide and orchiectomy has significant benefits in time to 
progression, and improved survival over orchiectomy and placebo. 
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Introduction 
Maximal androgen blockade (MAB), the addition of an antiandrogen to 
medical or surgical castration, represents a suitable improvement over castration 
alone in patients with advanced prostate cancer. Although castration leads to 
disease regression, and therefore, improved quality of life, prolonged survival is 
not evident.1,2 A possible explanation for this, is that although castration greatly 
reduces serum testosterone concentrations (by around 90%), androgens of 
adrenal origin remain unaffected.3,4 The combination of an antiandrogen plus 
castration, however, results in inhibition of androgens produced from both 
testicular and adrenal sources. 
The non-steroidal antiandrogen nilutamide has proved to be effective in 
combination with castration for advanced prostate cancer. Double-blind 
comparative studies have indicated beneficial effects for nilutamide and 
orchiectomy compared with orchiectomy plus placebo, with respect to best 
objective response, improvement in metastatic-related pain and normalization of 
tumor markers.1,2,5 In addition, significantly longer time to objective or subjective 
progression for the nilutamide and orchiectomy group has been indicated in a 
double-blind study, involving over 400 patients.6 In this large study, in which 
patients were followed for at least 18 months, a trend towards prolonged 
survival was also observed. However, this advantage was not statistically 
significant, even though the study was mature (since at least 50% of the 
patients had either progressed or died). These findings have been supported by 
a meta-analysis of seven double-blind studies including 1056 évaluable patients, 
which showed statistically significant differences in favor of nilutamide and 
orchiectomy for best objective response, improvements in bone pain, levels of 
tumor markers and disease progression.7 The odds of death from cancer and 
from other causes were also reduced in the nilutamide combination group, but 
the difference was not statistically significant. 
In the largest of the double-blind studies,6 the follow-up period is now 
about eight and half years and this second efficacy and safety analysis is 
reported here. The relationship between early normalization of prostate specific 
antigen (PSA) and disease progression in these patients is also examined (a 
preliminary report of these results has been published).8 This follows indications 
that normalization of PSA, rather than simply a reduction, is predictive of an 
improvement in the prognosis of advanced prostate cancer.9 
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Materials and Methods 
A total of 457 patients with stage D2 prostate cancer were initially 
enroled into this multicenter, double-blind, placebo-controlled study. Following 
orchiectomy, patients were randomized to receive either nilutamide (300 mg 
once daily for one month, then 150 mg once daily; η = 225) or identical placebo 
tablets (n = 232). 
Assessments 
During the extended follow-up period, clinical and laboratory evaluations 
(see previous publication)6 were repeated every six months. Objective 
progression was assessed using modified (more strict) National Prostatic Cancer 
Project (NPCP) criteria. 
Patients continued taking the study drug or placebo until they had 
objective progression, intolerance, or withdrew consent. When progression 
occurred, only patients who had been on nilutamide could continue with this drug 
on an open-label basis, so as to allow a comparison according to the initial 
randomization (such patients were included in the safety analysis). All patients 
were followed until death. This second analysis was performed on t w o main 
efficacy criteria: times to progression and death. Safety was assessed by 
questioning patients in a general manner at each visit, to determine whether any 
clinical adverse experience had occurred and by monitoring laboratory values. 
PSA was measured at a central laboratory (Pros-check PSA radio-immuno 
assay kit, Yang Laboratories Inc., upper normal value 2.5 ng/ml), before 
treatment, at one, three and six months after the start of treatment, then at 
regular six-monthly intervals. 
Statistica/ methods 
Progression-free and survival actuarial rates were computed with the 
Kaplan-Meier estimate, and the survival distribution of the two treatment groups 
was subjected to the log-rank test. An intent-to-treat analysis was also 
performed on all patients included in the study. 
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Results 
Patient and disease characteristics at entry were similar between the two 
groups.6 At the second cut off date for data-collection (31 December 1994), the 
follow-up period ranged from 82 to 102 months. This was, 55 months longer 
than the follow-up period of the previous analysis of progression and 47 months 
longer than the previous analysis of survival.6 In total 283 patients were 
withdrawn from the study because of progression, 127 in the nilutamide group 
versus 156 in the placebo group; and 70 because of intercurrent/adverse events, 
42 (19%) vs 28 (12%), respectively. 
Time to progression 
The progression-free actuarial rates over eight and half years for évaluable 
patients were consistently higher in the nilutamide plus orchiectomy group than 
in the placebo plus orchiectomy group (Figure 1), and the median times to 
progression were 21.2 and 14.7 months, respectively. This 6.5 month difference 
(44% improvement) was statistically (p = 0.002) significant. Even after five years 
of therapy, 20% of patients receiving nilutamide had not progressed, compared 
with 12% of patients receiving placebo. 
u
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Nilutamide 202 173 137 105 66 48 43 33 29 24 21 21 17 13 6 5 
Placebo 208 160 118 75 55 43 28 21 20 17 14 11 10 7 4 
Number ol patients at risk by time Interval 
Fig. 1. Progression-free actuarial rates: objective progression (évaluable). 
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Time to death 
Over eight and half years, the median times to death from prostate cancer 
were 37.0 for patients in the nilutamide plus orchiectomy group and 29.8 
months for the placebo plus orchiectomy group (Figure 2); representing a 
statistically (p = 0.013) significant difference of seven months (24% increase). 
At six years, the survival rates were 3 2 % and 21 %, respectively. 
When all causes of death for all patients were taken into account, the 
16% survival gain is still in favor of the therapy combining nilutamide and 
orchiectomy (p = 0.033; Figure 3). 
u
~ l — ι 1 1 1 1 1 1 1 1 1 — ι 1 — ι 1 — ι 1 1 
Months 0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 90 96 102 
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Number of patients at risk by time interval 
Fig. 2. Prostate cancer survival actuarial rates fall patients). 
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Fig. 3. Overall su/viva/ actuarial rates (all patients). 
Tolerability 
At the time of the first analysis, 102 (45%) patients had been exposed, 
for at least 18 months, to nilutamide combined with castration and 89 (38%) to 
castration alone. After seven to eight years of follow up, 12 patients (5%) of the 
nilutamide group and 6 (2.5%) of the placebo group were still taking the 
randomly allocated treatment. After 8.5 years of treatment the number of 
patients remaining in the study is very low and can be seen on actuarial curves 
for progression (number of patients at risk). 
Despite this longer exposure to treatment, no new cases of drug-specific 
adverse events were experienced, such as interstitial pneumonitis or visual 
disorder. Moreover, since the first analysis, only seven patients from the 
nilutamide group and eight more from the placebo group have discontinued 
treatment due to adverse or intercurrent events. Age-related intercurrent events, 
not necessarily leading to drop out, occurred with the same incidence in both 
treatment groups. 
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PSA 
Among the évaluable patients, PSA levels were measured in 268. 
Regardless of the treatment group, PSA levels were elevated in 97% of these 
patients at baseline. After three months of treatment, PSA values normalized in 
119 (44%) patients and remained elevated in 149 (56%) patients. No further 
improvements in PSA values were observed after six months or more of 
treatment. Patients whose PSA values were normal at three months had 
significantly longer median time to disease progression (p< 0.0001) and death 
(p< 0.0001) than those with elevated PSA levels at three months: the median 
progression-free times were 24 vs 17 months and the median time to disease-
related death was 49 vs 28 months, respectively: median time to death from all 
causes (overall survival) was 37 vs 24 months, respectively (p< 0.0001). 
When PSA levels were analyzed by treatment group, the percentage of 
patients who had normal PSA levels at month three was significantly (p< 0.001) 
higher in the nilutamide plus orchiectomy group (57%), than in the placebo plus 
orchiectomy group (28%). 
Discussion 
Eight and half years of follow up of patients in a large, double-blind, 
randomized study has indicated that orchiectomy in combination with nilutamide, 
when compared with orchiectomy plus placebo, results in statistically significant 
improvements in cancer survival (p = 0.013), overall survival (p = 0.033) and time 
to progression (p = 0.002). In an earlier (mature) analysis, there was a significant 
difference (p = 0.005) in time to progression, and a trend towards improved 
survival.6 
In both analyses, the median time to death from cancer was 37 months 
for the nilutamide group, however, with prolonged follow up the difference was 
confirmed and became statistically significant. Moreover, the 6.5 month 
difference in the time to progression, reported here with extended follow up, 
increased the statistical significance found in the previous study (from ρ = 0.005 
to ρ = 0.002). 
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It is of interest to note that patients who were prematurely discontinued 
from treatment because of adverse events were included in the analysis of time 
to progression and censored at the time of treatment discontinuation. So the 
progression analysis was less likely to favor the nilutamide group, as the 
percentage of drop-outs for adverse events was slightly higher in the nilutamide 
group (19%) than in the placebo group (12%). However, even with this 
unfavorable bias, time to progression was significantly longer in the nilutamide 
group. 
The a priori statistical determination of the power of the study was made 
under the assumptions that time to objective progression for the placebo plus 
orchiectomy group would be 65 weeks and that 200 patients per treatment 
group would have provided a 94% chance of detecting a 38% improvement on 
the median progression-free survival from 65 to 90 weeks at the 0.05 level of 
confidence. These assumptions were met, and the clear benefit of adding 
nilutamide to castration has been demonstrated. 
Nilutamide was generally well tolerated, and most of the adverse events 
reported were consistent with those found with other endocrine therapies.6 
Moreover, with prolonged (8.5 years) exposure to nilutamide, there were no 
increases in the incidences of specific adverse events, for example, problems 
with visual adaptation when going from bright light to dark and interstitial 
pneumonitis. In the previous analysis, visual disturbance was the second most 
frequent adverse event (after hot flushes), affecting 27% of patients receiving 
nilutamide in combination with orchiectomy.6 Visual disturbances are generally 
mild and tend to disappear after the scheduled dosage reduction from 300 mg 
to 150 mg, or spontaneously: they only lead to around 2% of withdrawals from 
therapy, and are always reversible on treatment discontinuation.2'5,6,10 
Interstitial pneumonitis is a very rare adverse event (one out of 225 patients in 
this study) and is reversible on discontinuation of nilutamide.2,11 
An extended follow-up period, as seen in this study, allows for statistical 
confirmation of earlier trends in efficacy results and for assessment of the long 
term safety of combined androgen blockade. The efficacy results reported here 
have followed a similar pattern to those for a European Organisation for Research 
and Treatment of Cancer (E0RTC) study (No. 30853), where patients were 
randomized to receive either combined androgen blockade (flutamide and an LH-
RH analogue), or orchiectomy.12 In the EORTC study, a follow-up duration of 
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around five years indicated the MAB treatment to be statistically significantly 
better in terms of both progression and duration of survival, yet again there had 
only been a trend to increased survival in a previous analysis.13 
Statistically significantly longer progression-free survival and median 
survival duration have also been reported in a large National Cancer Institute 
(NCI) study for flutamide and an LH-RH analogue, compared with an LH-RH 
analogue alone.14 In the NCI study the benefits for CAB were most evident for 
patients with a good performance status and minimal disease. In contrast, other 
generally smaller studies have indicated no improvements in survival or time to 
disease progression for CAB compared with castration.2·10,15,16,17'18 
In this study, orchiectomy was chosen over LH-RH agonists not only to 
avoid any compliance problems relating to the method of castration, but also to 
avoid disease flare found in up to 5% of patients receiving LH-RH agonists as 
monotherapy.19 This choice also allows the long-term efficacy of the 
antiandrogen to be related to its self effect rather than to the prevention of 
disease flare. 
Early normalization of PSA was shown to be predictive of an improved 
long-term response to hormonal treatment in terms of time to disease progression 
and time to death. Nilutamide plus orchiectomy increased the chance of a patient 
having a normal PSA within three months of treatment, and therefore, improved 
the probability of longer progression-free time and survival time. This is 
consistent with the results of a previous study of nilutamide and a luteinizing 
hormone-releasing hormone (LH-RH) analogue compared with the antiandrogen 
plus placebo, in which gains in median time to progression and survival were 
reported in patients whose PSA normalized by three months, regardless of the 
treatment group.20 
Nilutamide, with its long plasma elimination half-life (56 hours) offers the 
convenience of a once-daily dosing regimen.21 Although nilutamide was initially 
used in clinical studies in divided doses (every 8 hours), this study has shown it 
to be effective and well tolerated as a single daily dose. Once-daily dosing has 
obvious benefits in terms of compliance over three or four-times daily 
schedules.22 Moreover, compliance is particularly important in the elderly, and 
prostate cancer mainly affects men over 60 years of age.23 
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Conclusions 
In conclusion, the treatment for advanced prostate cancer is still only 
palliative, it is important to delay the progress of the disease, and hence maintain 
and/or improve the quality of life of patients, for as long a period as possible. 
The long-term follow up of patients with advanced prostate cancer, has indicated 
significant benefits in time to progression, and also survival for a combined 
orchiectomy and nilutamide regimen, compared with orchiectomy and placebo. 
Furthermore the prognostic value of monitoring PSA early in therapy has been 
demonstrated on the outcome of disease in terms of survival and progression, 
possibly making PSA a surrogate marker of efficacy. 
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Abstract 
A statistical analysis of prognostic factors in 175 patients with 
hormonally treated disseminated prostatic cancer was done. The prognos­
tic significance of performance status (PS), hemoglobin (Hb), alkaline 
phosphatase (Alk Ρ), and testosterone was assessed with a univariate 
analysis. The authors did not find significant prognostic value in age, 
tumor size or grade, prostatic acid phosphatase, and prostate-specific 
antigen in these patients. In a multivariate logistic model (Cox regression), 
PS, Hb, and Alk Ρ were found useful for dividing patients into prognostic 
groups. The prognosis for high-risk patients on standard hormonal treat­
ment was very poor. The authors concluded that research on prognostic 
factors is useful and permits a division of patients into risk groups that 
makes choice of treatment more accurate. The use of new treatment 
combinations as a start treatment is appropriate for high-risk patients with 
disseminated prostatic cancer. Cancer 1990; 65: 2758-2761. 
Introduction 
Since the development of "androgen deprivation" by Huggins et al., 
over 45 years ago, hormonal manipulation has been the best available 
treatment for patients with disseminated prostatic carcinoma.1 The impro­
vements brought about by new methods of hormonal deprivation are 
mainly a better subjective response and reduction of side effects, but so 
far no important prolongation of survival has been observed. The value of 
chemotherapy remains limited, partly by its poor effectiveness and its side 
effects.2 , 3 New kinds of therapy, therefore, are needed, especially for 
patients who are refractory to the current ones. 
Extended knowledge regarding prognostic factors is essential for 
the design of future studies. It is important to be able to divide patients 
into risk groups so that we can select appropriate therapeutic options. On 
basis of a retrospective study we analyze here the value of various pro­
gnostic factors in the selection of treatment for patients with disseminated 
prostatic cancer. 
Patients and Methods 
Between September 1984 and January 1988, 191 patients with 
newly diagnosed prostate cancer entered two trials organized by the Dutch 
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South Eastern Urologie Oncology group: 75 patients received luteinizing 
hormone-releasing hormone (LHRH) as a monthly depot (Zoladex, ICI, 
London), and 116 patients underwent orchiectomy with or without admi­
nistration of an anti-androgen (Anandron, Roussel, Paris).4,5 The results of 
the two trials were similar in hormonal deprivation, and the groups were 
pooled for analysis of prognostic factors. Of the 191 subjects, 16 with 
advanced, but local, disease were excluded; 175 patients with bone 
metastasis (M + , according to the TMN classification) remained. 
Pretreatment factors analyzed for prognosis were age, performance 
status (PS, Kamofsky score), tumor size (T) according to the TMN classifi­
cation, with rectal palpation and transrectal ultrasonography), and grade 
(according to Mostofi6). Laboratory results included were hemoglobin (Hb; 
in anemia Hb < 8.5 mmol/l), alkaline phosphatase (Alk Ρ), prostatic acid 
phosphatase (PAP), prostate-specific antigen (PSA), and testosterone. 
Liver function tests were performed to ensure that elevation of Alk Ρ was 
due to bone metastases. Prostate-specific antigen was determined with 
the immune-enzymetric Tandem-e-psa assay (Hybritech, San Diego, CA). 
Testosterone was measured in 75 patients who were in a pharmacokinetic 
clinical trial; 59 with M + were evaluated. Because the patients were 
treated at different centers, Alk Ρ and PAP were standardized and classi­
fied relative to the upper limit of the normal range. 
A patient was declared to have progression if his area of bone 
lesion involvement (entire body) increased more than 25% or the number 
of bone lesions increased, as compared with the best response. 
Statistical Methods 
Time to progression and survival, calculated from the start of 
treatment, were used as end points in this study. Survival was considered 
with respect only to death related to cancer. To assess the influence of 
the mentioned above factors, the Kaplan-Meier method was used for 
estimation, and the log-rank test was applied for statistical testing. 
In a multivariate analysis using the proportional hazard model (Cox 
regression), we analyzed the variables simultaneously with a stepwise 
procedure (on level p = 0.10).7 
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Results 
During the period of follow-up (mean, 2.3 years), 92 of 175 
patients had progression on hormonal treatment. Of those 92, 82 died. 68 
because of prostatic cancer. 
The results of univariate analysis of prognostic factors are shown in 
Table 1. The values of prognostic factors were the same for time to 
progression during hormonal treatment and for the survival, so only the 
values for survival are given. Bad PS, anemia, and high Alk Ρ were signifi­
cantly related to shorter survival. Low testosterone concentration at the 
start of therapy was also associated with poor prognosis. Histologic grade 
was not significantly related to survival. Only PAP showed a numerical 
trend. As for PSA, no significant relation to prognosis could be detected in 
these patients with disseminated prostatic carcinoma, although there was 
a trend to better 2-year survival with lower initial value of the antigen. We 
could not find a relation of age and T- category at the beginning of therapy 
to survival. 
After this univariate analysis, we did a multivariate analysis accor­
ding to the Cox regression model. All the variables (Table 1) were included 
in a stepwise analysis. The results are given in Table 2. Performance 
status, Hb, and Alk Ρ were useful for obtaining prognostic groups. The 
other variables did not give additional information for these groups. In the 
case of testosterone levels it could be due to the relatively small number of 
patients (59) in whom it was measured. 
We were able to form three groups for predicting the duration of 
survival. The good prognostic group existed of 64 patients, the 2-year 
survival was 75%. The moderate prognostic group (n = 46) had a 2-year 
survival of 6 5 % , and the bad prognostic group (n = 57) had a 2-year sur­
vival of 35% (Table 3 and Fig. 1). 
Table 2. Results of Cox Regression Model 
Factor ß P-value 
Hb < 8.5 mmol/l 0.50 0.07 
Alk Ρ > 1.25 χ upper limit 1.14 <0.001 
PS 
< 1 0 0 % 0.85 0.018 
< 6 0 % 0.95 0.022 
Hb.Hemoglobin; Alk P:alkaHne phosphatase; PS.performance status (Karnofsky score). 
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Table 1. Univariate Analysis of Prognostic Factors 
Factor No. 
2-yr survival 
(Kaplan-Meier) 
P-value 
(log-rank-test) 
Age 
Grade 
PS 
Hb 
Alk Ρ 
PAP 
PSA 
Test 
< 6 0 yr 
6 0 - 7 0 yr 
7 0 - 8 0 yr 
> 8 0 yr 
0 
1 
2 
3 
4 
1 
2 
3 
1 0 0 % 
8 0 % - 9 0 % 
6 0 % - 7 0 % 
0 % - 5 0 % 
> 8 . 5 mmol/l 
< 8 . 5 mmol/l 
Normal 
-2.5 χ υΛ 
More 
Normal 
-2.5 χ Ш 
- 1 0 . 0 χ U/l 
More 
< 1 0 0 ¿/g/l 
100-300 //g/l 
300 -800 //g/l 
> 8 0 0 //g/l 
< 3 0 0 ng/dl 
> 3 0 0 ng/dl 
10 
58 
8 0 
27 
19 
18 
31 
4 6 
59 
21 
74 
74 
4 3 
73 
41 
14 
83 
90 
58 
57 
57 
22 
36 
45 
71 
3 0 
31 
37 
34 
17 
42 
0.34 
0.64 
0.61 
0.48 
0.45 
0.47 
0.47 
0.58 
0.65 
0.69 
0.63 
0.62 
0.72 
0.65 
0.43 
0.51 
0.76 
0.48 
0.76 
0.51 
0.47 
0.74 
0.61 
0.62 
0.55 
0.79 
0.62 
0.48 
0.47 
0.49 
0.74 
0.44 
0.70 
0.17 
0.0006 
<0.001 
<0.001 
0.16 
0.47 
0.024 
PS: performance status (Karnofsky score); Hb: Hemoglobin; Alk Ρ: alkaline 
phosphatase; PAP: prostatic acid phosphatase; PSA: prostate-specific antigen. 
175 
Chapter 4-5 
Table 3. Prognostic Groups 
Alk Ρ < 1.25 χ upper normal value 
and PS = 100% 
Alk Ρ < 1.25 χ upper normal value 
and PS = 60%-90% and no 
anemia 
Not in good or bad group 
Alk Ρ > 1.25 χ upper normal value 
and PS < 50% 
Alk Ρ > 1.25 χ upper normal value 
and PS 60%-90% and anemia 
Alk Ρ: alkaline phosphatase; PS: performance status (Karnofsky score). 
Discussion 
At least 25% to 3 0 % of patients with disseminated prostatic 
cancer do not react to hormonal treatment, and an equal percentage 
becomes resistant to the treatment within 2 years.8 New treatments are 
needed to prevent growth of both hormone-dependent and hormone-
independent tumor cells from the beginning and to lengthen time to 
progression and therefore improve survival.9 Possibilities of new hormonal 
and cytotoxic treatment were reviewed earlier in this journal.10"12 To 
identify patients with a poor prognosis before the start of treatment, 
analysis of factors that influence survival are useful. 
In our study, PS, Hb, Alk Ρ, and testosterone were found to be of 
prognostic significance. The importance of PS and Hb has been reported 
by Berry et al., but they used these factors for hormonally unresponsive 
prostatic cancer treated with chemotherapy." The unfavourable influence 
of high Alk Ρ on survival was remarkable and has been established by ot­
hers.14"16 
According to Wilson et al., a low testosterone concentration at the 
start of hormonal treatment is an adverse prognostic sign." Generally PAP 
is accepted as having prognostic significance, but we could not find a 
significant influence of PAP on survival in our patients.1 8 , 1 9 Prostate-
specific antigen is widely accepted as the most important factor for 
detection of prostatic cancer and monitoring of its treatment.2 0 , 2 1 In our 
patients with disseminated carcinoma, PSA did not influence survival 
Good 
(n = 64) 
Moderate 
(n = 46) 
Bad 
(n = 57) 
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significantly, although there was a steady decrease in survival with in­
creasing PSA. 
Comparable results were obtained by Kuriyama et al.2 2 Age was not 
a significant prognostic factor in our study. That result confirmed the 
findings of Harrison,23 but Wilson et al. detected a worse prognosis for 
patients younger than 60 and older than 80 years.24 
On the basis of our multivariate analysis, we defined three risk 
groups that react differently on hormonal treatment. High-risk patients 
included those with a disseminated prostatic cancer that is so far advan­
ced that it worsens PS, results in anemia, and raises Alk P. Those patients 
should be subject to new kinds of treatment, the use of currently accepted 
standards should be questioned. That is in view of the expected early 
escape from hormonal therapy, which is more likely to occur with their 
more aggressive tumors. It is logical to select this group of patients to 
examine whether early combination of hormone and cytotoxic therapy or 
radiotherapy is superior to hormonal manipulation alone. 
In summary, we conclude that treating patients with disseminated 
prostatic cancer in a general way does not justify the heterogeneity of 
response to standard therapy. By statistical analysis, we established the 
importance of prognostic factors for forming risk groups. Especially for the 
high-risk group, innovative combination treatment is needed. 
T-
3 4 
Survival time (years) 
Fig. 1. Prognostic groups 
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Introduction 
The attending urologist is faced with a significant dilemma concern-
ing the optimal therapy for relapsed advanced and/or metastatic prostate 
cancer that has failed initial hormonal therapy. Although approximately 70-
80 percent of patients with advanced disease will show a clinical response 
to hormonal therapy [1], many patients either do not respond or relapse. 
Resnick reported that 20-30 percent of patients with advanced 
prostate cancer do not react to first-line hormonal treatment but, if they 
do, within two to three years, approximately the same percentage have 
metastatic hormone-resistant adenocarcinoma of the prostate (HRPC) [2]. 
The androgen sensitivity of prostate cancer cells is of limited duration, 
about 30 percent of patients becoming hormone-resistant within one year 
[3]. Moreover, it is apparent from clinical studies that the probability of 
progression is highly dependent upon grade and stage of the tumour. 
Isaacs and Coffey noted that, after castration, an initially androgen-
dependent cell can undergo adaptive changes induced by environmental 
factors to become an androgen-independent cell; or, due to the 
heterogeneity of androgen-sensitive and -insensitive cells, can be cloned 
into androgen-insensitive cells [4,5,6]. 
Trachtenberg observed a marked drop in plasma testosterone 
within the first days of treatment with high dose ketoconazole (HDK), an 
antifungal imidazole derivative, given to 15 patients with metastatic 
prostate cancer. HDK was considered to be effective and well tolerated as 
a first-line treatment compared with castration [7,8]. Mahler and Denis 
have discussed the therapeutic and endocrine effects of HDK and liarozole 
hydrochloride (R75251) in patients with disseminated prostate cancer 
including data both from the literature as well as from their personal 
experiences [9]. 
The Dutch South East Cooperative Oncology Group (DSECOG) have 
published the results of a study including 28 patients receiving HDK after 
relapsing on anti-androgen therapy. Witjes concluded on behalf of DSECOG 
that a clear beneficial subjective effect (less pain) was noted in a substan-
tial number of patients, and disease stabilisation was achieved in a number 
of patients who previously had clearly progressive disease. However, 
gastric intolerance including atrophic gastritis, loss of appetite, vomiting 
and possible hepatotoxicity remain a major limitation of the use of HDK 
[10]. 
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Introduction 
A successor to ketoconazole ¡s R61405 (liarozole base), which was 
later substituted by the hydrochloride (HCl) salt of liarozole (R75251). The 
latter compound was further tested in animals and man, as described 
below. In addition to the encouraging results of clinical studies, liarozole 
HCl has shown to reduce the growth of androgen-dependent Dunning-G 
prostate carcinoma in nude mice and in rats to the same extent as castra-
tion. The anti-tumoral effect of liarozole HCl is not mediated by a 
suppressiond of plasma testosterone. Compared with castration, liarozole 
HCl treatment also has less effect on the prostate and seminal vesicles. 
Furthermore, liarozole HCl treatment significantly reduces tumour volume 
in castrated animals in which tumour growth is restored by exogenous 
testosterone administration [11]. 
These anti-tumoral effects have been evaluated in the androgen-
independent R3327 Matlu tumour, a highly aggressive anaplastic subline of 
the parent R3327 Η-tumour. Liarozole HCl significantly reduced tumour 
volume whereas castration had no effect [12]. 
In vitro liarozole HCl inhibits several cytochrome P450-dependent 
steroid biosynthetic reactions: 17 alpha- and 17, 20-hydroxylase, 
aromatase, 11 beta-hydroxylase [13], and the 4-hydroxylation of retinoic 
acid (RA). In vitro, liarozole inhibits the catabolism of all-trans retinoic acid 
and the polymer which binds and activates the same family of nuclear 
receptors [14,15]. Retinoic acid (a physiological derivative of Vitamin A) 
plays an important role in increasing cell differentiation and decreasing 
proliferation [16,17]. However, liarozole does not have any direct 'retinoid-
like' properties, nor does it act as a steroid receptor blocker or cytotoxic 
drug. 
In an open pilot study liarozole HCl was administered to a group of 
24 stage D relapsed prostate cancer patients; liarozole HCl reduced tumour 
or lymph node volume by more than 50 percent in 9 out of 17 évaluable 
patients. In addition, PSA levels fell by more than 50 percent in 12 of 24 
patients, and there was a favourable reduction in bone pain and dysuria in 
11/14 and 8/9 patients, respectively [18]. 
In view of the fact that, until now, the response to the advocated 
treatment regimens has been disappointing, we were prompted to use 
liarozole HCl in several Dunning rat prostate adenocarcinoma sublines that 
differ widely in their histological degree of differentiation, growth rate and 
androgen sensitivity, with the aim of: 
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1. evaluating the drug's in vivo anti-tumoral effects. 
We also conducted an open dose-effect study of liarozole HCl in HRPC 
patients who had relapsed after a first hormonal treatment. The objectives 
of this study were to: 
2. define the subjective and objective response to different doses of 
liarozole HCl. 
3. assess the toxicity of the drug. 
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Abstract 
We examined the in vivo antitumoral effects of liarozole against 
androgen-dependent and independent Dunning rat prostatic tumors. 
Liarozole, applied as a dietary admixture, at a dose of 120 mg./100 gm. 
food, equivalent to 100 mg./kg. per day, inhibited the growth of the slow 
growing, well-differentiated, androgen-dependent Dunning-H tumor 
(median tumor volume decrease of 60%). At the same dose it also 
significantly reduced the growth of the androgen-independent, moderately 
differentiated PIF-1 (-60%) and androgen-independent, anaplastic AT-6 
tumors (-73%). The growth of AT-6 sq tumor showing squamous 
metaplasia was unaffected by liarozole. When administered by oral gavage, 
liarozole at 40 (-82%) mg./kg. twice a day was as effective as castration (-
92%) in reducing the androgen-dependent, poorly differentiated Dunning 
R3327-G tumor. Liarozole, administered by savage, twice a day, also 
significantly reduced median tumor volume in the androgen-independent, 
AT-6 sq (-90% at 60 mg./kg., twice a day). This difference between 
liarozole administration by gavage and food admixture will have to be 
taken into account in further experimental studies. 
Inhibition of the growth of several androgen-dependent and, chiefly, 
androgen-independent Dunning prostate carcinoma sublimes that differ 
widely in their histological degree of differentiation and growth rate 
suggests that liarozole may be a suitable agent for evaluation in second 
line treatment of hormone refractory prostate carcinoma in patients who 
relapse after androgen ablation. 
Introduction 
Prostatic carcinoma is one of the leading cancers in the industrial-
ized Western world, and its incidence is still increasing.1 In local advanced 
diseases and/or metastatic prostate cancer, androgen withdrawal is able to 
delay the progression of the disease but, inevitably, the neoplasm will 
develop to a hormone-resistant stage and will lead finally to death. In these 
patients, responses to second line endocrine treatments are minimal and 
chemotherapy is of limited value. Therefore, an important objective is to 
preserve the quality of life as long as possible.2 
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The imidazole derivative liarozole (used in these experiments as the 
hydrochloride salt, R 75 251) reduced the growth of the androgen-depend-
ent transplantable R3327-G prostatic adenocarcinoma in the rat to the 
same extent as castration.3 Evidence is accumulating that this antitumoral 
effect is not associated with inhibition of the circulating androgens. 
Indeed, serum testosterone levels, prostate and seminal vesicle weights 
were essentially unaffected by liarozole treatment. On the other hand, 
R3327-G tumor growth was inhibited by liarozole in castrated rats 
implanted with testosterone pellets.3 
In an open pilot study in 31 stage D prostate carcinoma patients in 
active progression after orchiectomy, liarozole induced subjective 
responses (marked improvement in pain and performance) in the majority 
of évaluable patients, and some remissions were seen. After 3 months of 
treatment, PSA levels decreased by at least 50% in one-half of the 
patients.2 In these orchiectomized patients, as well as in male volunteers, 
no changes in serum adrenal androgen levels were detected.2,4 
These preclinical and clinical data indicate that the antitumoral 
effects of liarozole are not related to suppression of peripheral androgen 
levels. This prompted us to evaluate this compound in several Dunning 
prostate adenocarcinoma sublines that differ widely in their histological 
degree of differentiation, growth rate and androgen sensitivity. The 
androgen-dependent R3327-H parent line is a well-differentiated, slowly 
growing adenocarcinoma, while the androgen-dependent R3327-G subline 
is a poorly differentiated, relatively slowly growing adenocarcinoma. The 
androgen-independent PIF-1 subline is moderately differentiated, rapidly 
growing, 5"7 whereas the AT-6 is an anaplastic, rapidly growing subline. 
This line arose in an R3327-H line bearing animal and grows with similar 
growth rates in castrated and intact rats.8,9 Two variants of this AT-6 
tumor have been used: one which is purely anaplastic and one showing 
squamous metaplasia (AT-6 sq). Special attention was devoted to poorly 
differentiated or anaplastic sublines and particularly to the androgen-
independent AT-6 sublines in which the effect of castration and full dose-
response curves were evaluated. 
The results presented in this paper show that liarozole inhibits tumor 
growth in androgen-dependent and also in androgen-independent, 
anaplastic prostatic tumors in rats, suggesting that liarozole is of value for 
second line treatment of hormone resistant prostate carcinoma in patients 
who relapse after androgen ablation. 
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Material and Methods 
Test compound 
The crystalline powder of R 75 251 (5-[(3-chlorophenyl) (1H-
¡midazol-1-yl)methyl]-1H-benzimidazole monohydrochloride) was mixed 
with food in a rotating container for 24 hours. Control rats received 
nonmedicated food. Medicated food was prepared monthly, and the 
liarozole concentration in food varied between 88 and 95% of expected 
value immediately after preparation, and between 75 and 86% after 1 
month. In two other experiments involving rats bearing the R3327-G and 
AT-6 sq sublines, liarozole was administered by oral gavage, twice a day. 
For these experiments, liarozole was dissolved in 20% polyethyleneglycol. 
Animals 
Adult male F1 hybrid rats (Fisher female χ Copenhagen male) were 
obtained from the breeding colony at the Janssen Research Foundation, 
Beerse, Belgium {for the G and AT-6 sq) and from the Harlan OL AC 
Limited, Bicester, United Kingdom for the other experiments. The animals 
were housed in a humidity- and temperature-controlled room with a 12 
hour light-12 hour dark schedule. Free access to food and tap water were 
given. 
Table 1. Biological characteristics of the Dunning R3327 rat prostatic cancer 
sublines used in this study 
Tumor 
H 
G 
PIF-1 
AT-6 
AT-6 sq 
Histology 
Well differentiated 
Poorly differentiated 
Moderately differentiated 
Anaplastic 
Squamous metaplasia 
In Vitro 
Cell Line 
No 
Yes 
Yes 
Yes 
No 
Androgen 
Sensitivity 
Yes 
Yes 
No 
No 
No 
Metastatic 
Potential 
< 5 
< 5 
< 5 
> 9 0 
< 5 
Percentage of subcutaneously inoculated rats that developed metastases to 
lymph nodes and lungs. 
192 
Antitumoral Effects of Liarozole in Prostate Adenocarcinomas 
Tumor lines 
Two well-characterized sublines of the Dunning tumor, R3327-H 
and R3327-PIF-1, were kindly provided by Dr. J.T. Isaacs (Johns Hopkins 
Oncology Center, Baltimore, Maryland). The characteristics of the H, G, 
PIF-1 and AT-6 sublines are summarized in table 1. 
For the tumor growth experiments, solid tumors were excised from 
tumor-bearing animals under aseptic conditions. After removal of necrotic 
tissue, tumor fragments of approximately 1 mm.3 were implanted subcu-
taneously in the dorsal flank of male syngeneic F,, rats under ether 
anesthesia. The animals were allowed to recover and replaced in their 
cages. For the Dunning-H experiment treatment was started or castration 
was performed when the tumors reached approximately 0.25 cm.3 in 16 
animals and 3 cm.3 in 13 animals, approximately 8 and 14 weeks after 
implantation, respectively. For the PIF-1 (22 rats) and the AT-6, subline 
(36 rats), treatment was initiated 7 and 12 days after implantation, 
respectively, when the tumors reached approximately 0.25 cm.3 Treatment 
for the AT-6 sq (73 rats with food admixture and 72 rats treated by oral 
gavage) and for the G-tumor (50 rats) was initiated when tumors reached 
0.4 and 2 cm.3, respectively (table 2). 
Table 2. Overview of the different treatment schedules 
Tumor Treatment Dose Volume of Days Duration of 
Tumor at after Treatment 
the Onset Tumor (days) 
of Treat- Implan· 
ment tation 
Dunning H 
Dunning G 
Dunning AT-6 
Dunning AT-6 
sq 
Dunning PIF-1 
admixed in food (fig. 11 60,120mg/100gm food 0.25 and _+56 104-73 
3cm3 and 98 
gavage (fig.2) 20,40,80mg/kg bid 2cm3 .+.55 49 
admixed in food (fig. 3) 20,40,80,120mg/100gm 0.25cm3 12 60 
food 
admixed in food (fig. 4) 7.5,15,30,60mg/100gm 0.4cm3 +.15 72 
food 
gavage (fig. 5) 3.75.7.5,15,30,60,80 0.4cm3 +.17 35 
mg/kg bid 
admixed in food (fig. 6) 120mg/100gm food 0.25cm3 7 15 
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Treatments and monitoring 
Animals bearing the Dunning-H tumors received liarozole at doses 
of 60 and 120 mg./100 gm. food. To confirm previous findings obtained in 
the R3327-G subline, with liarozole admixed in food,3 animals bearing this 
poorly differentiated, androgen sensitive, prostate adenocarcinoma 
received twice daily oral administration of 20, 40 and 80 mg./kg. liarozole. 
Animals grafted with the AT-6 and AT-6 sq tumors were treated with 
various doses of liarozole, ranging from 20 to 120 mg./100 gm. food. 
Furthermore, animals bearing the AT-6 sq tumors were treated by twice 
daily oral administration of 7.5 to 80 mg./kg. liarozole. Finally, animals 
grafted with the PIF-1 tumors were treated with liarozole at 120 mg./100 
gm. food. An overview of these treatment schedules and doses of liarozole 
is presented in table 2. The exact daily dose of liarozole can be calculated 
from the data on food consumption when the drug was administered via 
dietary admixture. The dose in mg./100 gm. food corresponds approxi­
mately to the same dose expressed in mg./kg. per day. Indeed, the mean 
food intake during these experiments was about 10 gm. food/100 gm. 
body weight. 
Tumor growth was measured at regular intervals with calipers by 
the same measurer throughout the experiment. The volume of the tumor 
(assumed to be bar shaped) was calculated using the equation: volume = 
length χ width. 2 
In all the animals, treatment was continued until the first control 
tumors ulcerated to allow reliable comparison of tumor volumes between 
treated and control groups, that is, around day 73 (treatment started at 
tumor volume of 3 cm.3) and 104 (treatment started at tumor volume of 
0.25 cm.3) (H), day 49 (G), day 22 (PIF-1), day 35-72 (AT-6 and AT-6 sq). 
At this time, macroscopic examination revealed the presence of solid 
tumors with no important necrotic area or cystic hemorrhage. 
Statistical analysis 
Tumor growth curves were compared with one another using the 
distribution-free test developed by Koziol, et al., 1 9 8 1 . 1 0 In short, this 
method as a whole and is based on multivariate rank statistics. 
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Results 
Effects of liarozole against the androgen-dependent Dunning-H and G-
tumors 
Liarozole, admixed in food at a concentration of 60 and 120 
mg./100 gm. reduced the growth of the androgen-dependent Dunning-H 
prostate carcinoma. When the treatment (60 mg./100 gm. food) was 
started at a tumor volume of 0.25 cm. 3 , the median tumor volume was 
reduced by 4 5 % (p = 0.052, fig. 1, A;table 3). These effects were less 
pronounced than those observed after castration (87% reduction, 
ρ = 0.004). Median (range) doubling times relative to first measurement 
were also increased from 16 (8-33) to 28 (8-103) days by castration, but 
not only by liarozole treatment: 13 days (8-27). When treatment (120 
mg./100 gm. food) was initiated at a volume of 3 cm. 3 , liarozole reduced 
tumor growth by 6 0 % (p = 0.06), fig. 1, B; table 3) and increased doubling 
time from 12 (5-65) to 54 (23-63) days. 
Day· Days 
Fig. 1. Effect of dietary administration of liarozole on growth of androgen-dependent 
R3327-H prostate adenocarcinoma in rats. Treatment was started or castra­
tion performed when tumors reached volume of about 0.25 cm.3 (A, 
n = 8/groupl or 3 cm.3 (Β, η = 7/group). Tumor volumes are plotted as mean _+ 
standard error of mean. 
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Table 3. Tumor volume at the end of treatment. Results are shown as median (range) 
Tumor Type 
H, Initial tumor volume vehicle 
0.25cm3 
3cm3 
G (gavage) 
AT-6 
(food) 
AT-6sq 
(food) 
AT-6sq 
(gavage) 
PIF-1 
(food) 
castration 
liarozole 
vehicle 
liarozole 
vehicle 
castration 
liarozole 
vehicle 
liarozole 
vehicle 
castration 
liarozole 
vehicle 
castration 
liarozole 
vehicle 
liarozole 
Dose 
. 
-
60mg/1 OOgm food 
-
120mg/1 OOgm food 
. 
-
20mg/kg bid 
40mg/kg bid 
80mg/kg bid 
. 
20mg/100gm food 
40mg/1 OOgm food 
80mg/1 OOgm food 
120mg/1 OOgm food 
-
-
7.5mg/100gm food 
1 5mg/100gm food 
30mg/100gm food 
60mg/100gm food 
120mg/100gm food 
. 
-
3.75mg/kg bid 
7.5mg/kg bid 
1 5mg/kg bid 
30mg/kg bid 
60mg/kg bid 
120mg/kg bid 
. 
1 20mg/1 OOgm food 
Tumor Volume 
(cm3) 
11.1(3.6-16.3) 
1.5(0.4- 6.7) 
6.2(1.3-15.7) 
23.7(7.5-44.3) 
9.5(5.9-13.5) 
77.8(15.7-308) 
6.5(0.66-90.3) 
20.3 (2.3- 302) 
14.2 (7.8-106) 
7.5 (3.3-108) 
47.5 (9.1-69.1) 
28.4(15.4-64.3) 
51.8(12.5-131) 
26.5(11.6-71.6) 
12.7(6.8-85.3) 
8.2 (0-37.2) 
19.7(4.2 -47.5) 
19.5(4.6-90.9) 
7.5(1.5 -78.2) 
5.2(2.6 -18.9) 
6.1(0.52-16.8) 
7.0(2.4-14.2) 
18.4(0.60-34.8) 
17.5(0.53-92.4) 
6.4(0.37- 9.8) 
8.8(2.3 -20.2) 
3.6(0.62-18.9) 
2.0(0.1- 8.1) 
1.8(0.38-12.6) 
2.7(0.25-10.0) 
20.2(12.8-49.6) 
8.2(2.1-17.8) 
Liarozole also reduced the growth of the other androgen-dependent 
G-subline at doses ranging from 20 to 80 mg./kg. administered twice a 
day by oral gavage (fig. 2; table 3). The effects of castration and liarozole 
were similar after treatment with 40 and 80 mg./kg. twice a day (73, 82, 
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90 and 9 2 % reduction of median tumor volume after 20 (p = 0.27), 40 
(p = 0.01), 80 (p = 0.05) mg./kg. and castration (p = 0.01)m respectively. 
Effects of liarozol against the androgen-independent Dunning PIF-1, A T-6 
and A T-6 sq tumors 
Liarozole also reduced tumor growth in these three androgen-
independent Dunning adenocarcinoma sublines. Dose finding studies were 
undertaken with liarozole admixed in food, both with the parent AT-6 line 
(fig. 3; table 3) and with the subline AT-6 sq, showing squamous 
metaplasia (fig. 4; table 3). Liarozole reduced tumor growth in both the 
parent AT-6 (median tumor volume reduced by 40, 44 (p^.0.17) and by 
7 3 % (p = 0.009) at 20, 80 and 120 mg./100 gm food, respectively, 
whereas it was slightly increased by 9% at 40 mg./100 gm. food 
(ρ = 0.65, fig. 3). In the AT-6 sq subline, tumor volume was only marginal­
ly and not significantly (pM).27) reduced by liarozole treatment (fig. 4; 
table 3). 
Fig. 2. Effect of twice daily oral administration of liarozole on growth of androgen-
dependent R3327-G prostate adenocarcinoma in rats (n = 9 to 10/groupl. 
Treatment was started or castration performed when tumors reached volume 
of about 2 cm.3 Tumor volumes are plotted as mean ± standard error of 
mean. 
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Fig. 3. Effect of dietary administration of liarozole on growth of androgen-independent 
R3327-AT-6prostate adenocarcinoma in rats (n = 6/group). Tumor volumes are 
plotted as mean ± standard error of mean, i ; onset of treatment. 
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Days 
Fig. 4. Effect of dietary administration of liarozole on growth of androgen-independent 
R3327-AT-6 sq prostate adenocarcinoma in rats (n = 9 to 10/group). Tumor 
volumes are plotted as mean ± standard error of mean. 
After administration of liarozole by oral gavage twice a day, 
inhibition of tumor growth of the AT-6 sq subline was more pronounced at 
all doses, from 7.5 mg./kg. twice a day upwards, with a maximal inhibition 
of around 9 0 % after 30 and 60 mg./kg. (fig. 5; table 3). The level of 
statistical significance was reached after administration of 60 (p = 0.04) 
and 80 (p = 0.03) mg./kg. twice a day. 
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Days 
Fig. 5. Effect of twice daily oral administration of liarozole on growth of androgen-
independent R3327-AT-6 sq prostate adenocarcinoma in rats (n = 9 to 
10/group). Tumor volumes are plotted as mean ± standard error of mean. 
As expected, castration did not significantly alter the growth of 
both AT-6 and AT-6 sq sublines. 
In PIF-1 tumors, median tumor volume was reduced by more than 
6 0 % after 3 weeks of treatment at a dose of 120 mg. liarozole/100 gm. 
food (fig. 6; table 3, ρ < 0 . 0 0 1 ) . 
Days 
Fig. 6. Effect of dietary administration of liarozole on growth of androgen-independent 
R3327-PIF-1 prostate adenocarcinoma in rats (n = 20/group). Tumor volumes 
are plotted as mean ± standard error of mean. I : onset of treatment. 
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No drug-related overt toxicity or mortality was observed. Food 
intake was recorded in studies where liarozole was administered in food. 
Mean food intake of about 10 gm./100 gm. body weight was not altered 
by any treatment. Body weight at sacrifice ranged between 320 and 360 
gm. for the short-term experiments, and increased to 400 to 420 gm. for 
the long-term ones. Body weight was slightly reduced (-8 to - 1 1 % as com-
pared to controls) when the drug was admixed in food at the highest dose 
of 120 mg./100 gm. food, but was not altered when liarozole was given 
by gavage. 
Discussion 
A previous report described the antitumoral effects of liarozole in 
the poorly differentiated, relatively slowly growing androgen-dependent 
Dunning-G subline.3 Tumor growth was inhibited similarly by liarozole (120 
mg./100 gm. food) and castration. The present report confirms these 
results, using gavage. We showed that liarozole also reduced growth in 
the androgen-dependent, well-differentiated, slowly growing Dunning-H 
tumor. The initial tumor volumes were different in these experiments. 
However, no conclusion can be drawn on this particular point since the 
liarozole doses were not identical. More important, liarozole inhibited the 
growth of a moderately differentiated (PIF-1) and two anaplastic, 
androgen-independent Dunning sublines (AT-6 and AT-6 sq). For all these 
sublines, liarozole reduced median tumor growth 30% to 90%, indepen-
dent of their androgen-sensitivity or histological characteristics. In some 
cases, the level of statistical significance was not reached and a clear-cut 
dose-response was not observed, even in the presence of some decrease 
in mean and median tumor volume. This is probably due to the individual 
variations inherent to these models, and to the limited numbers of rats 
included in some experimental groups. This is confirmed by the more 
important spreading of individual tumor volumes observed at low dosages 
of liarozole {<_ 30 mg./kg./day). The results show that liarozole delayed 
the evolution of the tumors but did not completely inhibit tumor growth. In 
the Dunning models no other therapy so far has achieved this goal.11'13 On 
the other hand, liarozole was well tolerated at the doses used with no 
obvious toxicity. 
In two sublines, the androgen-sensitive Dunning G1 and the 
androgen insensitive Dunning AT-6 sq, liarozole administration via dietary 
admixture and gavage twice a day were compared. In both cases, tumor 
growth inhibition was more pronounced when the drug was gavaged twice 
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daily: maximal effects were obtained after daily doses of 60 to 160 
mg./kg./day after oral gavage (83 to 9 0 % decrease of median tumor 
volume), whereas less pronounced inhibition was observed after daily 
administration of the 120 mg./100 gm. food, which corresponds approxi­
mately to 120 mg./kg. per day (-36 to -73%). Higher dosage in food could 
not be evaluated due to markedly decreased food intake and body weight. 
This difference between oral gavage and food admixture might be related 
to the pharmacokinetics of the drug but remains to be elucidated. In any 
case, this difference has to be taken into account in further experimental 
studies. 
It is not surprising that liarozole alters tumor growth in both 
androgen-dependent and independent experimental prostate 
adenocarcinomas since liarozole reduced tumor growth in the androgen-
dependent Dunning-G tumor without interfering with peripheral testoster­
one levels and without affecting other androgen-dependent tissues.3 
Furthermore, antitumoral effects were still observed in castrated animals 
receiving erogenous testosterone.3 But the mechanism of action of 
liarozole remains to be fully elucidated. The drug does not inhibit the 
growth of human prostate and breast cancer cells in tissue culture,1 4 does 
not inhibit the 5a-reductase in rat prostatic cells,11 and does not bind to 
steroid receptors.3 Liarozole is also devoid of any intrinsic retinoid-like 
activity, measured by induction of plasminogen activator in F9 mouse 
teratocarcinoma cells.14 But liarozole enhances the retinoic acid induction 
of plasminogen activator secretion in F9 cells14 as well as the 
antiproliferative effects of retinoic acid in human breast cancer MCF-7 
cells.15 In these cells, as well as in vivo in intact rats,1 6 liarozole inhibits the 
catabolism of retinoic acid. Liarozole also exerts some retinoid-mimetic 
effects in animal models,14,17 and in patients.1 8 These retinoid-mimetic 
properties of liarozole are being investigated and may shed more light on 
the mechanism of action of the antitumoral effects of this compound. 
In conclusion, the inhibition of the growth of several Dunning 
prostate adenocarcinoma cell lines, androgen-dependent as well as 
androgen-independent that differ widely in their growth rate, differentiation 
and metastatic potential, suggests that liarozole may be an effective agent 
for second line treatment of hormone resistant prostate carcinoma in 
patients who relapse after androgen ablation. Early clinical trials indeed 
show that liarozole, in wond or third line therapy, induces clinical remission 
in about 30 to 5 0 % of patients.2-1B'21 
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Message 
In this group of patients with hormone resistant prostate 
carcinoma, liarozole reduced pain and improved ability without serious 
toxicity. Patients in a better condition present a better response. It may be 
advisable in the future to carry out trials in an earlier phase of the disease. 
Abstract 
Background 
Liarozole is an imidazole derivative that has been identified as an 
inhibitor of the cytochrome P450-dependent all-trans retinoid acid (RA) 
breakdown. RA is one of the principal endogenous compounds that 
controls growth and differentiation of epithelial tissues in mammals. 
Methods 
55 patients with hormone-resistant prostate cancer in progression, 
following at least first-line androgen ablation therapy, were evaluated. 31 
patients were treated with liarozole 300 mg bid while 24 patients started 
with 150 mg bid which was increased to 300 mg bid after 4 or 8 weeks. 2 
patients were not évaluable because they withdrew after initial consent. 
The WHO performance status was 0 (n = 8), 1 (n = 22 ), 2 (n = 17) and 3 
(n = 6). Most patients (80%) used analgesics. 
Results 
For 11 out of the 53 patients, treatment lasted less than 1 month 
(and were therefore not évaluable for response) due to: poor compliance 
(n = 1); early death (n = 3); side-effects (n = 2) and decline of physical 
condition and progression (n = 4). One patient refused to report for follow-
up. In all responders, except one, the dose was increased to 300 mg bid. 
In 23 of the 42 patients évaluable for response, the pain score improved. 
In 5 patients the pain score had reduced from 2 or 3 to 0. In 11 out of the 
42 patients there was a 1-point improvement of the WHO performance 
status. The PSA response rate was 4 1 % ; 15 out of 42 évaluable patients 
presented a decrease of >_50%, whereas PSA normalized in 2 patients. 
Most of the side-effects mimicked retinoid acid toxicity: cutaneous mani-
festations (dry skin, dry lips, sticky skin, brittle nails, erythema, itch). All 
patients experienced one or more of these side effects. Other side effects 
are nausea, fatigue and slight alopecia. 
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Conclusions 
Liarozole is an easy-to-administer, palliative treatment without 
serious toxicity in hormone-resistant prostate cancer patients. 
Introduction 
Prostate cancer is one of the most common malignancies of the 
male population worldwide. Estimates in the USA for 1996 (NCI) predict 
317,000 new cases, with 41,400 deaths related to prostate cancer. It is 
the second leading death-related cause of cancer in men.1 Up to 40% of 
patients present with metastases and a large proportion of the remainder 
develop metastatic deposits during their disease.2 
Since the fundamental observation of Huggins and his colleagues3, 
who discovered the hormone dependency of prostatic cancer, the treat-
ment of this disease has aimed essentially either at inhibiting androgen 
secretion or interfering with its action at the prostatic tissue level. Endo-
crine therapy of prostatic carcinoma includes surgical or medical castration 
either alone or in combination with anti-androgens. With first-line hormonal 
manipulation an objective response rate of 80-90%, depending upon the 
response criteria, can be obtained in metastatic or recurrent disease. At 
least 10% of the patients have hormone-refractory prostate carcinomas at 
the time of diagnosis and another 20-30% become resistant during the 
first year of hormonal therapy.4 This is caused by proliferation of hormone-
independent cells, even in a hormone-deprived milieu.5 Although second-
line hormonal therapy is often used, its efficacy is poor, with a response 
rate of only 30%, lasting for a period that barely exceeds 6 months. The 
palliative role of chemotherapy in the management of hormone-indepen-
dent metastatic prostate carcinoma is also moderate, with an overall 
response rate of 20-30%, but with an objective response of 7.5%6 and 
considerable toxicity. Hence, there is a need for a therapy combining 
efficacy and acceptable toxicity. 
Liarozole, a new imidazole derivative, was recently identified as an 
inhibitor of the cytochrome P450-dependent a\\-trans retinoid acid (RA) 
breakdown.7,8 RA is one of the principal endogenous compounds control-
ling growth and differentiation of epithelial tissues in mammals.9 Recently, 
antitumoural effects of RA were observed in acute promyelocytic 
leukemia10 as well as in solid tumours, such as lung cancer, carcinoma of 
head and neck and the skin.11 
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In cultured human breast cancer MCF-7 cells, liarozole potentiated 
the anti-proliferative and differentiating effects of RA.7,12 This enhance-
ment of the retinoid effects can be explained by the inhibition of the 
enzymatic degradation of RA in these cells. 
In rats, liarozole delayed the elimination of RA from plasma after 
intrajugular injection of the retinoid and enhanced the endogenous plasma 
and tissue RA concentrations13, resulting in RA-mimetic effects in v/vo.B 
Moreover, liarozole increased the plasma RA or 13-c/s-retinoid acid levels 
after oral administration of these retinoids in cancer patients.14,16 
Liarozole did not affect rat prostatic 5a-reductase, converting testosterone 
into its biologically more potent metabolite, dihydrotestosterone.15 In 
addition, the compound had no antimitotic activity in various representa-
tive human breast and prostate carcinoma cell lines.15 Liarozole is not a 
receptor blocker either. Liarozole reduced tumour growth in Dunning 
R3327 rat prostate adenocarcinoma models in both androgen-dependent 
(G and H) and androgen-independent (PIF1 and AT-6) tumours.17,18 In the 
latter, liarozole treatment dose-dependently enhanced tumour RA levels 
and induced a shift of the morphological differentiation status from a 
keratinizing towards a nonkeratinizing squamous carcinoma.19 
In view of these preclinical findings, it was decided to start a phase 
II trial in relapsed patients. A single-institution trial was initiated with 
liarozole 300 mg bid to study the tolerance and efficacy of liarozole in 
hormone-resistant relapsed prostate cancer. A second international trial 
was started shortly thereafter in which a dose increase of liarozole was 
tested. 
Materials and Methods 
This phase II study started in 1988. Patients were included with a 
metastatic (D2) histologically proven prostate carcinoma. 55 patients were 
included in this study. All patients had already experienced a relapse after 
first-line hormonal treatment. All patients had to have a baseline perform-
ance (WHO) status of ¿ 3 , a histologically proven prostate adeno-
carcinoma treated with systemic hormonal therapy consisting of either 
orchiectomy or LHRH agonist at some point in their history. This report 
deals with two subgroups of patients, treated at two institutions. The first 
group (A) comprised of 31 patients who at the start of the trial were 
treated with 300 mg bid until progression was detected. The second group 
(B) consisted of 24 patients who started at 150 mg bid for 4 weeks, after 
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which a dose increase 300 mg bid could be installed. 
A comprised group of 31 patients (group A), was treated at the 
Academic Hospital Middelheim, Antwerp, Belgium (L. Denis), and group B, 
which consisted of 24 patients, visited the University Hospital Nijmegen 
St. Radboud, Nijmegen, The Netherlands (F. Debruyne). Liarozole was 
administered orally as 150 mg tablets. Group A was treated with 300 mg 
bid throughout the trial while group В underwent a dose-escalation from 
150 mg bid at the start of the trial to 300 mg bid after 4 or 8 weeks of 
treatment. The dose was increased after 4 weeks if the pain and/or 
urological score were still ^ 2 or if PSA had not decreased by more than 
50%. If a patient did not report any improvement, the dose could be 
increased after 8 weeks. A further dose increase was not allowed. Once 
the maximum dose of 300 mg bid was reached, it was to be maintained 
until progression or acceptable toxicity was observed. The response was 
evaluated according to the EORTC criteria. The serum PSA was analysed 
by the Hybritech assay. The assessment of prostate volumes was done 
only in group A using a ALOCA 620 apparatus and the prostate volume 
was calculated according to the formula: 
Laterolaterale diameter χ anteriorposterior diameter χ length! = anterior-posterior diameter + 0,2 cm) 
2 
The mean age for all patients was 70 years (range group A, 51-82 
y; group B, 55-83 y). Of the 55 patients, two were non-evaluable because 
of an early refusal to comply with the protocol or because of loss to 
follow-up. For 10 patients previous treatment consisted of orchiectomy 
alone (group A: 6 patients and group B: 4 patients), for 15 patients 
orchiectomy plus radiotherapy (all group A), for 9 patients LHRH agonist 
followed by orchiectomy (all group A), for 6 patients LHRH alone (group 
B), 1 patient received anti-androgen as monotherapy (group B) and 12 
patients were treated with maximal androgen blockade (group B). For all 
patients baseline performance (WHO) and pain severity was scored. Eight 
patients had a normal performance score (WHO = 0) and 22 patients were 
ambulatory but symptomatic (WHO = 1). A total of 17 patients were 
confined to bed for less than half their waking hours (WHO = 2), while 6 
were bedridden (WH0 = 3). At the start of the trial 11 patients in group A, 
but none in group В were free of pain. A total of 11 patients experienced 
mild pain while respectively 15, 9 and 7 patients had moderate, severe or 
intractable pain necessitating continuous administration of narcotic anal­
gesics (table 2). The criteria used to score the pain are shown in table 1. 
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Table 1. Pain 
Grade Score 
0 No pain 
1 Mild (analgetics not or rarely required) 
2 Moderate (only non-narcotic analgesics required) 
3 Severe (narcotic analgesics required now and then) 
4 Very severe (narcotics analgesics regularly required) 
5 Intolerable (insufficient pain relief in spite of narcotics analgetics) 
Table 2. Baseline performance and pain scale 
Performance (WHO) 
Group A Group В Group A 
Pain 
Group В 
Score 0 8 0 11 0 
1 11 11 6 5 
2 6 11 6 9 
3 5 1 5 4 
4 - - 2 5 
Results 
All 55 patients started their treatment as scheduled. One patient 
refused further therapy after a few days, another patient failed to report 
for the out-patient control visits. A total of 11 other patients were not 
évaluable for response because they were treated for less than 5 weeks. 
They discontinued the trial because of poor compliance (n = 1), early death 
(n = 3), side-effects (n = 2), worsening of physical condition with no 
response (n = 4), and no report for follow-up (n = 1). 
The treatment duration for the remaining patients was at least 5 
weeks (n = 5), 8 weeks (n=13) , 12 weeks (n = 14), 20 weeks (n = 5), 10 
months (n = 5). Four patients were treated for over a year - 15, 22, 34 and 
60 months respectively. The median time to progression for all patients 
was 19.3 weeks. For group A the median time to progression was 26.8 
weeks, for group В 11.8 weeks. Only two patients could be evaluated for 
objective response of their measurable lesions. Both patients with pelvic 
lymph nodes had a 50% decrease in tumour volume (partial response). The 
volume of the primary tumour was assessed in 15 patients in group A. 7 
out of 15 had a 50% decrease in prostate volume under treatment with 
liarozole. A total of 42 patients were évaluable for serum PSA measure-
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ments, i.e. they had a baseline assessment as well as repeated measure-
ments during the trial. A ^ 5 0 % decrease (partial response) in PSA was 
obtained in 15 patients and a normalization of PSA in two more, yielding 
an overall PSA response rate of 4 1 % . All responders had been treated 
with 300 mg bid. 
In the 42 patients who were treated at least 8 weeks, a decrease 
of at least 1 point in the pain score occurred in 23 patients (17 in group A 
and 6 in group B). In 5 patients in group A the pain score decreased from 
2 or 3 to 0. Data of two patients on performance status were missing. Of 
the 40 remaining patients, 11 had an amelioration of one point on the 
WHO performance scale. The micturition symptoms improved in 22 
patients (67% in group A and 39% in group B). 
53 patients were évaluable for toxicity, 30 patients in group A and 
23 patients in group B. Not évaluable were 2 patients who lost follow up 
immediately after entry. In group A the severity of adverse experience was 
not specified. Most side-effects mimicked retinoid acid toxicity. The most 
common were cutaneous reactions, which occurred in almost all patients, 
i.e. brittle nails, dry skin and/or lips, itch, alopecia, sticky skin. Less 
frequent effects were nausea (2 patients) and fatigue (3 patients). Bad 
taste was experienced by all patients in group A. In group В adverse 
events experiences were specified according to the WHO scale (table 3). 
Table 3. WHO toxicity score: number of patients per toxicity grade 
Grade 1 Grade 2 Grade 3 
Dry skin 10 7 
Dry lips 7 7 
Brittle nails 6 1 
Erithema 1 
Alopecia 4 2 
Nausea 5 3 2 
Hot flushes 2 1 
Itch 3 1 1 
Fatigue 1 
Erisipela 1 
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Discussion 
After maximal androgen blockade therapy approximately 75% of 
the patients with metastatic prostate cancer disease will show objective 
and subjective improvement lasting from a few months to several years. In 
many patients a hormonal refractory state of the prostate cancer cell will 
appear after a median time of 18 months based on of tumour cell 
heterogeneity.20 
Since the beginning of the 70's many clinical studies were initiated 
testing single and combinations of cytotoxic drugs on their effectiveness 
and tolerance profile in hormone relapsed prostate cancer patients. Exten-
sive review reports on single agent and combination regimes recorded an 
objective response rate (CR + PR and SD according to NPCP criteria) of 
6.5% to 30% in phase III studies.21,22,23,24'25 In these studies pain decrease 
was the most frequently observed subjective improvement and a statisti-
cally significant increase in survival was not observed. The development of 
less toxic drugs is highly desirable. Mitoxantrone is such a less-toxic 
analogue of doxorubicin and carboplatin from cisplatin. The first-mentioned 
drugs possess dose limiting side effects of cardiotoxicity and nephro-
toxicity respectively. Mitoxantrone (12-14 mg/m2) caused a 20% objective 
tumour regression and 30% improvement of bone pain, performance 
status and other subjective indices.26 
In a recent publication, Moore et al. reported the advantage of mi-
toxantrone in combination with prednisone.27 In 25 hormone refractory 
patients this treatment was well tolerated and more than 36% beneficial 
effect on disease related symptoms and quality of life was shown. Current 
development of new systemic drugs is focused on various biological 
response modifiers and drugs that inhibit tumour growth factors. Recent 
experience with suramin is promising effectiveness. However, the side-
effects are important and include neurotoxicity, renal toxicity, thrombocy-
topenia and infection. Different dose schedules are currently evaluated in 
order to obtain maximal efficacy with acceptable toxicity. Eisenberger et 
al. obtained a response in 50% of the patients with measurable disease; 
77% of the patients had a PSA reduction of more than 50%; pain 
decrease was noticed in 83% of the patients.28 Dawson et al. reported a 
response rate of 7 1 % with suramin combined with total androgen block-
ade in patients with newly diagnosed metastatic disease, however, the 
follow up of the study was too short for the assessment of survival.29 
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Hormone relapsed prostate cancer patients with severe metastatic 
disease were treated with liarozole. Liarozole seems to be a good alterna-
tive drug for symptom palliation. Pain was reduced in 55% of the patients 
( 7 1 % in group A and 33% in group B) and the performance status 
improved in 28% of the patients (32% in group A and 22% in group B). In 
terms of response criteria serum PSA is considered as an objective 
response criterium. In the group of patients treated with 300 mg bid a 
partial response ( > 5 0 % decrease of initial PSA value) was observed in 
36% and a complete response (PSA decrease to < 4 mmol/l) was observed 
in 4 % of the patients. The median time to progression was 26.8 weeks in 
group A and 11.8 weeks in group B. Some of the differences between the 
two groups can be explained because the patients in group A had a better 
condition (pain and performance status). This may explain why the 
patients in this group stayed longer in the trial and had a longer intake of 
study medication. We established that the patients who started at a dose 
of 300 mg presented a greater efficacy, and the toxicity profile of the 
patients who entered in this study was acceptable. 
Conclusion 
The patients included in this phase II study who were at the end 
stage of their prostate cancer related disease and had a severe related 
decrease in life expectancy, did nevertheless respond on liarozol medica-
tion in objective and subjective measurements. Pain decrease and improve-
ment in performance status is the most important gain for this group of 
patients. In terms of redifferentiation and antiproliferation agent liarozol 
shows an acceptable effectiveness and tolerability in the treatment of 
hormone relapsed prostate cancer patients. 
Randomised phase III trials have been conducted and are being 
analysed. Presently, a placebo controlled trial is in progress in a group of 
asymptomatic patients with advanced prostate cancer recurring after first 
line hormonal treatment. 
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A review of the literature on the epidemiology of prostate cancer is 
presented in Chapter 1. It has been widely assumed that latent prostate 
cancer occurs at a uniform frequency around the world. The incidence of 
this latent form of prostate cancer increases with age such that, by the 
age of 80, approximately 75 percent of prostates contain focal 
carcinomas. Thus, a 50-year-old man's lifetime risk of having a cancer that 
will be detected at autopsy is over 14-fold greater than the risk of dying 
from the disease. 
Clinical prostate cancer is dependent on race: an African American 
male in the United States has a relative risk approximately 1.8 times that 
of an American white male. In addition, men with a family history of 
prostate cancer disease are considered to be as much as 2.5 times more at 
risk than men with no prior family history. Geographic variations in the 
incidence of clinical prostate cancer worldwide are considerable, with a 
120-fold greater incidence in the United States (SEER) than in China 
(Shanghai). 
There are few risk factors, other than age, race and family history, 
that are relevant to the development of prostate cancer. One of these 
additional risk factors is a western lifestyle: the high intake of animal fat; 
low intake of vitamin A; exposure to sunlight (Vitamine D synthesis); these 
play an important role in the multistep genesis of human prostate cancer. 
If the role of animal fat is confirmed, it might lead to the development of 
low-cost, low-risk interventions to reduce disease progression among men 
with latent disease, and/or to improve survival. It is well documented that 
there is no causal relationship between sterilisation and the long-term 
development of prostate cancer. 
Prostate cancer is an epidemic disease. Although an average of 30 
percent of men over 50 years of age have latent prostate cancer, the 
incidence of diagnosed clinical prostate cancer has risen dramatically in the 
past few years largely (but not exclusively) due to increased awareness 
and diagnosis due to techniques such as digital rectal examination, pros-
tate specific antigen (PSA) monitoring, and trans-rectal ultrasound of the 
prostate with guided biopsies. For instance, during the period 1990-1993, 
among five laboratories in the metropolitan district of Detroit, USA, the 
number of PSA samplings increased from 15,377 to 84,500 in contrast to 
only a slight increase in mortality rate. 
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In 1991 in The Netherlands, prostate cancer was the second most 
common cancer after lung/bronchus cancer, i.e., 24.3 percent and 14.1 
percent respectively of registered invasive tumours, reflecting an inci-
dence of 4.343, or an incidence rate of 38.7 per 100.000 men per year, 
and a mortality of 2108, mortality rate of 17.9 per 100.000 men per year. 
Gary J . Miller stated that: "if the current trends continue, the death 
rate will increase by approximately 50% over the next 15 years as the 
incidence rate climbs in proportion to the average age of our population ". 
Worldwide there is a tendency for mortality from all tumours to stabilise, 
with a trend to a slight decrease. Nevertheless, prostate cancer shows a 
slight increase in mortality although this increase lags behind the brisk 
increase in incidence seen in the past. The age-adjusted death rate per 
100,000 men was less than 15 in 1930, more than 20 in 1960, and 
approximately 25 in 1990. In contrast to the 1960s and 1970s when 
extensive soft tissue lesions and bone metastases were seen in 70 - 80 
percent of prostate cancer patients, nowadays, patients have less locally 
advanced and/or metastatic disease. According to Murphy, the rate of low-
stage detection has increased from 56 percent in 1974, to 67 percent in 
1990, and 94 percent in 1993. 
Chapter 2 presents an overview of current considerations in the 
management of advanced prostate cancer and hormone-refractory prostate 
cancer (HRPC). Medical alternatives to surgical castration include 
luteinizing hormone-releasing hormone (LH-RH) analogues, anti-androgens, 
and oestrogens. However, it is believed that for complete androgen 
ablation, both sources of androgen (testes and adrenals) should be 
blocked. The literature appears to show a pattern indicating that maximum 
androgen blockade (MAB) benefits prostate cancer patients in a few 
randomised trials, with a significant advantage for MAB in terms of median 
time to progression of 2.6 to 12 months, and an overall median survival 
advantage of 7.3 months. Other randomised trials demonstrated no 
difference. It is expected that patients stratified for minimal disease might 
experience more beneficial effects in terms of progression-free survival and 
median survival compared with those having more extensive metastases 
and poor prognostic factors. 
In Chapter 3 the pharmacokinetic and pharmacodynamic properties 
of a three-month depot formulation of the LH-RH analogue, Zoladex 
(goserelin acetate), are described. In the first part of the study, the three-
month Zoladex depot (containing 10.8 mg goserelin acetate) produced 
castrate levels of serum testosterone after 21 days, and this was main-
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tained for at least 12 weeks. The second part of the study demonstrated 
that the three-month Zoladex depot was pharmacodynamically equivalent 
to three sequential doses of the standard one-month Zoladex depot, 
containing 3.6 mg goserelin; serum testosterone levels reached the 
castrate range within 21 days. Serum PSA decreases after 3 months of 
therapy in 94 percent with the 10.8 mg and 92.5 percent with the 3.6 mg 
depot. The tolerability profile of Zoladex 10.8 mg depot was comparable 
with that of the Zoladex 3.6 mg depot. Hot flushes were the most com­
mon adverse event and reactions at the injection side is low (0.3 percent 
in 614 doses). The availability of the three-month Zoladex depot will 
improve convenience to patients and healthcare workers and can be 
expected to improve patient compliance. Assessments of patient prefer­
ence and attitudes to treatment have only been performed to a limited 
extent. To date, patients have clearly preferred LH-RH therapy for the long-
term improvement of their 'quality of life', and to avoid the psychological 
distress of surgical castration. 
In Chapter 4 the advantages of MAB, in terms of quality of life, 
disease progression, survival, and serum PSA changes are discussed. MAB 
is controversial and highly debated in the literature. In our double-blind 
clinical trial, patients with histologically proven metastatic prostate cancer 
were randomised to either orchidectomy plus placebo or orchidectomy plus 
nilutamide (Anandron). The median follow-up period was 35 months. A 
significant increase in median time to progression-free survival of 5.9 
months (20.8 vs 14.9, ρ = 0.005) was shown in those patients treated 
with MAB. The median time to death from prostate cancer was 7.0 
months (37 vs 30, ρ = 0.071), with objective regression being present in 
41 percent of the nilutamide group and 24 percent of the placebo group. 
Improvement of subjective parameters such as metastatic pain 
improved significantly more with nilutamide; performance status improved 
equally in both treatment arms, although in Karnofsky category 1 patients, 
23 percent worsened in the placebo arm against 15 percent in the 
nilutamide arm. Among patients who had no signs of obstruction at entry, 
urinary obstruction was more common in the placebo arm (14 percent) 
than in the nilutamide arm (2 percent). An overall significant benefit on 
subjective improvement of 31 percent was observed in the group receiving 
nilutamide in combination with castration. 
During the follow-up period (range: 38 - 102 months), the median 
time to progression improved to 44 percent (21.2 and 14.7 months), a 
significant difference (p = 0.002). After 5 years of therapy 20 percent of 
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the patients receiving nilutamide had not progressed compared with 12 
percent of the patients receiving placebo. The median time to death over 
8,5 years significantly increased with 7.2 months, 37.0 months versus 
29.8 months, p = 0.013 (24 percent) which is significant. At six years, 
survival rates were 32 percent and 21 percent, respectively. Taking into 
account all causes of death, there is still a 16% survival gain (p = 0.033) in 
favour of MAB therapy. Overall PSA value normalization was seen in 4 4 % 
after 3 months of treatment; in 57% in the nilutamide plus castration 
versus 2 8 % in the orchiectomy group (p<0.0001). PSA normalization 
within 3 months is expected in a significant longer: 
• median time to disease progression (24 and 17 months), ρ < 0 . 0 0 0 1 
• disease related death (49 and 28 months), p < 0 . 0 0 0 1 . 
A retrospective analysis of prognostic factors was performed with 
the aim of gaining information on disease prognosis. Performance status, 
haemoglobin, alkaline phosphatase and testosterone were found to be of 
prognostic value. There was no significant value in monitoring PSA 
although an increase in PSA correlated with a steady decrease in survival. 
In Chapter 5 a new treatment strategy for HRPC patients was 
demonstrated in a phase II study. Liarozole, an imidazole derivative, has 
been shown to be a suitable drug for HRPC based on the encouraging 
results with F1 hybrid rats implanted with different Dunning prostatic 
carcinoma sublines. Dose-dependent inhibition of the growth of several 
androgen-dependent and androgen-independent sublines was observed. 
Liarozole reduced the median tumour growth by 60 - 90 percent, indepen­
dent of their androgen sensitivity or histological characteristics. In a clinical 
phase II study, 55 patients were treated with liarozole and 42 patients 
were evaluated for clinical response and 54 patients for tolerability of the 
study medication. One group (A) received 300 mg liarozole twice daily 
(bid) and group В received escalating doses (from 150 mg bid at the start 
to 300 mg bid at 4 or 8 weeks). Median time to progression for all patients 
was 19.3 weeks (for group A, 26.8 weeks, and group B, 11.8 weeks). 
The volume of primary tumour decreased by more than 50 percent in 7 of 
the 15 évaluable patients in group A. The 150 mg bid dose was con-
sidered to be insufficient. 
In terms of subjective response, pain improved in 55 percent, and 
performance status improved in 27.5 percent of patients. Normalisation of 
serum PSA was noted in 4.7 percent of patients, and decreased by more 
than 50 percent in 35.7 percent; an overall respons of 41 percent. 
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Samenvatting 
In hoofdstuk I wordt de epidemiologie van prostaatkanker belicht 
door terug te blikken op en samenvatten van de literatuur. Het is algemeen 
geaccepteerd dat de latente vorm van prostaatkanker in gelijke mate 
voorkomt, wereldwijd. De incidentie van de latente vorm van 
prostaatkanker neemt zodanig toe dat rond de leeftijd van 80 jaar in bijna 
75% deze vorm van prostaatkanker voorkomt. Een man van 50 jaar heeft 
een 14 maal grotere kans om gedurende zijn leven prostaatkanker te 
ontwikkelen wat bij lijkschouwing kan worden aangetoond, dan dat hij er 
aan overlijdt. 
Prostaatkanker is ras-afhankelijk: iemand die tot het negroïde ras 
behoort in Amerika heeft een 1.8 maal grotere kans om prostaatkanker te 
ontwikkelen dan iemand van het kaukasische ras. Mannen met een familair 
voorkomen van prostaatkanker hebben een 2.5 maal grotere kans om 
prostaatkanker te krijgen dan mannen waar prostaatkanker niet familiair 
voorkomt. De geografische verscheidenheid in de incidentie van prostaat-
kanker wereldwijd is aanzienlijk, met een 120 maal grotere kans van 
voorkomen in Amerika (SEER gegevens) dan in China (Shanghai). 
Weinig risicofactoren anders dan leeftijd, ras en familiair voorkomen 
spelen een rol in de ontwikkeling van prostaatkanker. Hoofdzakelijk de 
Westerse eetgewoonte is een belangrijke risicofactor: het eten van veel 
dierlijke vetten; te weinig voorkomen van Vitamine A in de voeding 
benevens blootstelling aan zonlicht (Vitamine D synthese) spelen een 
belangrijke rol in de gefaseerde ontwikkeling van het prostaatcarcinoom bij 
de man. Als de risicofactor van dierlijke vetten waar is, dan zou dit 
aanleiding kunnen geven tot een goedkoop en weinig risico dragend advies 
om voortschrijding van het prostaatcarcinoom onder mannen met de 
latente vorm te voorkomen dan wel de nog resterende levensverwachting 
onder mannen met een aangetoond prostaatcarcinoom te verbeteren. 
Het is voldoende weerlegd dat de invloed van een sterilisatie op 
langere termijn niet als oorzaak voor de ontwikkeling van prostaatkanker 
kan worden aangemerkt. 
Prostaatkanker is een epidemisch wereldwijd voorkomende ziekte. 
Ofschoon bij mannen boven de 50 jaar de latente vorm van prostaatkanker 
in 30% voorkomt is de incidentie van het klinisch gediagnostiseerd 
prostaatcarcinoom dramatisch toegenomen in de afgelopen jaren, 
voornamelijk (maar niet louter alleen) tengevolge van de dwangmatige 
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bewustwording van prostaatkanker door media en klinische centra bij de 
man. Evenals de toegenomen veelvuldigheid van diagnostische moge-
lijkheden zoals rectale palpatie van de prostaat, serum PSA tests 
(gedurende de periode 1990-1993 is het aantal serum PSA bepalingen in 
de regio Detroit toegenomen van 15.377 naar 84.400) en transrectale 
echografie van de prostaat al dan niet in combinatie met biopsiën zijn 
voornamelijk in de Westerse samenleving hiervoor verantwoordelijk. Het 
sterftecijfer is ondanks al deze interventies niet gedaald. 
In Nederland komt prostaatkanker voor op de tweede plaats achter 
longkanker in respectievelijk 24.3% en 1 4 . 1 % van de meest geregistreerde 
invasieve tumoren in 1991 met een incidentie van 4.343 en een leeftijd 
specifiek incidentie cijfer per 100.000 van 38.7, het sterfte aantal tenge-
volge van de ziekte van 2.108 met een leeftijd specifiek sterftecijfer per 
100.000 van 17.9. 
Gary J . Miller stelt:"Als de huidige trend doorgaat zal het sterfte 
cijfer met ongeveer 50% toenemen in de komende 15 jaar terwijl de 
incidentie stijgt in verhouding tot een aantal behorend bij een gemiddelde 
leeftijd van onze bevolking." Het sterftecijfer stabiliseert wereldwijd wat 
betreft alle tumoren met een lichte neiging tot een dalende trend. Echter, 
het sterftecijfer van prostaatkanker vertoont een lichte stijging, ofschoon 
deze toename ver achter blijft bij de forse stijging van prostaatkanker 
incidentie in het verleden. De leeftijd gebonden sterfte per 100.000 
mannen was minder dan 15 in 1930, meer dan 20 in 1960 en bijna 25 in 
1990. 
In de 60er en 70er jaren hadden prostaatkanker patiënten in 70 tot 
80% van de gevallen uitzaaiingen in weefsel en botten. Hedentendage 
worden prostaatkanker patiënten gezien met een veel minder lokaal 
voortgeschreden dan wel uitgezaaide aandoeningen. Volgens Murphy is de 
"low-stage" opsporing toegenomen van 56% in 1974, 67% in 1990 en 
94% in 1993. 
In Hoofdstuk 2 wordt een algemene samenvatting gegeven van 
overwegingen die tot nu toe tot gebruikelijke therapieën aanleiding hebben 
gegeven bij patiënten met voorgeschreden prostaatkanker. Het recidief 
prostaatkanker op basis van hormoon ongevoeligheid (HRPC) wordt in het 
bijzonder belicht. 
Alternatieven voor chirurgische castratie behelst behandeling met 
LH-RH analogen, steroidale en niet-steroïdale anti-androgenen en 
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oestrogenen. Echter, voor complete hormonale blokkade gaat men ervan 
uit dat zowel de gonaden als de bijnieren als bron van mannelijk hormoon 
moet worden onderdrukt. 
In de literatuur wordt slechts in een klein aantal gerandomiseerde 
trials aangegeven dat behandeling van patiënten met Maximale Androgene 
Blokkade aantoonbaar voordeel hebben wat betreft mediane tijd tot 
progressie variërend van 2.6 tot 12 maanden en een algemene 
overlevingswinst van 7.3 maanden. Echter, in een groot aantal andere 
gerandomiseerde trials wordt geen verschil aangetoond. Het is te 
verwachten dat verdeling van patiënten met minimale verschijnselen meer 
profijt van MAB zullen hebben wat betreft een langere periode van uitstel 
van progressie en sterfte in vergelijking met patiënten die meer 
systemisch zijn aangedaan in combinatie met ongunstig voorspellende 
factoren. 
In hoofdstuk 3 wordt de biologische pharmacokinetic en 
pharmacodynamic van het 3 maandelijkse LH-RH (Zoladex) depot 
beschreven. In het eerste deel van de studie wordt het 3 maandelijks 
Zoladex depot (bevattend 10.8 mg Gosereline acetaat) onderzocht waarbij 
testosteron castratie niveau binnen 21 dagen wordt bereikt en wat 
tenminste 12 weken duurt. 
In het tweede deel van de studie wordt aangetoond dat één enkel 
Zoladex 10.8 mg depot farmacodynamisch gelijk is aan drie opeenvolgende 
toedieningen van het maandelijks depot 3.6 mg en dat het castratie niveau 
binnen 21 dagen wordt bereikt. Hiermee wordt aangetoond dat Zoladex 
3.6 mg depot en Zoladex 10.8 mg depot vergelijkbaar en uitwisselbaar 
zijn. Daling van serum PSA waarde binnen 3 maanden is in 94% het geval 
met het 10.8 mg depot en in 92.5% met het 3.6 mg depot. 
De verdraagzaamheid van Zoladex 10.8 mg is geheel vergelijkbaar 
met die van Zoladex 3.6 mg. Opvliegers zijn de meest voorkomende 
bijwerkingen en het percentage huidreacties ter plaatse van de 
injectieplaats is laag (0.3% in 614 depotplaatsingen). Het voorhanden zijn 
van Zoladex 10.8 3 maandelijks depot zal het gemak dienen van de patient 
en werkers in de gezondheidszorg met een grotere zekerheidsstelling van 
toediening. De voorkeur van de patient is ten aanzien van het depot slechts 
beperkt onderzocht. In onderzoekingen tot nu toe gedaan, wordt de LHRH 
analoge Zoladex depot verkozen boven castratie op basis van verbetering 
van kwaliteit van leven en het om niet "psychologisch gecastreerd zijn" 
gevoel. 
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In hoofdstuk 4 wordt het voordeel van maximale androgene blok-
kade wat betreft kwaliteit van leven, voortschrijding van de ziekte, 
overleving en de waarde veranderingen serum PSA bepalingen onderzocht. 
Over MAB behandeling bestaat geen eenduidigheid en over de voor- en 
nadelen wordt veel gepubliceerd. In dit dubbel-blind klinisch onderzoek 
worden slechts patiënten toegelaten met door weefselonderzoek bewezen 
en uitgezaaid prostaatkanker, verdeeld in een groep die chirurgische 
castratie krijgen met een placebo, of chirurgische castratie met nilutamide. 
De mediane controle periode bedroeg 35 maanden. Een significante 
toename van de mediane tijd van progressie was 5.9 maanden (20.8 
versus 14.9, p = 0.005) in het voordeel van patiënten behandeld met MAB 
en de mediane sterfte-tijd van 7.0 maanden hetgeen niet significant was 
(37 versus 30, p = 0.071) en een objectieve waarneembare regressie van 
41 % in de Nilutamide groep en 24% in de placebo groep. 
Verbetering van subjectieve parameters zoals uitzaaiings-botpijn 
verbetert significant. De performance status verbetert gelijk in beide 
groepen, ofschoon de Karnofsky index met 1 verslechterde in 23% in de 
placebogroep tegenover 15% in de Nilutamide groep. Urineweg obstructie 
werd in 14% bemerkt in de placebogroep tegenover 2% in de Nilutamide 
groep ten aanzien van die groep patiënten die aan het begin van de studie 
geen plasklachten hadden. Patiënten in de groep die behandeld worden 
met MAB hebben alles bij elkaar een subjectieve verbetering van 31 %. 
In de tweede analyse periode van 38 tot 102 maanden werd de 
mediane tijd van progressie verbeterd met 44% (21.2 en 14.7 maanden), 
een 6.5 maanden significant verschil (p= 0.002). Na 5 jaar behandeling is 
20% van de patiënten die Anandron kregen toegediend, niet verslechterd 
in vergelijking met 12% van de patiënten die met een placebo zijn 
behandeld. De mediane sterftetijd na 8,5 jaar verbeterde met 7.2 maanden 
(37 versus 29.8 maanden) een 24% significant verschil (p = 0.013). Na 6 
jaar bedraagt de overleving 32% en 2 1 % respectievelijk in de nilutamide 
en placebogroep. Rekening houdend met alle doodsoorzaken bestaat er een 
16% overlevingsvoordeel (p = 0.033) ten gunste van maximale androgeen 
blokkade. Na 3 maanden behandeling werd een PSA normalisatie in 44% 
over beide behandelingsgroepen vastgesteld; in 57% in de nilutamide plus 
castratie groep versus 28% in de orchiectomie groep (p<0.001) . 
Normalisatie van de PSA binnen 3 maanden verwachte een significant 
langere: 
• mediane progressie ziektevrije periode (24 en 17 maanden), ρ < 0 . 0 0 0 1 
• ziekte gerelateerd overlijden (49 en 28 maanden), ρ < 0 . 0 0 0 1 . 
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Een retrospectieve studie analyse aangaande prognostische 
factoren werd uitgevoerd met het doel meer informatie te verkrijgen 
aangaande ziekteprognoses. Performance status, haemoglobins, alkalische 
fosfatase en testosteron zijn van prognostische waarde en de toename van 
serum PSA bepalingen beïnvloedt de overleving niet significant. In 
tegenstelling hiermee laten de resultaten van de 8,5 jaar follow-up studie 
zien dat serum PSA normalisatie binnen 3 maanden overeenkomt met een 
langere mediane tijd tot progressie en sterfte. 
In Hoofdstuk 5 wordt een nieuwe behandelingstherapie beschreven 
bij patiënten met een H.R.P.C. R75251 (Liarozole HCL) is blijkens de 
bemoedigende studieresultaten met volwassen mannelijke F1 hybride 
ratten (Fisher female χ Copenhagen male) die geïmplanteerd zijn met 
verschillende prostaatcarcinoom-Dunning sub- cellijnen een geschikt studie 
medicijn. Doses-afhankelijke remming van de tumorvolume groei van ver-
schillende androgeen gevoelige en ongevoelige subcellijnen werd 
waargenomen. Liarozole verminderde de mediane tumorvolume groei in 60-
90% onafhankelijk van de androgene gevoeligheid of histologische 
gradering. 
In een klinische fase II studie werden 55 patiënten behandeld met 
R75251 (Liarozole). 42 Patiënten waren evalueerbaar wat betreft klinische 
respons en 52 patiënten voor de verdraagzaamheid van de 
studiemedicatie. Groep A kreeg direct 300 mg bid R75251 (Liarozole) 
toegediend terwijl groep В 150 mg bid R75251 (Liarozole) kreeg bij de 
aanvang van de studie met een dosisverdubbeling na 4 of 8 weken 
behandeling indien een patient geen verbetering liet zien wat betreft pijn of 
urologische symptomen. De mediane tijd tot progressie voor alle patiënten 
bedroeg 19.3 weken; voor groep A 26.8 weken en voor groep В 11 
weken. Het volume van de primaire tumormassa slonk meer dan 50% in 7 
van de 15 evalueerbare patiënten in groep A. Subjectieve respons: 
pijnvermindering 55%, performance status verbetering in 27.5%. Serum 
PSA normaliseerde in 2 van de 42 evalueerbare patiënten (4.7%) en in 15 
van de 42 patiënten (35.7%) werd een daling van het serum PSA gezien 
van meer dan 50% (P.R.), met een algehele PSA respons van 4 1 % . 
De meeste bijwerkingen zijn retinoic acid-achtige verschijnselen 
gerelateerd en 150 mg. bid R75251 is een te lage effectieve dosis 
gebleken. 
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It is sadly enough generally accepted now that patients with 
disseminated prostate cancer cannot be cured. Since the discovery by 
Huggins and Hodges that androgen ablation generally influences prostate 
cancer growth, therapy of advanced prostate cancer is based on reducing 
circulating androgens. More recently, also inhibition of androgen stimula-
tion by anti-androgens is used in combined androgen ablation therapeutical 
regimens. Despite all efforts to optimize treatment modalities based on 
partial or total androgen blockade, a beneficial gain in median time to 
progression could be obtained but none of these have resulted in a general 
accepted significant improvement in patient survival. 
Clearly, new therapeutic targets are needed. It was more or less a 
serendipitous finding that an agent originally designed to interfere with 
synthesis of adrenal androgens, the imidazole derívate, liarozole (R75251), 
seemed to work through a completely different pathway. Liarozole treat-
ment appeared to impair cytochrome P450 dependent catabolism of for 
instance Retinole Acid(RA). RA being a potent 'differentiation agent' may 
thus prevent progression of the disease by inducing differentiation and/or 
apoptosis. Initial findings in model systems for prostate cancer have not 
only shown an antitumour effect against androgen independent tumours 
(this thesis), but later experiments have indeed confirmed that liarozole 
treatment can result in a change in differentiation pattern of epithelial 
structural proteins such as Cytokeratin (CK). The clinical findings were 
hopeful, although no significant improval in survival was seen. It should be 
noted that the trials so far included patients with advanced prostate cancer 
that progressed after androgen ablation therapy. Considering the putative 
mode of action, early treatment by liarozole is more likely to succeed. 
Prevention of progression of prostate cancer is an interesting 
concept, particularly since this disease is considered to develop relatively 
slowly. Provided we could asses the biological potential of an individual 
lesion treatments based on prevention of progression of the disease seem 
to be justified. In case the agents used have an acceptable low long term 
toxicity, one can even consider to use these in a truly preventive setting, 
i.e. all me at risk for developing prostate cancer. In the United States such 
a chemoprevention trial using finasteride is ongoing, and also retinoid 
dérivâtes and vitamine D are considered. 
Once prevention is considered also food supplements that might 
make the diet of 'high risk' populations (Western males) more comparable 
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to that of ' low risk' men (e.g. Asian ) should be taken into account seri-
ously. Unfortunately the complexity of the diet makes this a difficult 
enterprise. However, once a tumour has become biologically aggressive it 
is unlikely that chemopreventive strategies will be effective. The tumour 
cells have usually become genetically instable, proliferate autonomously 
and can anthropomorphically be considered anarchistic. Even then the 
mitotic index of prostate cancers is usually relatively low, which might 
explain the discouraging results of chemotherapy, which usually requires 
proliferating cells to be effective. 
In the past two decades basic research aimed at elucidating the 
mechanisms that underlay normal and abnormal growth of the prostate. 
Interestingly, it appeared that in the regressing prostate a process termed 
apoptosis becomes very evident. This prompted many investigators to 
explore the potential of apoptosis, also termed programmed cell death as 
new therapeutical target. The drugs that can activate this process of 
cellular suicide have yet unacceptable toxicity profiles, hence clinical use 
seems limited. Efforts to design prodrugs that can be activated by the 
prostate specific serine protease PSA are currently undertaken by Isaacs 
and colleagues. Deprivation of polyamines can also lead to activation of 
apoptosis. Here again toxicity of the drugs used, and even more the 
replacement by polyamines synthesized by gut-flora has complicated 
polyamine-deprivation based therapies. A better understanding of the 
polyamine metabolic routes and the development of new analogs can lead 
to more clinically useful therapies. 
Another theoretical concept that led to the design of new therapies 
is to interfere with growth factor stimulation. Suramin is a drug that is 
interfering with a number of growth factor mediated signalling pathways. 
Despite the fact that it is known toxicity can now be controlled fairly well, 
the clinical trials are not very hopeful. 
Also other attempts are currently exploited to corrupt the complex 
pathways of signal transduction. Likewise, in the activation of small G-
proteins of the ras-family farnesylation is crucial. Farnesyl-transferase 
inhbitors are currently being evaluated in fase-1 and -2 trials. Inhibition of 
EGF mediated signalling using anti EGFR antibodies is now clinically tested 
and the inhibition of signalling through neurotrophins may be tested in 
clinical trials now the preclinical studies using specific inhibitors of the 
corresponding receptors (trk-A, -B, -C), seem very promising. It should be 
stressed that all the latter therapies are based on the assumption that one 
interferes with a critical signalling pathway. 
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Finally, gene therapy programs are raising a lot of expectations and 
in fact the first clinical trials are underway. Considering the somewhat 
disappointing experiences to date we have to be realistic in what we can 
expect from these in the near future. The high tech aspects of 
transduction of for instance cytokine genes is appealing but it is in fact a 
'trial and error' approach. Identification of prostate cancer specific 
antigens or proteins overexpressed in the cancer would enable the design 
of therapies aimed at inducing the immune system to fight the cancer. 
It is hopeful to see that there is an explosion in the field of new 
therapeutics for prostate cancer. Most of these are based on a better 
understanding of the complex growth regulatory processes in the prostate. 
An important issue that remains in the design of clinical trials is the 
't iming' of the new therapies. Therefore, a clinician needs to be able to 
predict the biological potential of an individual prostate cancer. Clinical 
evaluation of the traditional clinical and histopathological parameters 
together with recently developed molecular prognostic factors (e.g. 
PSA/PSM, RT-PCR, E-cadherin/alpha catenin, nuclear morphometry) is now 
underway in the background of an EC funded programm (BIOMED II). 
Taken together both activities, i.e. evaluation of new therapeutical 
modalities and prediction of biological potential, one can expect clinical 
trials evaluating 'new concept' drugs before the turn of the century. It will 
undoubtedly take longer to gain insight in the clinical efficacy. 
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Dankwoord 
Met veel plezier richt ik mij tot eenieder die hun bijdrage hebben geleverd bij de 
totstandkoming van dit proefschrift. 
Allereerst wil ik Prof.dr. W.A. Moonen, voorheen hoofd van de afdeling Urologie 
Radboudziekenhuis te Nijmegen en de afdeling Urologie Grootziekengasthuis te Bois-le-
Duc, bedanken voor uw boeiende colleges Urologie, een combinatie van de actuele 
urologie en de geschiedenis hiervan, die mij ertoe hebben doen besluiten in opleiding 
Urologie genomen te worden. Zoals met iedere toekomstig assistent in die tijd, vond op 
de veranda van Theere Heide te Vught vanaf 1968 het jaarlijkse gesprek met Wim 
Moonen plaats waarbij de Professor werd geïnformeerd over de medische vorderingen 
van de toekomstig assistent en zijn te uiten vurige wens Uroloog te worden. 
Na de periode co-assistentschappen en chirurgische vooropleiding belde ik Wim Moonen 
dat ik met de opleiding Urologie kon beginnen en hij zei: "Ben je nu al zo ver!" Rudi 
Janknegt en Louis Schreinemachers waren zijn mede-opleiders op de afdeling Urologie 
van het Grootziekengasthuis; Frits Maréchal was de oudste assistent, waarna San de 
Kort, Cor Kerkhoffs en Adriaan Smans mijn latere collegae werden. Deze twee jaar 
durende urologische opleiding diende de basis te leggen voor datgene wat eenieder voor 
zichzelf wil investeren naar de toekomst toe. Wim, deze periode zal ik nooit vergeten. Ik 
ben blij dat ik jouw assistent mocht zijn. Niet alleen de opleiding zelf, maar veeleer in 
welk perspectief deze opleiding door jou werd gesteld heeft mij in hoge mate geboeid. 
Van Rudi Janknegt en Louis Schreinemachers heb ik veel mogen leren wat betreft het 
tableau van de urologische diagnostiek en endo/open chirurgische mogelijkheden; u was 
vaak chirurgisch zo snel, en uw patiënten te moeilijk. 
In 1984 werd door Prof.dr. Frans Debruyne, als uitwerking van zijn eerder voor de 
Nederlandse Vereniging voor Urologie in 1979 gehouden lezing: "De Urologie in een 
Toekomstperspectief", de Dutch South East Cooperative Oncology Group opgericht. Dit 
ter stimulering en bundeling van klinisch wetenschappelijk onderzoek van de aangesloten 
perifere urologische klinieken. Gezien de aard van sommige klinische studies kreeg het 
Urological Research Laboratory, met als hoofd Prof.dr. Jack Schalken, de mogelijkheid 
direct met de urologische kliniek samen te werken en richting te geven aan klinisch toe-
pasbare urologische research. De deelnemers van dit samenwerkingsverband wil ik 
bedanken voor de mij gegeven mogelijkheid om van de verzamelde data van de ver-
schillende klinische studies gebruik te kunnen maken. 
Samen met zuster Riet van Dongen, hoofd polikliniek afdeling Urologie van het 
Ignatiusziekenhuis te Breda gingen de eerste klinische studies van start, na goedkeuring 
door de Commissie Wetenschappelijk Onderzoek bij Mensen. Alle patiënten die aan deze 
klinische studies hebben deelgenomen wil ik bedanken voor het in mij gestelde 
vertrouwen. Riet, dankzij jouw niet aflatende inzet, zorg en toewijding is het steeds 
mogelijk geweest uitvoering te geven aan de noodzakelijke dataverzameling van al deze 
klinische studies die aan de totstandkoming van dit proefschrift ten grondslag liggen. 
Ik wil je hiervoor bedanken. 
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De begeleiding en samenwerking van het Trialbureau Nijmegen werd hechter en Pilar 
Fernandez del Moral was degene die hieraan zichtbaar uitvoering gaf. Dankzij jouw 
persoonlijke, vrijblijvend overkomende ontwapende charme wist je de deelnemers voor je 
te winnen om in goede harmonie met jou te blijven samenwerken om opgestarte studies 
tot een goed eind te brengen en "protocol violation" tot een minimum te beperken. 
Tijdens de verdere totstandkoming van dit proefschrift in de afgelopen jaren ben je mij 
steeds tot steun geweest. ¡Por todo lo que has hecho, te agradezco de todo corazón! 
Door de inspirerende Nijmeegse refereeravonden waaraan Prof.dr. Frans Debruyne zijn 
persoonlijk cachet gaf ontstond de behoefte om niet louter waterdrager alleen te zijn, 
maar ook direct betrokken te raken bij de totstandkoming van het wetenschappelijk 
bouwwerk. Tijdens het internationale symposium "On Recent Advances in Urological 
Cancer Diagnosis and Treatment", juni 1 989 te Monaco, werd door Frans Debruyne mij 
toegezegd dat hij wilde opteren als promotor van dit proefschrift. 
Prof.dr. Rudi Janknegt en Prof.dr. Jack Schalken hebben nadien hun bereidheid als 
mede-promotor en co-promotor toegezegd. 
In overleg met Frans Debruyne werd een indeling gemaakt van onderwerpen benevens 
een tijdspad. Mijn eerste zomervakantie viel hiermee in duigen. Vele andere "vrije tijds 
periodes" zouden volgen. Ondanks alle moeite van Diny de eerste 2 hoofdstukken uit te 
typen is hiervan wel de geest maar geen zin nadien meer verwerkt in dit proefschrift. 
Diny, het is niet tevergeefs geweest. Voor mij was het een prelude en zoals je ziet heeft 
het wel degelijk zin gehad. 
Tussentijds werd uitvoering gegeven aan het dierexperimenteel research gedeelte, 
waarvoor ik Jack Schalken en Jeroen van Moorselaar veel dank verschuldigd ben. Jack, 
jij hebt mij in menig middag wegwijs proberen te maken in het doolhof van urologisch 
researchland. Dat een eerder concept van dit proefschrift als basis heeft gediend ter 
richting van jouw kerstboom heeft mij veel voldoening geschonken. 
Jeroen, jij was vele malen handiger met de diertjes en met "gavage" kon ik niet over-
weg. Bedankt voor je loyale begeleiding en stimulans aan het begin van dit avontuur. 
Veel steun en medewerking heb ik mogen ontvangen van: 
Berry Fürr, Martin Sykes, John Callagher, David Lee, Geert Kolvenbag en Henk Tissing 
van de firma Zeneca, 
Annie de Géry, Division Santé Domaine Endocrinologie, van de firma Hoechst Marion 
Roussel Uclaf, 
Roland de Coster, Peter de Porre en Jan Bruynseels van de firma Janssen 
Pharmaceutica. Dankzij uw company belang en de statistische en redactionele 
ondersteuning heeft ertoe bijgedragen dat ik dit proefschrift heb kunnen afronden. 
Annette Heyman, hoofd huisdrukkerij IZB, dankzij jouw bundelingstalent werd dit 
"boekje" voor mijn promotors steeds zichtbaarder. Geen literatuurlijst was te lang of 
artikelen copieëren te veel of Jan van Trier, bibliothecaris en hoofd documentatie-
centrum IZB, stond mij met raad en daad bij. Jan en Annette, bedankt voor jullie hulp. 
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Caroline Muurmans, je was vaak een aanspreekpunt waarmee ik kon overleggen als "het 
artikel" weer niet wilde vlotten en dit heeft lang geduurd! Uiteindelijk heb jij de knoop 
doorgehakt en de postzegel erop geplakt. Bedankt voor je inzet. 
Anne-Marie Eggenhuizen, je hebt me versteld doen staan over je creatieve secretariële 
ondersteuning in het "Camera Ready" maken van dit proefschrift. Je moet het echt leuk 
gevonden hebben anders had je het niet op deze manier opgepakt. Jouw persoonlijke 
betrokkenheid spreekt boekdelen als ik de lay-out zie. 
Lia Laurijssens, mijn secretaresse. John, je man, heeft ons de mogelijkheid gegeven om 
in de vele uren mijn redactionele spinsels aan de computer en papier toe te vertrouwen 
en dat moesten we vaak opnieuw doen. Lia, bedankt voor je geduld om altijd hiervoor 
klaar te staan. Mag ik hopen dat naar de toekomst toe het "Normale" weer normaal 
wordt. 
Hooggeleerde Frans, Rudi en Jack, jullie wil ik bedanken dat we samen deze uitdaging 
konden aangaan. Dankzij jullie inzet mij wegwijs te maken is het mij mogelijk geweest 
het voor ogen gestelde tot een goed einde te brengen. De realisering hiervan heeft 
bijgedragen aan de afronding van een van mijn urologische taakstellingen en meer dan 
dat alleen: aan de uitbouw en verdieping van mijn eigen leven. Ik ben u hier blijvend 
dankbaar voor. 
Ton Schlatmann stelde mij eens gerust: promoveren is louter een hele grote Limburgse 
vlaai opeten; blijven eten en door blijven eten. Nu is het tijd voor de laatste hap. U heeft 
mij er op gewezen dat het meer dan de moeite waard was. 
Mijn vader en moeder hadden zich binnen het gezin tot taak gesteld hun kinderen te 
begeleiden en hebben zich zelf hiervoor vaak ontzien. Het is jammer dat u dit moment 
niet meer kan meemaken. U dacht toen ik arts werd dat uw taak was volbracht. U 
leerde: "discipline leidt tot creativiteit en productiviteit". Hierin bent u mij voorgegaan. 
Lieve Marjan, vandaag zijn we 27 jaar getrouwd. Om 11 uur gingen we naar de St. 
Janskerk in Laren om elkaar het ja-woord te geven. Het is meer dan dat alleen 
geworden. Nu zijn we om 11 uur weer hier samen, nu met Jeroen en Marije en onze 
vrienden. Je hebt mij de vrijheid gegeven om dit te kunnen doen. Dat was meer dan wat 
anders ook jij mij hebt kunnen geven. 
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Stellingen behorende bij het proefschrift 
Progress in the Management of Prostate Cancer 
door 
Gerhard Α. Dijkman 
Nijmegen, 6 september 1996 
1. Prostaatkanker is "global" en epidemisch. 
(dit proefschrift) 
2. De sterke toename van de incidentje van het prostaatcarcinoom is 
niet louter en alleen te verklaren door de toename van de leeftijd, 
maar veeleer door toedoen van "awareness" en "screening". 
(dit proefschrift} 
3. Preventieve geneeskunde dient er op gericht te zijn dat voeding rijk 
is aan groente en fruit; dierlijke vetten dienen zoveel mogelijk 
vermeden te worden. Dit leidt tot vermindering van: 
- cardiovasculair lijden 59% 
- voorkomen van kanker 48% 
- overgewicht 64% 
4. De kans prostaatkanker te krijgen is mede gerelateerd aan het 
familiair voorkomen van prostaatkanker/borstkanker in de eerste, 
tweede en derde graads mannelijke/vrouwelijke lijn. 
(dit proefschrift) 
5. Opeenvolgende Zoladex 10,8 mg depot injecties iedere 12 weken 
onderdrukken de serum testosteron waarde beneden castratienivo. 
(dit proefschrift) 
6. Een chemische castratie door middel van een LHRH-analoog is 
vergelijkbaar met castratie; vooralsnog blijft chirurgische castratie 
de gouden standaard. 
7. Maximale androgene blokkade veronderstelt een algemene onder-
drukking van androgenen en vergroot het therapeutische voordeel 
van deze behandeling maximaal. 
(dit proefschrift) 
Bij de vroege behandeling van het hormoon ongevoelig geworden 
prostaatcarcinoom verdient het Imidazole derivaat Liarozole-HCL als 
redifferentiatie en antiproliferatie therapie de voorkeur. 
(dit proefschrift) 
De kennis van de basale moleculaire en biologische veranderingen, 
wat resulteert in normale en abnormale prostaatcelgroei, staat nog 
in de kinderschoenen. 
(Brantley Thrasker, Journal of Urology 1996) 
Inductie van E-cadherine expressie kan een belangrijk aangrijpings-
punt zijn voor nieuwe therapeutische behandelingsmodaliteiten. 
Prostaatkanker in de "peripheral zone" met een volume van meer 
dan 12 cc en een Gleason score van 4-5 (Graad II) is niet te gene-
zen met een radicale prostatectomie. 
(A. Stamey, AU A Orlando 1996) 
Niemand wordt het recht ontnomen een eigen levensritme er op na 
te houden en eigen doelstellingen na te streven. Dat is een 
individuele keuze. Maar je mag je niet als een koekoeksjong 
nestelen in een milieu waar anderen wel prestatiegericht opereren. 
(Cor Boons tra, Vice-President Philips) 
Echt-trouw en celibaat is niet mogelijk wanneer men in de jeugd 
niet heeft leren omgaan met affectiviteit. 
(Bisschop Simonis) 
Een doctorandus is diegene in gespannen afwachting op de verdedi-
ging van het "Specimen Inaugurale". In de vorige eeuw duurde dit 
slechts enkele dagen tot weken. 



